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Liver disease is one of the top five leading causes of premature death in the UK, with incidence rising 
sharply by 20% over the last decade, and mortality increasing over 400% since 1970. Liver disease 
incidence and mortality is rising in stark contrast to trends in the other top healthcare burdens, with 
stroke, cancer, heart disease and lung disease incidence and mortality rates plummeting and 
continuing to fall. 
Liver disease’s hallmark pathology of late diagnosis and rapid acute disease progression leads to an 
urgent need for donor organs; the only curative treatment for end stage liver disease. However, a 
chronic and ongoing shortage of suitable organs for transplant means many die before a donor liver 
can be found, and countless others live with severe, debilitating symptoms at a high cost to both the 
patient and the healthcare system. 
As part of the push for a solution to this problem, tissue engineers are focussing on creating niche 
microenvironments for hepatocytes which support their survival and function in as close to an in vivo 
like state as possible; addressing the need for an ideal in vitro model of the human liver and for lab 
created ‘organoids’ which could be used to treat patients. Such an environment would allow for the 
study of new pharmaceuticals, disease biology and hepatocyte behaviour in the laboratory and lead 
to more effective treatments for patients. While research to date is making inroads into this dilemma, 
we are yet to see a lab created environment which accurately recapitulates the complex, finely tuned 
and responsive extracellular matrix (ECM) of the liver. In an effort to address this, researchers have 
been incorporating bioactivity into scaffold environments for hepatocytes. 
This thesis presents three methods of incorporating bioactivity into scaffolds for liver tissue 
engineering; drug induced ECM biodecoration, synthetically derived ECM biodecoration and 
decellularized human liver ECM incorporation. Scaffolds were seeded with hepatocyte cells and their 
response to their microenvironment analysed. Mechanical characterisation and 
iii 
 
immunohistochemical analyses demonstrated the differences between the scaffold and the ECM 
biodecoration, as well as retention of ECM proteins through the manufacturing process. Each method 
altered the protein production and gene expression of hepatocytes, indicating that these methods 
provide a viable, translatable platform for creating a niche microenvironment for hepatocytes, 
supporting and manipulating phenotype and function. These scaffolds offer great potential for tissue 






Liver disease is the only increasing cause of death in the UK, last year alone 2 people a week died 
waiting for a liver transplant. By creating a liver ‘on the bench’ we could test new drug treatments and 
study disease causes and progression and reduce this disease burden.  
Bioengineering aims to create solutions to the problems of a shortage of donor organs for transplant 
and a lack of appropriate models in which we can study human biology and diseases. Bioengineers use 
a combination of materials science; researching new substrates, molecular biology; manipulating cells 
and proteins to create new environments and fluid dynamics; to create dynamic ‘blood-flow’ devices 
in which we can grow and manipulate cells to behave optimally. Eventually we hope to provide 
artificial organs which we can use to test new drugs, transplant into patients and replace animal 
models in research. 
A particular challenge in liver tissue engineering is creating a replacement for the extracellular matrix 
(ECM). The ECM is a scaffold for cells to grow on which is a complex combination of organ specific 
proteins, growth factors and cell signalling molecules. It supports cell growth and modifies/responds 
to cell behaviour. This project focusses on creating new scaffolds for liver tissue engineering, as a 
replacement for the native liver ECM.  
Research for liver tissue engineering scaffolds has focussed on two avenues; polymeric scaffolds and 
decellularized tissue. Polymer scaffolds; such as hydrogels, phase separated and electrospun scaffolds 
provide a reproducible, mechanically stable and consistent environment for liver cells. Decellularized 
organs, organs which have had all the cells stripped out of them with detergents, theoretically provide 
all of the biological cues and vascular network that the liver cells need to survive and function well. 
However, neither of these methods has yet proved sufficient. This project combines the two methods 
to provide novel environments which can influence liver cells; using engineering to affect a cellular 
response. Three methods were used to biodecorate electrospun polymer scaffolds. Firstly; an initial 
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sacrificial cell layer was grown on electrospun scaffolds and treated with protein production altering 
drugs. This cell layer was decellularized to leave behind a hybrid protein:polymer scaffold to grow liver 
cells on. The second method was similar; but the sacrificial cell layer was treated with a protein 
producing vector which increased fibronectin production, an important protein in the liver. Finally, 
decellularized human liver was incorporated directly into an electrospun scaffold and compared with 
scaffolds created with single ECM proteins. 
Each of the scaffolds altered the behaviour of liver cells; changing gene expression, protein production 
and cell survival. Bioengineering of scaffolds can be used to alter liver cell behaviour and, in the future, 
optimise function. Creating novel environments such as these is one step closer to a more realistic 




Justification for thesis research 
According to the NHS, liver disease is one of the top five causes of premature death in the UK, with 
incidence rising sharply by 20% over the last decade1. While liver disease incidence is rising, other top 
healthcare burdens, such as stroke, cancer, heart disease and lung disease mortality rates continue to 
fall 2,3. In the UK, 5 people a month die whilst waiting for a donor liver4. 
Liver disease’s hallmark pathology of late diagnosis and rapid acute disease progression leads to an 
urgent need for donor organs; the only curative treatment for end stage liver disease5. However, a 
chronic and ongoing shortage of suitable organs for transplant means many die before a donor liver 
can be found, and countless others live with severe, debilitating symptoms at a high cost to both the 
patient and the healthcare system2. 
One of the major obstacles within the liver tissue engineering field is recapitulating the ECM. The ECM 
is a dynamic, organ specific collection of proteins, cytokines and other small molecules which provides 
physical support, mediation of cell:cell communication and modulation of cell behaviour6–8. Various 
studies have demonstrated the influence of altered ECM on the behaviour of hepatocytes in culture; 
including that of diseased ECM9,10, of synthetically derived ECM8,11 and of individual ECM 
components12,13 on the behaviour of hepatocytes. . 
As part of the solution to this problem, tissue engineers are focussing on creating niche 
microenvironments for main cell type of the liver, the hepatocyte, which support cell survival and 
function and could be used to treat patients in the future11,14–16. Such an environment would also allow 
for the study of new pharmaceuticals to treat human disease more effectively 17. While research to 
date is making inroads into this dilemma, there is yet to be a lab created environment which accurately 
recapitulates the complex, finely tuned and responsive extracellular matrix (ECM) of the liver12,18. 
Tissue engineers are attempting to solve this problem by engineering liver ‘organoids’; laboratory 
created organs which can function as a liver in vivo19–22. The 3D environment exerts extensive influence 
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on the behaviour and function of hepatocytes11,21. With this in mind, tissue engineers employ scaffold 
manufacturing technologies to create structures which encompass key characteristics of the native 3D 
ECM23–28. Several different methods of creating a scaffold are in use, and they can be made from a 
myriad of substances; both natural and synthetic29, and enhanced with bio-decoration methods11.  
There has been particular focus on organ decellularization, which provides an ECM bioscaffold with 
the 3D site-specific vasculature and highly conserved sinusoidal gradient required for hepatocyte 
function upon their repopulation of the organ30. Decellularized organs have been repopulated with 
hepatocytes and endothelial cells which subsequently survive and exhibit some level of function, 
clearly demonstrating the importance of the ECM in supporting hepatocyte survival and phenotype31–
35. However, decellularization requires a human or animal source of whole, undamaged organs and  
while research is showing great promise, the field is fragmented and to date no scaffold has been 
created which allows hepatocytes to function as well as in vivo36,37. 
Detergents such as sodium dodecyl sulphate (SDS), Triton-X100 and sodium deoxycholate (SDOC) are 
employed to strip the ECM of cells. These detergents disrupt native tissue ultrastructure, decrease 
glycosaminoglycan (GAG) content and reduce collagen integrity38,39 as well as disrupt lipid-lipid, lipid-
protein and protein-protein interactions40.  
Scaffold manufacture has been employed; using engineering technologies to create a synthetically 
derived structure which mimics the characteristics of the native ECM. There are several different 
methods of creating a scaffold, and they can be made from a myriad of substances; both natural and 
synthetic29. Hydrogels have been of particular interest to liver tissue engineers, gels biofunctionalized 
with collagen I enhance P450 (Cyp450) activity, cell adhesion markers and innate hepatocyte 
fibronectin production41. Gels biofunctionalized with galactose increase albumin production and 
promoted the proliferation of hepatocytes42. Viability and hepatic functions of primary hepatocytes 
are improved by culturing them in hydrogels made with liver extracellular matrix43, and when 
encapsulated in collagen-alginate composite hydrogels44. PEG hydrogels have been shown to augment 
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cell-cell interactions of bipotential mouse embryonic liver (BMEL) cells, subsequently improving their 
survival and function45, however incorporating ECM components into scaffolds at the manufacturing 
stage has proved challenging, with the harsh solvents require to solubilize major components of ECM 
alter their microstructure and functionality46,47. Ongoing research is showing great promise, however 
to date no scaffold has been created which allows hepatocytes to function as well as in vivo36,37.  
Both ECM components and scaffolds have shown great promise in tissue engineering 12,26,48, and each 
provides benefits to the cells seeded upon them. With these considerations in mind, this thesis 
focusses on ECM components obtained from decellularization and protein production/incorporation 
and scaffold engineering were combined to create novel environments which influence hepatocytes.  
By manipulating ECM production using pharmaceuticals, producing hepatic ECM components using 
synthetic biology and combining decellularized proteins and exploiting polymer characteristics novel 
hybrid polymer-ECM platforms for liver tissue engineering were produced. To validate the platforms 





















Hypothesis and Aims 
 
The hypothesis of this project is that hepatocytes can be influenced by novel hybrid scaffold platforms.  
 
The aims are as follows; 
 
1. The manufacture of electrospun polymer scaffolds capable of maintaining hepatocyte survival 
2. Combine polymer scaffolds with cutting edge protein production techniques to manufacture 
practical, reproducible and translatable hybrid polymer:protein scaffolds for liver tissue engineering 





















1.1 Liver Anatomy 
The human liver is the largest solid organ and the largest gland in the human body. In females, the 
liver weighs 1.2 - 1.4 kg and in males 1.5-1.7 kg, accounting for approximately 2.8% of the total body 
weight. The liver is located on the upper right side of the body, protected from impact by the lower 
rib cage. A healthy, perfused liver is reddish brown in colour and is soft, highly malleable and easily 
lacerated; in addition to being highly vascularised49. The liver performs central metabolic, 
detoxification, synthetic, digestive, endocrine, immunoregulatory, and exocrine functions and is 
estimated to be vital for over 500 live sustaining processes in the human body17. 
The superior surface of the liver is attached to the diaphragm and anterior abdominal wall by a 
triangular fold of peritoneum; the falciform ligament. The line of attachment of the falciform ligament 
divides the liver into right and left lobes. Additionally, the transverse fissure divides the liver 
additionally into two further lobes; the quadrate and caudate lobes. The gallbladder is attached to the 
quadrate lobe at the rear of the liver by the cystic duct49.  
The liver is the most richly perfused organ in the human body, containing 13% of the total blood 
volume at any one time. There are two distinct sources of blood to the liver, the hepatic artery, which 
provides oxygenated blood to the organ and the portal vein, which provides nutrient dense blood 
derived from the intestinal tract, spleen, pancreas and gallbladder and provides 80% of the blood flow 
to the liver, highlighting the liver’s pivotal metabolic role. The hepatic vein drains deoxygenated blood 
from the liver into the inferior vena cava. Bile is drained from the liver via the right and left hepatic 
ducts, which join the cystic duct to form the common bile duct, draining from the liver to the intestine. 











Each of these arteries, veins and ducts subdivides to feed the smallest histological compartment of 
the liver; the lobule. Liver lobules are hexagonal honeycomb-like arrangements of cells, approximately 
1mm in diameter, fed by the smallest subdivision of the capillary system in the liver; the sinusoids51,52. 
Sinusoids are highly specialised capillaries which are lined by a specialized, discontinuous fenestrated 
endothelium as opposed to the traditional basement membrane. These sinusoids are in immediate 
proximity to the Space of Dissé, which borders the liver cells, and allow for unfettered diffusion of 
metabolites and metabolic products to and from cells53,54.  
Each lobule consists of three zones based on their proximity to the portal triad; the collection of 
hepatic artery, portal vein and bile ducts. Zone I is closest to the portal triad, and receives the highest 
level of oxygenation, making the cells within zone I least susceptible to ischemic injury. Conversely, 
zone II lies adjacent to the central vein of the lobule and receives the lowest level of oxygenation, 
making the cells within most susceptible to ischemic injury. Additionally, cellular function is related to 
lobule zonation, with major metabolic processes such as albumin production, ammonia detoxification, 
urea synthesis, glutamine synthesis, cytochrome p450 drug metabolism, gluconeogenesis, glycolysis, 
Figure 1.1; Labelled anatomy of the human liver. Donor liver received January 2017. 
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oxidative phosphorylation, lipogenesis and the TCA cycle all displaying zone based 
functionality22,50,55,56. 





1.2 Resident Cells of the Liver  
The myriad of functions of the liver are enables by the complex assembly of its highly specialized cell 
types. Non-parenchymal cells (NPCs) comprise 30-40% of the liver’s cellular mass; and includes Kupffer 
cells (liver macrophages), sinusoidal endothelial cells, stellate cells, biliary epithelial cells and roving 
immune cells such as leukocytes and lymphocytes57. Parenchymal cells, the hepatocytes, make up the 
majority (60-70%) of the cell mass. The hepatocytes carry out the bulk of the metabolic activity of the 
liver; producing circulating proteins such as albumin, protease inhibitors and coagulation factors, 
regulating pH and performing ammonia detoxification58. Hepatocytes control the homeostasis of 
glucose/glycogen, cholesterol, bile and vitamins A and D, as well as metabolize amino acids, heme and 
bilirubin. The NPCs of the liver exist in functional and structural organisation alongside the 
hepatocytes, mediating hepatocyte survival and function59.  
Figure 1.2; Diagram representing the size and zonation of liver lobules, with periportal, transitional 
and pericentral regions labelled. 
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Sinusoidal endothelial cells (SECs) line the sinusoids of the liver lobules and lack a consistent basal 
lamina; resulting in no continuous barrier between the blood and the hepatocytes. SECs possess large 
pores (0.1-0.3µm) which allow free flow of molecules to and from hepatocytes. However, the SECs 
also possess lymphatic function, undertaking scavenger receptor mediated clearance of various 
molecules, including endotoxins and bacteria, recruiting leukocytes and regulating inflammatory 
cascades. They also possess the ability to behave as antigen presenting cells to circulating T-cells. SECs 
contribute to the extracellular matrix (ECM) by producing fibronectin and collagen IV. Additionally, 
they activate transforming growth factor beta (TGF-β) to the active form. SECs also produce autocrine 
vasoactive compounds, such as endothelin-1 (ET-1), to affect blood flow and uptake from the 
sinusoidal lumen60,61. 
Hepatic stellate cells (HSCs) reside in the Space of Dissé, between the hepatocytes and the SECs. These 
cells are considered to be ‘stem-like’, displaying neuronal and neuroendocrine markers such as nestin 
and CD133 as well as haemopoietic markers such as GATA1. Under normal physiological conditions, 
stellate cells store vitamin A, but during phases of inflammation they are the source of liver 
myofibroblasts; playing a pivotal role in hepatic fibrosis progression and regression and maintenance 
of the extracellular matrix by producing matrix metalloproteinases, hepatocyte-influencing growth 
factors, and ECM molecules62–64. 
Kupffer cells, or liver macrophages, reside in the microvessels of the sinusoids, ideally situated to 
screening for pathogens entering the liver and underscoring the role of the liver in acute immune 
responses; in fact 80% of the body’s macrophages are Kupffer cells located in the liver. As 
macrophages, they play the classical role of clearing cellular debris and exogenous particles and of 
mediating inflammatory responses by releasing cytokines, chemokines, eicosanoids, proteolytic 
enzymes, reactive oxygen species (ROS) and nitric oxide65,66. 
Biliary epithelial cells, or cholangiocytes, line the biliary tract and interact directly with their 
neighbouring hepatocytes to secrete and modify bile; a vital acid for digestion. They maintain 
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osmolality of the bile secretions and absorb hormones, amino acids, neurotransmitters, and other 
molecules to mediate homeostasis within the liver lobule67–70.  
Table 1.1; Resident cells of the liver 
Cell Type Location 















Biliary epithelial cell 
(Cholangiocyte) 
Bile duct lining 3% 
Form bile ducts to transport 
bile 
Control rate of bile flow 
Secrete water and bicarbonate 







Form sinusoidal plexus to 
facilitate blood circulation 
Highly specialized to allow 
transfer of molecules and 
proteins between serum and 
hepatocytes 













Hepatic stellate cell 
 
Space of Dissé 2% 
Maintenance and modulation 
of extracellular matrix 
Vitamin A and retinoid storage 
Source of myofibroblast cells 
Cytokine secretion 
 
1.3 Hepatic extracellular matrix 
The extracellular matrix (ECM) is a non-cellular component of all tissues, which provides essential 
support for the cells of the tissue. The ECM, formed by the complex network of water, proteins and 
polysaccharides surrounding cells in all solid tissues, is among the most important regulators of cellular 
and tissue functions in the body. As well as being a physical scaffold and structural support for cells, 
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crucial biochemical and biomechanical signals are initiated by the ECM, necessary for tissue 
homeostasis, differentiation, and morphogenesis, and considered essential for normal physiology 71,72. 
The ECM regulates essential cellular functions, such as adhesion, migration, proliferation, and survival. 
Cellular response and function is dependent upon the niche microenvironment provided by an organ’s 
ECM, and dysregulation of ECM production and proteolysis is often associated with the development 
of pathologies. Each tissue has its own specific ECM ‘recipe’; driven by a dialogue between various 
cellular components and the microenvironment within the tissue. Of these, collagen I, collagen II, 
elastin, fibronectin and laminin are often considered the main structural components, present almost 
ubiquitously throughout the mammalian body, providing strength, structure, and flexibility. 
Moreover, the ECM is a highly plastic structure, subject to constant modification and can vary 
dramatically between tissues 73. 
Liver extracellular matrix is a highly specialised cellular microenvironment predicated by the Space of 
Dissé 74. Where other organs of the human body possess two basement membranes and a collagen-
based ECM between endothelial and epithelial cells, liver lobules have a discontinuous low density 
basement membrane and an attenuated ECM. This specialised ECM, together with the abundant and 
large pores of the sinusoidal endothelial cells, ideally facilitates the rapid bidirectional exchange of 
macromolecules between the blood and hepatocytes and sustains the differentiated stage of the 
surrounding cells53,54,75,76.  
In a normal liver, ECM represents less than 3% of the relative area on a tissue section, and 
approximately 0.5% of the wet weight. The hepatic ECM is composed mainly of collagen, fibronectin, 
laminin and proteoglycans. Liver ECM proteins are mostly detected in the Glisson’s capsule, portal 
tracks, central veins, and in the space of Dissé. Collagen types I, III, IV, and V are the predominant 
collagens detected in the liver; collagen types I, III, and V are mostly interstitial ECM proteins in the 
portal and central regions, whereas collagen IV is highly detected in basement membranes31,77,78. 
Fibronectin is abundantly expressed in the hepatic ECM; it is detected in the subcapsular connective 
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tissue, in septa, and portal areas, and it is the main ECM component in the space of Dissé in normal 
livers79,80. Laminin similarly to collagen IV is a main component of the hepatic basement 
membranes12,81–83.  
1.3.1 Fibrillar collagens 
Fibrillar collagens are ECM proteins which form striated fibrils, providing mechanical structure to the 
ECM. Collagen I is the most abundant ECM component of the adult liver. Together with the other 
fibrillary collagens; III and V they comprise the largest proportion of ECM proteins in the liver. Fibrillar 
collagens are named as such because they possess rigid triple helix amino acid structures and form 
heterogeneous fibre bundles which infer structural strength to the liver. Collagen I is found in the 
highest concentrations in the periportal and pericentral regions of the liver lobule, adjacent to the 
portal triad and the central vein. It contains several binding sites per peptide that attach α1β1 and 
α1β2 integrins, and interacts with other ECM proteins including other collagens, fibronectin, and 
proteoglycans84,85. 
Collagen III possesses a similar structure to collagen I, but is most prevalent in the periportal region. It 
associates strongly with collagen I bundles, providing mechanical integrity to the portal triad 
region84,86,87. Collagen V links multiple collagen types to each other, regulating the formation of 
collagen fibrils78. 
1.3.2 Non-fibrillar collagens 
Non-fibrillar collagens possess fragmented triple-helical structures, and are traditionally classed as a 
category of basement membrane molecules. They create networks linking other ECM components. 
Collagen IV is the main non-fibrillar collagen of the liver ECM. It secures non-collagenous components 




Collagen VI is present in small amounts in the human liver. They form networks with other collagen 
molecules, particularly collagen I and III to stabilise collagenous fibre bundles. Collagen VI also 
interacts with collagen IV to anchor larger structures such as blood vessels and with soluble molecules 
such as mitogen-activating protein kinases (MAPKs) to function in tissue repair62,88,89.  
1.3.3 Non-collagenous glycoproteins 
The most common non-collagenous glycoproteins in the human liver are fibronectin and laminin. 
Fibronectin is a particularly high molecular weight protein dimer (440KDa) which can be found in two 
forms; the insoluble cellular and soluble plasma fibronectin. Plasma fibronectin is primarily 
synthesised by hepatocytes and is the most abundant glycoprotein in the liver. Plasma fibronectin is 
an essential protein in the clotting process. In healthy liver, cellular fibronectin exists in low levels and 
is particularly concentrated in the pericentral region, produced primarily by the stellate cells. Cellular 
fibronectin binds collagen I, perlecan and fibrin and attaches to hepatocytes in the Space of Dissé.  
Fibronectin contains a particular cell binding motif, Arginine-Glycine-Aspartic acid (RGD). It’s increased 
presence in the regenerating liver functions as a chemoattractant, cell adhesion molecule and growth 
factor for migrating cells. During tissue repair, plasma fibronectin at the site of the injury is degraded 
and remodelled by Kupffer and stellate cells. The hepatocytes then replace this plasma fibronectin 
with the insoluble cellular fibronectin which is incorporated into the ECM.   
Laminins, another RGD-containing ECM molecule, is also produced by hepatic stellate cells and is 
concentrated around the portal triad and sinusoidal walls. During development, laminins migrate 
throughout the perisinusoidal region, and have a particularly important role in the maintenance and 
differentiation of hepatocyte phenotypes, as well as being vital to vascular structural integrity. 
1.3.4 Proteoglycans 
Proteoglycans are a remarkably variable component of the ECM, macromolecules with a protein core 
and one or more glycosaminoglycans (GAGs) bound covalently. GAGs are long unbranched 
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polysaccharides consisting of a repeating disaccharide unit. There are six total GAG types that are 
classified into four structurally distinct families; heparan sulfate (HS)/heparin, chondroitin 
(CS)/dermatan sulfate (DS), keratan sulfate (KS), and hyaluronan. Proteoglycans are encoded for by 
43 distinct genes, and an exponential number of variants exist due to alternative splicing 90. Due to 
the polar nature and specific structural confirmation of GAGs they can bind to a variety of proteins, 
rendering them negatively charged. Importantly, they can then attract water molecules, keeping the 
ECM hydrated 91.  
Traditionally, proteoglycans are categorised according to their relative size (large or small) and the 
nature of their protein cores. However this has recently been replaced with a more complex 
taxonomy, classifying the proteoglycans according to their location, homology and protein core 90. 
They are found throughout the cell, cell surface and ECM, and vary greatly according to their function.  
Dermatan sulfate, chondroitin sulfate and hyaluronan possess viscoelastic properties which allow 
them to retain water and influence osmotic pressure 92,93. Heparan sulfate binds a variety of ligands 
including FGF (fibroblast growth factor), VEGF (vascular endothelial growth factor) and PDGF (platelet 
derived growth factor) and is responsible for regulating a wide range of biological processes including 
coagulation, angiogenesis and developmental processes 94. Keratan sulfates have a particularly 
important role in the formation of scar tissue 92,95,96. 
All GAGs increase the half-life of soluble growth factors by binding them covalently and protecting 
them from proteolytic degradation. This process also enhances and controls the presentation of 
growth factors to cells by clustering them in close proximity to the receptors of cells anchored to the 
ECM, and concentrating them in specific tissues and regions97,98.  
1.4 Growth factors and the liver 
Growth factors are soluble signalling molecules which control cellular responses through specific 
binding of transmembrane receptors on target cells. They have a wide range of roles, in cell growth 
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and proliferation as well as differentiation and phenotypic maintenance. Of the 100s of growth factors 
present in the liver, three have the most significant impact on hepatic function; hepatocyte growth 
factor (HGF), epidermal growth factor (EGF) and fibroblast growth factor (FGF)99–102. 
HGF is secreted by the HSCs and SECs in the liver, and functions as a very powerful mitogen; 
stimulating both hepatic progenitor cells and differentiated hepatocytes via the c-MET/HGF receptor 
and subsequent tyrosine kinase pathways of both epithelial and endothelial cells. HGF has been 
implicated in liver regeneration and recovery from liver disease, and in the development of particular 
types of cancer. By binding to the ECM via GAGs, heparin, hyaluronan and collagen; HGFs half-life 
increases from as low as 4 minutes to several hours, allowing for long term exposure to cells103,104. 
EGF s produced out with the liver, in the Brunner’s gland of the duodenum, and is transported into 
the liver via the portal vein; where is activates cell division and is vital for normal liver regeneration. 
Exposure to EGF is dependent upon lobule zonation; with hepatocytes in zone 1 (closest to the portal 
triad) receiving exposure to EGF more rapidly and in higher concentrations than those in zone 3105,106. 
FGF is secreted by HSCs in the perisinusoidal region and influences wound healing, regeneration and 
angiogenesis in the liver; interacting with the liver ECM in a similar manner to HGF101,107. 
1.5 Liver regeneration 
The liver is the only visceral organ capable of regeneration, and can return to 100% of its weight/mass 
even following a loss of up to 60% of its own bulk80,108.  The adjustment of liver weight to the needs of 
the body suggests a complicated set of control points, a ‘hepatostat’. Liver regeneration and this 
mechanism of hepatostat control is a heavily researched process which provides insights into the 
development of other organs and disease processes. The interaction of all the discussed components; 
cells, growth factors and ECM molecules in the liver are not only vital for normal function but also for 
hepatic development and healing/regeneration. A complex and highly conserved cascade of signalling 
molecules coordinates all liver components to expand and organise new tissue, however the precise 
mechanisms and methods of controlling hepatic regeneration remain unclear109. 
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Loss of or injury to normal liver tissue; either by physical or chemical means initiates the liver 
regenerative process. Two models of liver regeneration are proposed. One is that the Kupffer cells 
activate to clear cellular debris, which in turn activates the HSCs and hepatocytes to proliferate within 
the parenchyma, returning the liver/bodyweight ratio to 100. A second method is proposed where 
the regenerative capacity of hepatocytes is compromised, e.g. in chronic inflammatory conditions. In 
this situation, biliary compartment can function as a niche of facultative stem cells that can 
transdifferentiate into hepatocytes101,110. Conversely, in situations when there is a need to repair the 
damaged biliary epithelium but the proliferative capacity of biliary cells is compromised, the 
immediate periportal hepatocytes can function as a niche source of facultative stem cells and 
transdifferentiate into biliary cells69,101. 
Growth factors are vital to the process of liver regeneration. Urokinase-type plasminogen activator (u-
PA) is released as quickly as 1 minute following liver injury, and correlates with an increase in its 
receptor; u-PAR. In addition to releasing plasminogen, u-PA frees matrix-associated HGF; immediately 
stimulating the surrounding hepatocytes to proliferate100. Approximately 1 hour post liver injury, HGF 
release peaks. During this hour, HSCs, Kupffer cells, and SECs release HGF and EGF to promote further 
hepatocyte proliferation. Peaks in growth factor production occur at 24 hours and 48 hours post-
injury111. 
An important factor in liver regeneration is ECM remodelling. Matrix metalloproteinases (MMPs) are 
responsible for the degradation of most extracellular matrix proteins during organogenesis, growth 
and normal tissue turnover112–114. Degradation and remodelling of the liver ECM is vital in the 
regenerative process because it allows the unrestricted proliferation of hepatocytes and other liver 
cells. In healthy, non-inflamed liver ECM maintenance depends upon the simultaneous action of 
MMPs and HSCs to remodel and repair the hepatic microenvironment. Healthy adult livers have a 
moderate amount of ECM turnover, correlating with the small amounts of MMPs constitutively 
detected in those livers. However in liver injury, various MMPs are upregulated; aiding in the 
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degradation and replacement of damaged or missing tissue and regulating immune responses via their 
interactions with other growth factors and cytokines such as transforming growth factor-beta (TGF-β) 
and tumour necrosis factor-alpha, (TNF-α)115,116. 
1.6 Diseases of the Liver 
Liver disease is the only major cause of death still increasing year-on-year, and twice as many people 
now die from liver disease as did in 1991. Liver disease was described in 2014 as the one ‘glaring 
exception’ to the advances made in medicine for the treatment of chronic disorders; with mortality 
increasing by 400% and incidence in the under-65s rising by 500% since 1970. 3. There are over 100 
types of liver disease, and at least 2 million people in the UK are living with liver disease3,5.   
Figure 1.3; Liver mortality 
 
 
Generally, over 75% of liver tissue needs to be affected before a decrease in hepatic function occurs, 
leading to late diagnosis of advanced liver conditions. As a result, liver transplant is often the only 
treatment option available to end-stage disease patients 117. Due to increasing donor age, a higher 
incidence of obese donors and a change in the demographics of donor death away from sudden 
trauma to other causes there is a chronic shortage of donor organs, and many die whilst on the waiting 
Figure 1.3; Mortality by cause of death year on year. Williams et al 2014, The Lancet. 
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list. On March 31st 2018 there were 333 people left waiting for donor livers and 56 people died 
between April 1st 2017 and March 31st 2018 whilst waiting for a donor liver4. 
1.6.1 Acute liver disease 
Acute liver disease (ALD) is a rapid loss of liver function and usually occurs in a person who has no pre-
existing liver conditions. Loss of function occurs rapidly, as quickly as a matter of days, and indicates 
that severe hepatic damage has occurred even prior to clinical presentation. With an incidence of 
fewer than 10 cases per million persons per year in the developed world, acute liver failure is seen 
most commonly in previously healthy adults in their 30s, and is much rarer than chronic liver disease 
(CLD). Clinically, patients present with abnormal liver biochemical values and coagulation pathology; 
without dramatic clinical interventions encephalopathy follows < 8 weeks after onset and 50% of ALD 
cases are lethal118. 
ALD remains less common in the developed world, where improved public sanitation and vaccination 
public health measures have reduced the incidence of viral infections which are often responsible for 
ALD. The most common cause of ALD in the United States and Western Europe is drug induced liver 
injury (DILI)17. 
1.6.2 Viruses 
The hepatitis family of viruses are responsible for the majority of cases of acute liver failure. Hepatitis 
A and E are implicated heavily; with rates of death of more than 50% reported from the developing 
world. Hepatitis B can also lead to ALD, with incidence more common in Mediterranean and Asian 
countries. Patients with reactivation of previously stable subclinical infection with the hepatitis B virus 
have a particularly high mortality rate. This scenario is most common in patients with treatment-
induced immunosuppression during or after therapy for cancer. The identification of at-risk patients 
and the use of antiviral prophylaxis before the initiation of chemotherapy, immunotherapy, or 
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glucocorticoid therapy are effective in prevention119,120. Other rare viral causes of acute liver failure 
include herpes simplex virus, cytomegalovirus, Epstein–Barr virus, and parvoviruses108,118.   
1.6.3 Drug-induced liver injury 
DILI is responsible for approximately 50% of cases of ALD in the United States and Western 
Europe. DILI may be dose-dependent and predictable, as exemplified by acetaminophen-induced 
hepatotoxicity or can present as idiosyncratic, unpredictable, and independent of dose17,121. 
Although DILI can occur after consumption of a single excessive dose of a pharmaceutical, the risk of 
death is greatest with substantial drug ingestion staggered over longer periods of time rather than at 
a single time point. DILI is also a risk for patients on complex and extended drug regimens, particularly 
those taking acetaminophen for the relief of symptoms from hepatic illness or other 
causes. Malnourished patients and patients with alcoholism are at increased risk122.  
Idiosyncratic DILI is rare, even among patients who are exposed to potentially hepatotoxic medication; 
due to awareness and strict clinical monitoring practices. Factors such as an older age, increased 
elevations in blood aminotransferase and bilirubin levels, and coagulopathy are associated with an 
increased risk of death123.  
1.6.4 Other causes of acute liver disease 
Acute ischemic hepatocellular injury occurs in critically ill patients with primary cardiac, circulatory, or 
respiratory failure; often caused by severe sepsis124. This condition primarily requires supportive 
cardiorespiratory management rather than specific interventions targeted at the liver. The prognosis 
depends on both the cause of hepatic hypoxia and the severity of liver injury. A similar liver-injury 
pattern may also be seen in drug-induced liver injury caused by recreational drugs such as MDMA (3, 
4-methylenedioxy-N-methylamphetamine/ecstasy) or cocaine125. 
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Other causes of ALD are neoplastic infiltration, acute Budd–Chiari syndrome, heatstroke, toxic 
mushroom ingestion, and metabolic disorders such as Wilson's disease. ALD can occur during 
pregnancy due to the increased hepatic burden caused by the foetus126.  
1.6.5 Chronic liver disease 
Chronic liver disease (CLD) refers to a progressive destruction and regeneration of the hepatic 
parenchyma which results in fibrosis and cirrhosis, the thickening and scarring of the ECM and loss of 
functional liver cells. In contrast to ALD, this process takes place over a period of at least six months, 
and often many years. Clinically, CLD is reversible in some cases but only where diagnosed in the early 
stages. However, patients are often asymptomatic until the hepatic decompensation indicative of 
major loss of functioning liver tissue occurs. Approximately 40% of patients with late stage CLD are 
asymptomatic, and the condition is often discovered during routine laboratory or radiographic studies 
for other conditions, or at autopsy127. 
Global prevalence of CLD is estimated to be between 4.5% and 9.5% of the general population, and 
ranks 10th as a leading cause of death in developed countries, 14th globally. According to national 
morbidity statistics, CLD is the 5th leading cause of death in the UK and is estimated to reach the 3rd 
leading cause by 2020120. 
1.6.6 Chronic viral hepatitis 
Hepatitis B and C are precursors to CLD; similarly to that of ALD. Hepatitis B accounts for 0.34% and 
hepatitis C for 1.68% of all cases of CLD in the United States between 2005 and 2008 and chronic viral 
hepatitis is heavily implicated as a leading cause of CLD in developing regions and immigrant 
populations. Of the 12,656 death certificates that listed viral hepatitis in 2004, 42.6% listed hepatitis 
C as the underlying cause, and a total of 620,000 deaths were reported from HBV-related causes in 
2000 of which (94%) liver related. Similarly to ALD, if patients are not diagnosed with hepatitis B/C at 
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an early stage, the unmediated clinical progression of the virus leads to irreversible liver damage and 
is currently one of the main etiologic indications for liver transplantation128. 
1.6.7 Alcoholic liver disease 
Alcohol is consumed widely and for the majority of adult life; and has long been known to be a major 
risk factor for all liver diseases. According to the World Health Organisation (WHO), alcohol 
consumption accounts for 3.8% of global mortality. In 2010, alcohol-attributable liver cirrhosis was 
responsible for 493,300 deaths (156,900 female deaths and 336,400 male deaths); representing 0.9% 
(0.7% for women and 1.2% for men) of all global deaths. Alcohol is the primary etiological cause of 
liver-related death in Western Europe. France and Spain report approximately 30 deaths per 100,000 
per year are cause by alcoholic liver disease. Heavy alcohol consumption induces changes in lipid 
metabolism and an inflammatory response. This results in accumulation of lipids in hepatocytes called 
hepatic steatosis. Alcohol consumption and alcoholic liver disease also lead to hepatocellular 
carcinoma via a similar biological pathway120,129,130. 
1.6.8 Non-alcoholic fatty liver disease 
Non-alcoholic fatty liver disease (NAFLD) is a collective term for a group of conditions where there is 
an accumulation of lipid molecules in the livers of patients who drink moderately or not at all.  NAFLD 
affects 20-30% of the Western population and is largely asymptomatic; however incidence is rising 
rapidly with the concurrence of obesity in the developed world. NAFLD is predicted to affect 50% of 
the population by 2020120.  
5-6% of patients with NAFD worsen and develop non-alcoholic steatohepatitis (NASH), fibrosis, or 
cirrhosis. These individuals are at risk of liver failure in approximately 50% of cases. NAFLD is also a 
precursor to hepatocellular carcinoma; which the WHO estimates has an annual global incidence of 




1.6.9 Biliary obstruction 
Biliary obstruction can be cause by several factors, including gallstones, tumours, biliary atresia, cystic 
fibrosis and primary biliary cholangitis (PBC). Gallstones, insoluble collections of cholesterol, and 
tumours can cause physical obstruction of the bile ducts in the liver. PBC is an autoimmune disorder 
which results in progressive destruction of the small bile ducts of the liver. Biliary obstruction causes 
cholestasis; an accumulation of bile and other toxins in the liver and cholangiopathy; where the 
cholangiocytes of the bile ducts die, leading to inflammation and excess collagen deposition; blocking 
the bile ducts. Over time, the cholestasis and cholangiopathies lead to the fibrosis and cirrhosis typical 
of CLD124,131. 
In both Western Europe and the US, the incidence of PBC is estimated as 2-3 (peak incidence of 4-6 in 
women 40 years of age) and 21-40 (59-65 in adult women) per 100,000 persons per year, respectively, 
and mortality rate of 0.5 per 100,000 per year. Biliary obstruction was implicated in 16% of liver 
transplants between 1988 and 20142. 
1.6.10 Other causes of chronic liver disease 
CLD can also be caused by similar liver injury patterns to DILI, caused by long term use of 
acetaminophen, tramadol, cocodamol and concurrent use of heavy medication regiments such as 
those required for treatment of human immunodeficiency virus (HIV) and tuberculosis. Other causes 
include Alpha-1-antitrypsin deficiency, Wilson’s disease, Haemochromatosis, Tay-Sachs disease, 
Gaucher disease and Zellweger syndrome132.  
1.7 Cell based approaches for studying the liver 
There are several approaches being used to model the liver, study its biology and disease development 
and provide an alternative to increasingly rare donor livers for patient treatment. Cell culture studies 
form a key role in this narrative; informing our approach to liver tissue engineering. Liver cells can be 
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obtained from various sources and used in cell culture studies, in both 2D and 3D. These sources and 
their applications are summarized in table 1.2. 
Table 1.2; Cells for liver studies 
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1.7.1 Primary hepatocytes 
Primary human hepatocytes are considered the gold standard for studying the liver in vitro. They 
theoretically represent the closest researchers can come to the behaviour of a hepatocyte in vivo, 
however their availability is limited and their behaviour in culture  critiqued heavily by the field133. The 
majority are harvested from discarded cadaveric donor livers which are considered unsuitable for 
transplant and cryopreserved until they are needed for an experiment. Donor-donor variability, 
phenotypic instability over culture time and poor plateability/culture survival all compromise their use 
in routine testing and research. Using porcine primary hepatocytes overcomes the issues of availability 
and donor-donor variation; however they are subject to the same issues with phenotypic instability 
and deterioration over culture time. Rat and mouse primary hepatocytes can also be used, however 
their hepatic profile is markedly different to that of a human. It is commonly accepted that animal 
models of liver disease are not sufficient alone for the study of liver biology. Of 930 pharmacological 
compounds withdrawn from the market due to hepatotoxicity, only 17% demonstrated similar levels 
of toxicity in rodent and non-rodent studies134. Some conditions are impossible to replicate in animals; 
the human Hepatitis C virus does not infect rodents, only chimpanzees and tree shrew, and their 
clinical progression does not mimic that of the human disease135. Rodents metabolise alcohol much 
more rapidly than humans and do not develop severe liver fibrosis in response to alcohol toxicity130. 
As a result, while readily available; animal sources of primary hepatocytes do not provide results 
translatable to humans. 
1.7.2 Cell lines 
To combat the limitations and drawbacks of primary hepatocytes, researchers utilise cell lines. Cell 
lines are characterized by their unlimited proliferative abilities and stable phenotypes. They are readily 
available from manufacturers, are affordable and are easy to maintain in culture.  
Several tumour derived hepatocyte cell lines are used by researchers, including HepG2, HepC3A, 
Huh7, HepaRG, and Hep3B cell lines. Each hepatic cell line has been used in several experiments and 
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provided valuable data, however cell lines show a lower expression of drug metabolizing enzymes 
(CYPs) in comparison to primaries in culture and the human liver in vivo, thought to be a result of 
reduced transcription of enzyme genes 136. Additionally, drastic differences in the expression of key 
hepatic transcription factors and nuclear receptors observed in hepatoma derived cell lines in 
comparison to primaries/in vivo is thought to be linked to the reduction in CYP expression 137. HepG2s 
are derived from a hepatic carcinoma, which exhibit some of the required phenotypic traits of liver 
cells. However microarray studies have revealed significantly altered expression of over 5000 genes in 
comparison to primary cells and in vivo cells 138,139. HepC3As are derived from HepG2s but exhibit 
improved albumin and nitrogen metabolizing abilities 140. However, their lack of urea enzymes and 
drug metabolizing functions limits their use 137,141. The HepaRG cell line exhibits an expression pattern 
closer to that of primaries and in vivo in confluent cultures 142. Proliferating HepaRGs can be treated 
with dimethyl sulphoxide (DMSO) to force them towards a more primary/in vivo like phenotype and 
express higher levels of CYP3A4, however their gene expression of CYPs is still generally lower than 
the primaries. Huh7s can also be cultured for several weeks to produce higher levels of CYP3A4, and 
unlike HepaRGs this is done without differentiation inducers such as DMSO 143.  
Non-tumour derived cell lines can also be used. These cells are generally immortalized via gene 
transfer of the simian virus 40 (SV40) T antigen 144,145 but immortalizing can also be obtained by co-
transfection of albumin-promoter-regulated antisense constructs and transcription factors E2F and 
D1 cyclin 146. THLE-3/2 and Fa2N4 cell lines both exhibit induction of the major CYPs, however their 
enzyme activity is very low and only detectable using very sensitive analytical methods. More 
advanced genetic engineering methods have produced cell lines with reversible immortalization, using 
Cre-loxP excised oncogenes and suicide genes. The NKNT-3 hepatocyte line and non-parenchymal 
lines HNNT-2 (endothelials), TWNT-1 (stellates) and MMNK-1 (cholangiocytes) were all immortalized 




1.7.3 Embryonic stem cells and induced pluripotent stem cells 
Embryonic stem (ES) cells are so prized by researchers for their pluripotency; their ability to proliferate 
indefinitely and differentiate fully into any tissue. However, due to obvious ethical issues surrounding 
the use of human ES cells, researcher most often use mouse ES cells. These cells have been used in 
BAL devices, and several reports of differentiation protocols for hepatocytes exist 147–150; however 
none have been used at the scales required to produce a replicate of a human liver. Equally, the need 
for the use of Matrigel in such protocols introduces a further limitation to their use; Matrigel the trade 
name for an ECM product derived from Engelbreth-Holm-Swarm mouse sarcoma cells. Matrigel’s 
manufacturers cannot guarantee batch consistency of the product, and the risk of introducing mouse 
viruses from the Matrigel is a concern. 
Induced pluripotent stem cells (iPSCs) go some way to alleviate the concerns associated with ES cells. 
By circumventing the ethical concerns regarding cell source and using human cells to avoid the 
immunological challenges presented by animal sources, iPSCs present a potentially limitless source of 
stem cell derived hepatocytes151–155. However, the hepatocytes performance is not yet at the level of 
primary or in vivo cells, and differentiation protocols remain costly, lengthy and laborious.   
1.7.4 Adult stem cells 
Adult stem cells have been used in BAL devices and transplantation studies. They rely upon the trans-
differentiation of mesenchymal stem cells (MSCs) sourced from various adult, live donor tissues to 
hepatocyte-like cells. MSCs can be injected into the liver and subsequently transdifferentiate into 
hepatocyte-like cells in the liver. Use of adult stem cells circumvents ethical and immunological issues 
posed by other cell types, however inappropriate differentiation info myofibroblasts is observed at 
the injection sites. There are multiple in vivo differentiation protocols available to researchers for 
MSCs, however, as with iPSCs the protocols are costly, lengthy, laborious and are yet to produce a 
fully differentiated and stable human hepatocyte, limiting their translatability for clinical use 21,82,156. 
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1.7.5 Hepatic progenitor cells 
Hepatic progenitor cells are quiescent stem cells which reside in the liver at low numbers in a healthy 
state. Anatomically, these cells reside in the area called canals of Hering, which are terminal branches 
of biliary trees, and produce a mixture of the molecular markers of adult hepatocytes, cholangiocytes 
and foetal hepatoblasts. In cases of prolonged injury or inflammation of the liver, hepatic progenitor 
cells begin proliferating and subsequently differentiating into hepatocytes and cholangiocytes 157. 
Hepatic progenitor cells have been used in transplant studies in mice, and results are promising, 
however marker analysis indicates that the progenitor cell population is not homogenous and cells 
vary in their differentiation capacity, lineage potential and stage of differentiation. This, and the 
challenges associated with isolating the small number of progenitor cells in the liver, as well as their 
potential for producing cancer and their links with hepatocellular carcinoma limits their clinical 
application70,158. 
1.7.6 Human foetal hepatocytes 
Whereas adult hepatocytes are limited in their proliferative abilities, human foetal hepatocytes can 
divide multiple times in vitro, and have been immortalized by SV40 large T antigen and hTERT 
transfection to ensure researchers have an unlimited supply. These cells have been used in culture 
and transplantation studies, however the exhibit particularly limited urea production and ammonia 
clearance when compared with primary and in vivo hepatocytes. Additionally, when used in BAL 
devices, foetal hepatocytes are not functionally mature enough for clinical use. Transplantation 
studies have had promising early results, however ethical considerations regarding the use of foetal 







Hepatoblasts are similar to human foetal hepatocytes, however are isolated at an earlier stage of 
gestation and as such possess extensive proliferative abilities in vitro. They, like hepatic progenitor 
cells, can differentiate into both hepatocytes and cholangiocytes in in vivo conditions, and animal 
studies indicate that the hepatoblasts integrate into injured livers and proliferate to renew the liver 
mass. However, as with other stem and foetal derived cells, ethical issues and availability, as well as 
challenging differentiation protocols in vitro present researchers with challenges for their clinical 
translation45,68. 
1.7.8 Hepatocyte-like cells 
Advances in genetic modification, and particularly the advent of precise tools such as CRISPR gene 
editing has allowed researchers to generate adult cells which express hepatocyte transcription factors 
and functional genes; known as hepatocyte like cells or iHeps. iHeps were able to express hepatic 
genes and undertake hepatic functions and were able to engraft and reconstitute hepatic tissue in 
mice. By utilising tools like genetic engineering, researchers bypass the complex and costly 
differentiation protocols required for stem cells, and potentially create an unlimited and ethically 
preferable source of hepatocytes145,150–152. However, concerns regarding the longevity of their gene 
expression and their phenotypic drift away from a hepatocyte profile, as well as the recent discovery 
that tools like CRISPR can cause non-target mutations requires further research163–165. 
1.8 Tissue engineering of the Liver 
Traditional cell culture is undertaken in 2D, with cell monolayers grown on flat, polystyrene tissue 
culture plastic dishes. The knowledge gleaned from these cultures in invaluable and has formed the 
basis of biological studies since Ross Granville Harrison developed cell culture methods in 1910. 
However, researchers increasingly recognise the artificial environment which 2D cell culture results in 
has an immeasurable impact upon cells, skewing results and altering everything from their metabolic 
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profiles to their protein production. Liver cells are known to respond to their 3D microenvironment, 
altering their albumin and urea production, ammonia clearance, and CYP expression in response to 
their culture environment8,28. The rapid functional deterioration of primary hepatocytes and 
hepatocytes derived from other sources is a result of their artificial environment in culture. As a result, 
bioengineers are focussing on creating new niche microenvironments for optimising and altering 
hepatocyte behaviour and performance15,166. Hepatocyte function is highly plastic and regulated by 
the surrounding ECM, extracellular signalling molecules, cell-cell interactions and the mechanical 
influence of their environment; none of which researchers have yet fully elucidated the effects of. As 
a result, bioengineers are also attempting manipulations which are not explicitly ‘biomimetic’ or 
recapitulating physiological conditions but still influence hepatocyte behaviour. 
Various methods have been employed to mediate this functional deterioration. Arginine free 
media167, culturing with various growth factors and DMSO145, on collagen membranes168–170, with 
Matrigel75,171,172 and on various ECM materials18,28,173,174 have all been shown to influence hepatocyte 
function. Devices mimicking the hepatic shear environment, architecture mimicking that of the 
hepatic lobules and perisinusoidal space and co-culture of hepatocytes with non-parenchymal cells 
have also shown promise52,175–178. These methods can be broadly summarised as shown in table 1.3. 
Table 1.3; Tissue engineering of the liver 
Environment Techniques Advantages Disadvantages 
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1.8.1 Scaffold free 3D culture techniques 
Thus far, the most common non-scaffold based 3D culture methods have been sandwich culture, co-
culture of hepatocytes with non-parenchymal cells and spheroid formation. The complex 3D 
interaction involving of parenchymal cells, non-parenchymal cells and the ECM is believed to be crucial 
in regulating and maintaining hepatic function in vivo; particularly with regard to influencing 
hepatocyte polarization. Polarization of hepatocytes induces a distinct pattern if transporter protein 
expression on each of the cell ‘faces’ and is lost in many 2D and 3D cultures. Sandwich cultures; where 
hepatocytes are cultures between two layers of ECM, often collagen I or Matrigel, have been 
employed to maintain this polarization. In this type of model, cell–matrix adhesion from above and 
below reduces abnormal cytoskeletal flattening and maintains cell–cell contact between adjacent 
hepatocytes. By promoting polygonal hepatocyte morphology for extended culture periods and 
improving functionality sandwich cultures with matrix proteins can lead to prolonged hepatocyte 
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viability179,180, extended CYP activity181,182 and increased cell polarization toward more advanced bile 
canaliculi networks. Co-culture with non-parenchymal cells of the liver is also key to hepatocyte 
function. Kupffer cells, hepatic stellate cells and sinusoidal endothelial cells have all been used in 
culture with hepatocytes and are found to be superior when sourced from hepatic tissue; as opposed 
to traditional ‘feeder layer’ style co-culture where co-cells are sourced from other more readily 
available sources such as epidermal fibroblasts60,177,183. Ratios of NPCs to hepatocytes has also been 
shown to influence hepatocyte function52. In general, an improvement in hepatocyte function and 
maintenance of hepatic phenotype is achieved irrespectively of the type of cell used for co-culture. 
Culturing hepatocytes in conditions which promote aggregation into ‘spheroids’ also influences the 
hepatocytes functionality; with breakthrough research postulating that 3D cytoarchitecture and the 
increased number of homotypic cell-cell contacts between hepatocytes is key to improving the 
phenotype and function of cultured hepatocytes 44. However issues with the scale up of spheroid 
cultures, as well as longevity of the cells and necrosis due to insufficient oxygen diffusion to the centre 
of spheroid cultures continue to plague the field. Numerous methods including casting arrays, 
rotational cultures and encapsulation have been developed for the optimization and scale-up of 
hepatocyte spheroid culture153,184,185.  
1.8.2 Micropatterning and bioprinting 
The recent explosion in 3D printing technologies brought about by the 2014 expiration of key patents 
has led to a rapid expansion of applications; including bioprinting and micropatterning of smaller 
tissue features such as hepatic lobules186. Current research in tissue engineering focuses on the 
development of compatible methods (printers) and materials (bioinks) that are capable of producing 
biomimetic scaffolds, vascular structures and cell encapsulation187. Organovo’s exVive3D™ Liver is a 
bioprinted human tissue that has been used to provide toxicity assessments to supplement in vitro 
and preclinical animal testing 17,188. Several groups have reported their novel liver bioinks improver 
hepatocyte function. Combinations of gelatin-chitosan, agarose-collagen and agarose-chitosan have 
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been employed, as well as decellularized liver ECM and collagen I 189,190.  A liver-on-a-chip platform has 
been developed by with hepatic spheroids fabricated via direct write bioprinting using gelatin 
methacryloyl in a microfluidic bioreactor device. Micropatterned grids of collagen-chitosan hydrogels 
containing a hepatic cell line and hepatocyte growth factor (HGF) 191 have been implanted into nude 
mice, demonstrating the translatability of bioprinted liver tissue however concerns exist regarding the 
safety of crosslinking methods used to stabilise the bioinks and the longevity of cells encapsulated 
within due to reduced oxygen diffusion through larger constructs 192.  
1.8.3 Scaffolds 
The shortcomings of other 3D culture methods for hepatocytes have prompted a push for scaffolds 
for liver tissue engineering. Such scaffolds would be replicable and provide the 3D structure requires 
to prompt hepatocytes into the desired phenotypic behaviour, as well as overcome concerns 
regarding the transplantation of unanchored, ‘free’ cells into human patients. Researchers have used 
hydrogels193,194, ECM proteins173,195 and polymers28,196,197 to provide 3D environments for hepatocytes; 
be they biomimetic or otherwise, as well as to elucidate the effect of architecture upon hepatocyte 
function in a controlled manner. Researchers have reported altering hepatocyte function and 
maintaining hepatic differentiation using hydrogels and using electrospun polymers, both with and 
without ECM proteins. RegeneMed 3-D Liver is a liver tissue co-culture system used for screening 
hepatic ADME, using culture transwells with a nylon mesh. NPCs are seeded in a nylon screen 
sandwich mesh insert with hepatocytes to form a 3D liver tissue. Liver-specific functions, including 
production of albumin, fibrinogen, transferrin and urea, can be maintained up to three months, and 
the induction of CYP1A1, 2C9, and 3A4 activity for two months198. Co-culture with Kupffer cells allows 
for study of the inflammatory response as the release of pro-inflammatory cytokines can be observed 
with lipopolysaccharide (LPS) exposure199. Encapsulating hepatocyte co-cultures (hepatocytes, HSCs 
and SECs) in collagen-alginate hydrogels was shown to maintain their spheroidal shape, sinusoid-like 
structures, high viability and stable liver-specific functions for more than 1 month 44. Collagen-
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functionalized microsphere-template poly(ethylene glycol) (PEG) hydrogel scaffolds were shown to 
promote 3D hepatic sheet morphology; leading to improved albumin production and CYP450 activity 
as well as enhanced gene expression of cell-adhesion markers which stimulated innate hepatocyte 
fibronectin production200. Non-woven mesh scaffolds were created via total esterification of 
hyaluronan with benzyl alcohol (HYAFF-11), and seeded with fibroblasts which were subsequently 
decellularized to leave behind a hybrid ECM:HYAFF-11 scaffold201. Rat hepatocytes demonstrated 
higher proliferation rates and in vitro cell survival up to 4 weeks after seeding in hybrid scaffolds as 
opposed to HYAFF-11 alone scaffolds, and those seeded on hybrid scaffolds showed cells with a 
polyhedral morphology and establishing cell–cell contacts. Inverted colloidal crystal (ICC) microporous 
scaffolds were functionalized with fibronectin or collagen and shown to promote albumin production 
and liver-specific gene expression of Huh7.5 cells, compared with bare ICC scaffolds; and displayed 
differing aggregation patterns on fibronectin vs collagen functionalized ICC; possibly due to the 
distinct mRNA expression levels of cell adhesion-related genes and their interaction with liver specific 
genes197. Specific polymers also have an influence on hepatocyte function; with screening libraries for 
novel polymers revealing differing effects on differentiation and phenotypic behaviour of 
hepatocytes202,203. Scaffold stiffness has also been investigated with regard to primary hepatocyte 
function; those cultured on softer heparin gels with a low modulus of 11kPa demonstrated higher 
albumin synthesis and E-cadherin expression than those cultured on 26kPa and 116kPa gels, however 
this paper failed to properly disentangle the influence of heparin concentration on the hepatocytes 
204,205. Scaffold development is a rapidly evolving field, with promising results thus far however more 
targeted research for the future would add value to the field; elucidating the influence of mechanical 
changes, ECM proteins and scaffold morphology on hepatocyte function.  
1.8.4 Decellularized organs 
Decellularization refers to the process of removing cellular material to leave behind the surrounding 
ECM, and can be used to provide a niche environment for cells to repopulate206. In the case of whole 
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organ decellularization; the vascular network and ECM micro and nanoarchitecture are potentially 
maintained within the ECM and can provide vital cues to the repopulating cells. Decellularization 
removes potentially immunogenic components such as intracellular protein and DNA while 
maintaining the multifaceted ultra- structure and composition or bodies within the ECM, such as the 
sinusoids207. There is also strong evidence that ECM is a complex reservoir for growth factors and 
cytokines, the selective accumulation and release of which are important for robust cell growth, 
Recent publications by the Badylak group show evidence for microvesicle reservoirs of such factors 
being both present in the ECM and being tissue specific208–210. The first decellularized liver and its 
potential for hepatocyte survival was reported in 2004, by Lin et al.211  Since then, a multitude of 
decellularization methods have been reported; including freeze/thaw cycles, immersion and agitation, 
and perfusion. Most protocols make use of a combination of detergents such as sodium dodecyl 
sulphate (SDS) and Triton-X100, pH disrupting agents such as ammonium hydroxide and enzymes 
including trypsin and pepsin with the various physical methods and aim for a remnant DNA 
concentration of 50ng/mg, <200bp DNA fragment length and a lack of visible nuclear content when 
visualised with DAPI (4′,6-diamidino-2-phenylindole) or hematoxylin and eosin (HE) staining ; criteria 
proposed by leading researchers212 as the acceptable conditions for a decellularized tissue to minimise 
risk of immune response in recipients. 
Various protocols have been proposed for the decellularization and recellularization of liver tissue. 
However none to date have proven perfect for hepatocytes upon repopulation, and while they provide 
invaluable data for researchers; they still require a source of rare donor organs or require the use of 
animal tissue. Equally, a lack of uniformity in experimental parameters and cell type used for 
repopulation is limiting the field’s knowledge. More targeted approaches to the process, and co-
operation between both research groups and industry is required before researchers can truly reap 




1.8.5 Perfusion devices and microfluidic devices 
Hepatocytes and NPCs are known to be influenced by mechanical influences including shear stress 
and velocity of media flow. The incorporation of continuous flow into a culture system is known to 
facilitate more in vivo-like active transport of oxygen, nutrients and metabolites, as well as influence 
hepatocyte specific functions such as albumin production, urea synthesis and CYP drug metabolism 
activity. As a result; some groups are working on developing benchtop lab scale and microfluidic 
devices which expose cells to flow of media and nutrients. One of the main issues during the 
development of these devices is the balance between flow and shear stress applied to hepatocytes. 
The dynamic environment in the liver is particularly complex, with a dual circulatory system providing 
oxygen and nutrient flow to the hepatocytes and non-parenchymal cells; the portal vein and hepatic 
artery. Pressure in the portal vein measures between 4 and 10 mmHg, with a low pO2 of 30 to 40 
mmHg. In contrast, pressure in the hepatic artery hovers around 120 mmHg in a healthy individual, 
with the pO2 measuring 90-100 mmHg63,214.  Hepatocytes are extremely sensitive to oxygen 
concentrations and have a high metabolic demand which infers that they would respond well to high 
flow rates, however they are also vulnerable to shear stress exceeding 0.03 Pa215–217. Hollow fibre 
bioreactors are a popular choice for hepatocyte culture; with one group demonstrating that with only 
0.5ml of media and 20 x 106 cells they can maintain enzymatic activity and gene expression of CYP1A2, 
CYP3A4/5, CYP2C9, CYP2D6, CYP2B6, transporters, and phase II enzymes for up to 3 weeks218–220. 
Another method of controlling the shear hepatocytes are exposed to is the multichamber modular 
bioreactor, such as those made by Quasi-Vivo®. Different cell types can be cultured in the chambers 
and connected to each other. Interaction between the different chambers is reliant upon soluble 
molecules in the cultivation medium, enabling the imitation of exchange between different tissues – 
imitating the organs of the human body. In the liver module of the Quasi-Vivo® system CYP1A1, 1A2, 
2B6, 2C9, 3A4, UGT, MDR1, and MRP2 reached expression levels close to or above those of freshly 
isolated hepatocytes after two weeks of culture221. However, as in other silicone and PDMS based 
systems, high substrate adsorption can lead to incorrect data interpretation and subsequent errors in 
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analysis222. Microfluidics also provides an avenue for exposing hepatocytes to the challenging flow and 
shear environments required to optimize their phenotypic profile. Banaeiyan et al demonstrated that 
HepG2s and iPSC derived hepatocytes stabilized albumin secretion and urea synthesis when cultures 
under flow in microfluidic devices22. The hepatocytes also developed 3D tissue-like structure and 
immature bile-canaliculi networks in the chips. HepaChip® mimics hepatic sinusoids on a microscope 
slide; with eight micro-chambers containing three cell assembly ridges with the length and width of a 
human liver sinusoid, and electrodes to enable accurate cell positioning. In short term experiments (3 
hours), hepatocytes exhibited significantly higher activity of both CYP3A4, CYP1A2, and phase II 
enzymes than hepatocytes co-cultivated in 96-well plates in the presence of endothelial cells223–225. 
Arguable however, 96 well plates are not an appropriate control for the experiment and while low 
media volumes and low required cell numbers are an advantage, the system is highly complex to 
operate and as such is yet to be widely used.  
1.8.6 Bioartificial liver devices 
Bioartificial liver devices such as the Extracorporeal Liver Assist Device (ELAD) and HepatAssist 
incorporate hepatocytes into a purely mechanical, dialysis-based artificial liver support device. Other 
systems include the Modular Extracorporeal Liver Support (MELS), the Amsterdam Medical Centre 
Bioartificial Liver (AMC-BAL), and the Bioartificial Liver Support System (BLSS). With no reliable source 
of high quality human hepatocytes readily available for these systems, they rely upon a variety of cell 
sources and techniques to detoxify waste molecules such as ammonia, provide synthetic function of 
albumin and coagulation factors, decrease inflammation, and promote cell regeneration108,226,227. 
1.9 Summary 
To summarise, great progress is being made to establish an unlimited source of human hepatocytes; 
via iPSC and ESC work results as well as provide more appropriate cell lines for study such as iHeps 
and HepaRGs. The field now recognises the importance of conducting studies in 3D and limiting 
judgement of 2D derived results, and steps are being taken to provide 3D shear environments for 
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hepatic cells to study their interactions and metabolism; particularly spheroids and devices such as 
Kirkstall’s Quasi-Vivo® system and the HepaChip® system. However, the field of liver tissue 
engineering is heterogeneous and somewhat fragmented in its approach. Issues with historical use of 
products such as Matrigel® and inappropriate extrapolation of results from tissue culture plastic 
experiments have led to an unclear picture of the behaviour of hepatocytes in 3D environments and 
in vivo. This project therefore aims to use engineering to influence the behaviour and function of 







































Electrospinning is a method by which ECM-mimicking fibrous mats can be created by drawing fibres 
from a polymer solution. A high positive voltage is applied to the polymer solution, and the solution is 
extruded through a needle. The target surface is grounded or has a negative voltage applied to it, and 
fibres are drawn from the “Taylor cone”, which forms at the tip of the needle due to the electric field, 
towards the target where they accumulate on the surface. The voltages, flow rates, collection 
surfaces, humidity/temperature  and choice of polymer:solvent and their respective concentrations 
can all be varied to produce different fibres11,228. 
Figure 2.1; Electrospinning schematic 
 
Figure 2.1; Representation of electrospinning method 
 
All fibres were collected on a rotating mandrel covered with aluminium foil at room temperature. 
Polycaprolactone (PCL) (Mn=80,000 Da) was purchased from Sigma-Aldrich, UK, and polylactic acid 
(PLA) from Goodfellow, UK. Although no information regarding molecular weight is available PLA, 
Goodfellow has been used previously and shown to be comparable to the more commonly used 
Sigma-Aldrich PLA 229. The solvent 1,1,1,3,3,3-hexafluoro-2-isopropanol (HFIP) was purchased from 
Manchester Organics, UK. Information regarding purity was requested with each batch to ensure it 
was comparable to Sigma-Aldrich HFIP, which is commonly used for electrospinning. All 
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electrospinning solutions were mixed using a roller mixer (SRT9D, Stuart, UK). The mixing speed was 
kept consistent at 50 RPM, and all mixing was performed at room temperature. Measurements of 
fibres were undertaken using the ImageJ plugin, DiameterJ 230. 
2.2 Scaffold sterilisation 
There are several sterilisation techniques available for scaffolds, including the use of 70% ethanol 231. 
70% ethanol has been adopted as the lab standard of sterilisation, as it rapidly kills many different 
types of bacteria within 10 seconds 232. Ethanol sterilisation has been shown to be as effective as more 
complex methods of sterilization. Researchers have demonstrated that plasma treatment alone is an 
insufficient sterilization method, but that it does enhance the adhesive properties of PCL. By following 
plasma treatment with ethanol sterilisation, the water contact angle will be reduced due to the 
reaction of modified PCL groups with ethanol molecules; resulting in lower cell proliferation 233. 
Subsequently, ethanol sterilisation was performed prior to plasma treatment on PCL scaffolds.  
PLA is not sterilised using ethanol due to its solubility and as such isopropanol was used to sterilise 
PLA scaffolds. Isopropanol has been shown to be as efficient as ethanol sterilisation within the same 
time frame 234.  
Electrospun scaffolds were cut out using a rubber mallet and a 10mm biopsy punch, placed on a 
cutting mat. PCL scaffolds were soaked in 70% ethanol for 30 minutes, rinsed three times in phosphate 
buffered saline for 15 minutes each and allowed to dry completely at room temperature. The scaffords 
were freeze dried overnight in a FreeZone® 4.5 freeze-drier (Labconco®) before oxygen plasma surface 
coating (Harrick Plasma) at 10.2W for 30 seconds. Scaffolds were removed from the plasma chamber 
and placed into an antibiotic/antimycotic treatment solution of Eagles Minimal Essential Media 
supplemented with 10% foetal bovine serum, 2mM L-glutamine and 100U/ml penicillin, 100µg/ml 
streptomycin, 0.25µg/ml Fungizone® (amphotericin B) Anti-Anti solution (Gibco) for 1 hour.  
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PLA scaffolds were soaked in 70% isopropyl alcohol for 10 minutes, rinsed three times in phosphate 
buffered saline for 15 minutes each and allowed to dry completely at room temperature. Scaffolds 
were placed into an antibiotic/antimycotic treatment solution of Dulbeccos Minimal Essential Media 
supplemented with 100U/ml penicillin, 100µg/ml streptomycin, 0.25µg/ml Fungizone® (amphotericin 
B) Anti-Anti solution (Gibco) for 1 hour. 
2.3 Oxygen plasma surface coating 
Oxygen plasma surface coating is performed under low pressure oxygen, argon or normal atmospheric 
composition (air). A high frequency voltage is applied to the coil of a chamber containing this low-
pressure gas. This induces the ionization of molecules creating highly reactive free radicals. The 
presence of oxygen will result in the formation of oxygen containing groups on the surface of the 
scaffold, rendering the scaffold hydrophilic and sterile for as long as they are stored under sterile liquid 
conditions233. Hydrophobic recovery may take place if stored in air as these groups reorient from the 
surface into the bulk of the polymer; hence oxygen plasma surface coating was performed 
immediately before use.  
A Harrick Plasma cleaner and PlasmaFlo gas flow mixer (PPC-FMG-2, Harrick Plasma) were used to 
increase the hydrophilicity of the PCL scaffolds for cell culture. Initial pressure was lowered to 250-
400 mTorr before introducing O2, pressure was stabilised at 500-550 mTorr and medium power (10.2 
W) was applied for 30 seconds. Scaffolds were immediately submerged in antibiotic/antimycotic 
treatment solution of Eagles Minimal Essential Media supplemented with 10% foetal bovine serum, 
2mM L-glutamine and 100U/ml penicillin, 100µg/ml streptomycin, 0.25µg/ml Fungizone® 
(amphotericin B) Anti-Anti solution (Gibco) for 1 hour; preventing hydrophobic recovery. 
2.4 Decellularization 
The ECM is a known repository of growth factors and bioactive cryptic peptides which possess a 
diverse range of biological activities such as angiogenesis235, anti-angiogenesis236, antimicrobial237 and 
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chemotactic208 effects, as well as the complex macro and micro structure necessary for tissue 
function6,53. Several methods of decellularization have proven successful for liver tissue, including 
perfusion with detergents, enzymes, freeze thaw cycles and pH extremes30. The method chosen for 
decellularization is important, with the effects of inefficient decellularization and/or the use of overly 
harsh methods to achieve decellularization adversely affecting the ECM. Remnant cellular 
components left within the ECM or disruption of the architecture and growth factor content by 
excessive processing have been shown to promote a proinflammatory process which adversely affects 
cells downstream. Equally, chemical crosslinking methods used to mask cellular epitopes and/or to 
increase mechanical properties in many commercially available products significantly disrupts the 
ligand landscape of the material and prevents the release of cryptic peptides from the matrix material 
98,238–240. Differing decellularization agents have a differing effect on the ECM. The most effective 
agents for decellularization of each tissue depends on the tissue's cellularity, density, vascularity, lipid 
content and thickness 241. Each decellularization method will alter ECM composition and cause some 
degree of ultrastructure disruption. Minimization of these undesirable effects rather than complete 
avoidance is the objective of decellularization. 
All detergents, whether ionic, non-ionic or zwitterionic solubilize cell membranes and dissociate DNA 
from proteins, thus removing cellular material from tissue 242. A blinded comparison of detergents for 
peripheral nerve decellularization showed better preservation of ultrastructure by non-ionic and 
zwitterionic detergents but better cell removal by ionic detergents, however a low number of cell 
bodies in nerves limits the translation of the findings 243. While Sodium Dodecyl Sulphate (SDS) is 
effective in removing cell nuclei while preserving tissue mechanics; it has the associated drawback of 
ultrastructure disruption and growth factor reduction 213,244. Triton X-100 can effectively remove cell 
residues from thicker tissues where enzymatic/osmotic methods are insufficient, with the resulting 
ECM protein loss mediated by decreased adverse immune response in vivo 245. Care should be taken 
to rinse the tissue clean of residual chemicals following decellularization; particularly in the case of 
detergents. Cytotoxicity is observed at even low concentrations of residual detergent and will inhibit 
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recellularization 246. Ultimately, the decision on which decellularization detergent to use is a balancing 
act of desirable and undesirable outcomes. Triton X-100 was used to decellularize hybrid ECM:polymer 
scaffolds due to its effective removal of cell nuclei observed following titration and its recorded ability 
to reduce adverse immune response in vivo. SDS was used to decellularize human liver tissue as it is 
highly effective at removing all cellular material from organs. 
Decellularization is deemed successful where three criteria are met; less than 50ng of remnant DNA 
per mg of dried tissue, each of those fragments being less than 200bp in size and no visible DAPI 
staining one the decellularized tissue.  
Decellularization of hybrid ECM:Polymer scaffolds was performed using methods adjusted from Lu et 
al. (2012), under sterile conditions at room temperature (19 - 22°C) and agitation. Scaffolds were 
washed in phosphate buffered saline (PBS) for 15 minutes and then rinsed in 10mM tris buffered saline 
(TBS) for 15 minutes.  
The scaffolds were submerged in a 0.1% vol/vol Triton X-100 (Sigma-Aldrich) 1.5M potassium chloride 
(Acros Organics) 50mM TBS for 4 hours. They were rinsed for 15 minutes in 10mM TBS before being 
submerged in fresh 10mM TBS overnight. 
Scaffolds were given a final rinse in 10mM TBS for 15 minutes before being incubated in complete 
media for 15 minutes and then transferred to new 48 well plates for seeding. 
Decellularization of human liver tissue was performed at room temperature (19 – 22°C) in a custom 
made perfusion decellularization system (Fig 2.2).  Tissue was sliced into 3mm thick sections and 
35mm diameter punches resected from the sections. 
Tissue discs were placed in the decellularization device and secured between discs of 70µm stainless 
steel filtration mesh. A peristaltic pump (Watson Marlow 302 fixed speed pump) provided a flow rate 
of 200ml/min. Pressure was adjusted to 24mmHg using plasson pipes. 
44 
 
Tissue was subjected to an initial 4 hours of decellularization using 1L of 0.5% sodium dodecyl sulphate 
(Sigma) in MilliQ H2O with 0.1% 100U/ml penicillin, 100µg/ml streptomycin, 0.25µg/ml Fungizone® 
(amphotericin B) Anti-Anti solution (Gibco). After 4 hours, the decellularization solution was 
exchanged for fresh solution and the system ran overnight under the same conditions. The tissue was 
then washed with MilliQ H2O with 0.1% 100U/ml penicillin, 100µg/ml streptomycin, 0.25µg/ml 
Fungizone® (amphotericin B) Anti-Anti solution (Gibco) for 4 hours and stored in sterile containers at -
20℃ until use. 




Figure 2.2; Photograph and accompanying schematic of decellularization device which maintains 
pressurized flow to effectively decellularize tissue biopsies. Scale bar = 10cm. 
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2.5 Blending proteins for electrospinning 
To ensure equal distribution of the ECM proteins throughout the electrospun scaffold, decellularized 
ECM was suspended in 0.25M acetic acid. Acetic acid damages collagen fibrils to solubilize the ECM, 
with a corresponding reduction in ECM strength, but it does not affect sulfated glycosaminoglycans 
(sGAG)248 and produces cryptic peptides as a by-product of solubilisation; including the Arg-Gly-Asp 
(RGD) peptide derived primarily from fibronectin, collagen, vitronectin, and osteopontin 241. The RGD  
peptide has been used to promote cell adhesion to synthetic substrates 187,249,250.  
The decellularized ECM was lyophilized in a FreeZone® 4.5 freeze-drier (Labconco®) before milling in a 
PM100® planetary ball mill (Retsch®).  
The powdered ECM was solubilized in 0.25M acetic acid (Acros Organics) at a concentration of 25µg 
per ml. Bornstein and Traub Type I collagen (Sigma Type VIII) powder from human placenta, human 
recombinant laminin 521 (Biolamina), and human plasma fibronectin (Merck) were all solubilized and   
incorporated into the electrospinning solutions using the same methods. A control scaffold consisting 
of polymer only in the 9:1 HFIP:0.25M acetic acid was also fabricated.  
2.6 Culture of HepG2s 
HepG2 cells are a cell line derived from the hepatocellular carcinoma of a 15 year old Caucasian male. 
According to the supplier (ATCC), HepG2 cells express many of the phenotypic characteristics of 
hepatocytes, including α-fetoprotein, albumin, α-2 macroglobulin, α-1 antitrypsin, transferrin, α-1 
antichymotrypsin, haptoglobin, ceruloplasmin, plasminogen, C4 complement, C3 activator, 
fibrinogen, α-1 acid glycoprotein, α-2 HS glycoprotein, β-lipoprotein and retinol binding protein. They 
are nontumorigenic when injected into immunosuppressed mice, however they do produce tumours 
in semisolid media. They also possess a rearranged chromosome 1138. 
The cells were grown in non-coated culture flasks using Dulbeccos Minimal Essential Media 
supplemented with 10% foetal bovine serum, 2mM L-glutamine, 100U/ml penicillin and 100µg/ml 
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streptomycin (all Gibco). They were split when they reached 70% confluence and replated at 1:4 ratios 
using 0.05% Trypsin-EDTA (Gibco). 
2.7 Culture of THLE-3s 
THLE-3 cells are a cell line derived from normal primary liver cells derived from the left lobe of a human 
liver. The cell line was immortalized via infection with SV40 large T antigen; generated by introducing 
a retroviral vector containing the of BglI-HpaI fragment of SV40 T antigen into the amphotropic 
packaging cell line PA317.  According to the supplier (ATCC), THLE-3 cells express the phenotypic 
characteristics of normal adult liver epithelial cells. They are nontumorigenic when injected into 
athymic nude mice, have near-diploid karyotypes, and do not express alpha-fetoprotein. THLE-3 cells 
metabolize benzo (a) pyrene, N-nitrosodimethylamine, and aflatoxin B1 to their ultimate carcinogenic 
metabolites that adduct DNA, which indicates that they possess functional cytochrome P450 
pathways. Other enzymes involved in metabolism of chemical carcinogens, such as epoxide hydrolase, 
NADPH cytochrome P450 reductase, superoxide dismutase, catalase, glutathione S-transferases, and 
glutathione peroxidase are also retained144,251. 
The cells were grown in culture flasks coated with 100µg/cm2 gelatin (Sigma) using Dulbeccos Minimal 
Essential Media supplemented with 10% foetal bovine serum, 2mM L-glutamine, 100U/ml penicillin 
and 100µg/ml streptomycin (all Gibco), 5ng/ml human epithelial growth factor (Corning)., 70ng/ml 
human insulin (Sigma) 70ng/ml phosphoethanolamine (Sigma) and 70ng/ml hydrocortisone (Sigma). 
They were split when they reached 70% confluence and replated at 1:3 ratios using 0.05% Trypsin-
EDTA (Gibco). 
2.8 Culture of 5637 bladder epithelials 
The 5637 bladder epithelial cell line is derived from the grade II bladder carcinoma of a 68 year old 
Caucasian male. The cells are tumourogenic, and produce tumours in nude mice within 21 days of 
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subcutaneous inoculation with 1 x 107 cells in 100% of cases (5/5). One, or occasionally two, Y 
chromosomes is present in each cell252. 
The cells are grown in non-coated culture flasks using Dulbeccos Minimal Essential Media 
supplemented with 10% foetal bovine serum, 2mM L-glutamine, 100U/ml penicillin and 100µg/ml 
streptomycin (all Gibco). They were split when they reached 70% confluence and replated at 1:6 ratios 
using 0.05% Trypsin-EDTA (Gibco). 
2.9 Transfections 
Transfection is the process of artificially introducing nucleic acids (either RNA or DNA) into eukaryotic 
cells, by methods other than viral infection. Transfection is most commonly performed to express a 
protein of interest in cultured cells (or an animal model) through the use of a plasmid vector or mRNA. 
Most commonly, researchers use physical methods such as electroporation; using electrical current 
to compromise the cell membrane and allow nucleic acids to enter the cell or chemical methods like 
Lipofectamine (Invitrogen). Lipofectamine is a commercially available cationic liposome which 
provides high transfection efficiency and high levels of transgene expression in a range of mammalian 
cell types in vitro using a simple protocol253. Nucleic acids carry a net negative charge, and for a 
successful transfection they must cross the similarly negatively charged cell membrane. 
Lipofectamine’s positive charge allows it to complex with the negatively charged nucleic acids which 
combats the electrostatic repulsion of the cell membrane and allows the complex to be taken up by 
the cell. Or the cell to express the introduced nucleic acids, the DNA/RNA must reach the nucleus of 
the cell and become accessible to the transcriptional machinery. In actively dividing cells, transfected 
nucleic acids are trapped in the nucleus following the reassembly of the nuclear envelope at the end 
of mitosis. Lipofectamine however, also successfully transfects non-dividing cells such as neurons254 
and primary hepatocytes253,255 suggesting that the cationic lipofectamine:nucleic acid complex also 
overcomes the electrostatic repulsion of the intact nuclear envelope. 
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To perform the transfection, plasmids were purchased from the DNASU Plasmid Repository at Arizona 
State University. The human fibronectin gene (FN1) was placed into a retroviral expression vector, 
PJ1520, containing a selective gene for puromycin resistance in mammalian cells. The insert sequence 
was verified by sequence analysis and restriction enzyme digest by DNASU. The vector was obtained 
in DH5-alpha T1 phage resistance Escheria coli glycerol stock. The E. coli was cultured under selective 
conditions; 100µg/ml ampicillin, 34µg/ml chloramphenicol and 7%wt/vol sucrose in LB media. They 
were purified using the Zyppy™ plasmid miniprep kit (Cambridge Bioscience) following manufacturer’s 
instructions. 
Transfections were performed using Invitrogen Lipofectamine 3000®. Following titration experiments, 
a concentration of 1µg plasmid DNA and 0.75µL lipofectamine reagent per scaffold was chosen. The 
initial layer of 5637 epithelials was cultured on the scaffolds under standard conditions for 7 days. 
Transfection was performed on the scaffolds on the 7th day, under serum free conditions. 
Lipofectamine 3000® was diluted 1:1 with Opti-MEM® reduced serum medium and incubated with 
the plasmid DNA for 5 minutes at room temperature. The lipofectamine:plasmid complex was then 
incubated with the scaffold:cell constructs for 30 minutes at 37°C, then an additional 500µL of 
complete media without antibiotics was added to the constructs and incubated for 2 days. 
Scaffold-cell constructs were then placed into selective media containing 150µg/ml puromycin to 
select for successfully transfected cells. 
2.10 Primary cell extraction and culture 
Primary human hepatocytes are considered the gold standard cell in hepatology. No other cell 
accurately recapitulates the phenotypic gene expression and metabolic abilities of primary 
hepatocytes. Successful and consistent isolation of primary human hepatocytes remains challenging 
for researchers, however several groups have reported moderate success133,161,167,256. Steatotic liver 
has proven particularly challenging to extract healthy hepatocytes from59,257; of particular note with 
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regards to this work as all livers received were markedly steatotic and from adults weighing up to 
160kg.  
Percoll® density gradients are used following tissue digestion to remove cell debris, non-parenchymal 
cells and released proteases from a hepatocyte suspension, and increases the quality and half-life of 
an isolated hepatocyte suspension258. Percoll® is a low-viscosity, non-toxic media composed of 
colloidal silica coated with polyvinylpyrrolidone (PVP), which gives low osmolality and low viscosity. It 
is used for the separation of cells, subcellular particles and larger viruses (down to ~ 70S) under gentle 
conditions which preserve viability and morphological integrity. 
Primary human hepatocytes were obtained from tissue donated from organ donors. Tissue was 
collected as promptly as possible following brain/circulatory death of the donor, however due to 
obvious logistical reasons collection times and hepatocyte health varied between donors. A total of 6 
human livers were collected throughout the course of this body of work; one donor was used for the 
data presented in Chapter 4, and one donor was used for the data presented in Chapter 6.  
Upon receipt of the liver 8-10 small (2cm2) chunks of liver 
tissue were incubated in a 10cm2 petri dish with digest 
media; Blank DMEM (Gibco), 0.05% Trypsin-EDTA (Gibco), 
0.625mg/ml Collagenase I (Sigma) and minced finely with 
scalpels. The digest was incubated at 37oC for 30 minutes 
and filtered through a 70µm cell strainer (Corning). The 
filtrate was centrifuged at 135g for 1 minute at room 
temperature, then layered onto a gradient of 5ml 1.06g/ml, 
5ml 1.08g/ml and 3ml 1.12g/ml Percoll®. The sample was 
then centrifuged at 750g for 20 minutes at room 
temperature, and the phase between 1.06g/ml and 
1.08g/ml collected. The hepatocytes were cleaned with Williams E media at 135g for 1 minute at room 




temperature and plated onto gelatin coated tissue culture plastic (100µg/cm2 gelatin (Sigma)) or 
scaffolds as needed. Cell viability was assessed using the Trypan Blue exclusion method258 prior to 
plating and was found to be highly variable between donors. The hepatocytes used in chapter 4 
exhibited a viability of 72% immediately upon extraction. 
The primary hepatocytes were cultured in Williams E media with no phenol red (Gibco) containing 
10% Foetal Bovine Serum, 2mM glutamine , 1% Non-essential amino acids , 1% Sodium pyruvate (all 
Gibco), 2µg/ml Hydrocortisone (Sigma), 0.124 IU/ml Human insulin (Sigma) and 1µg/ml Human 
epidermal growth factor (Corning). They do not expand or split and were fed according to observations 
of the culture. 
2.11 Live/Dead® Viability/Cytotoxicity assay 
To determine cellular viability, cell/scaffold constructs were incubated with 10µm calcein and 2µm 
ethidium homodimer-1 (Ethd-1) as part of the two colour live/dead assay (Molecular Probes). Calcein 
is actively converted to calcein-AM in living cells, which then appear green when excited during 
fluorescence microscopy. Ethd-1 only accumulates in dead cells, which subsequently appear red. The 
method allows differentiation between dead and viable cells259.  
The scaffolds were rinsed three times in CaCl2/MgCl2 free PBS to remove excess media, and incubated 
in the two-colour calcein/ethd-1 stain for 30 minutes, then rinsed three times in CaCl2/MgCl2 free PBS 
and placed onto a standard microscope slide with a 25mm glass coverslip (VWR). All images were 
captured using a Zeiss Axio Imager fluorescent microscope (COIL, University of Edinburgh) and post 
processed using ImageJ. 
2.12 CellTiter-Blue 
CellTiter-Blue® assay is both colorimetric and fluorometric and utilises the dye resazurin to measure 
metabolic activity. Viable cells reduce resazurin to resorufin; a highly fluorescent molecule. According 
to the manufacturer (Promega) only viable cells metabolise resazurin, and as such the change in 
fluorescence is directly proportional to viable cell number260. The detection of dye is linear up until 
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the point of saturation so an estimation of cell number can be made from a tested known number of 
cells. However, as the result can be saturated and due to known variations in metabolic abilities of 
hepatocytes138,159 results were reported throughout as fluorescence, as opposed to cell number. 
Cell metabolism was assessed using the CellTiter-Blue® assay according to manufacturer’s instructions 
(Promega, UK). Scaffolds were washed 3 times in PBS and a 1:5 ratio of CellTiter-Blue® assay and 
appropriate cell culture media was vortexed together. This was added to cell cultures and incubated 
for 3 hours. On completion 3 x 100 µl of the CellTiter-Blue® solution was added to a black microplate 
for each sample Importantly, cell/scaffolds constructs were moved into fresh 48 well plates to prevent 
reading activity from tissue culture plastic bound cells. Measurements were read in a Modulus™ II 
microplate reader at an excitation wavelength of 525 nm and emission wavelength of 580-640 nm and 
reported as fluorescence.  
2.13 MTT assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay 
(Sigma) is used to indicate cell viability within a culture. MTT is reduced to purple coloured formazan 
by viable cells with an active metabolism, a product with an absorbance maximum near 570 nm. Dead 
cells and non-metabolically active cells cannot convert MTT into formazan, thus colour formation 
serves as a useful and convenient marker of only the viable cells. The exact cellular mechanism of MTT 
reduction into formazan is not well understood, but likely involves reaction with nicotinamide adenine 
dinucleotide (NAD) + hydrogen (H) (NADH) or similar reducing molecules that transfer electrons to 
MTT261.  
Samples were incubated with MTT for 2 hours. Incubation time was limited because of the cytotoxic 
effect of reagents which utilize NADH from the cell to generate a signal. Formazan accumulates as an 
insoluble precipitate inside cells as well as being deposited near the cell surface and in the culture 
medium. Thus, formazan was solubilized prior to recording absorbance readings using acidic 
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isopropanol (Sigma) and measurements were read in a Modulus™ II microplate reader at a wavelength 
of 570 nm and reported as absorbance. 
2.14 Picogreen DNA quantitation 
The Quant-IT™ Picogreen® dsDNA assay utilises a fluorescent probe which binds to DNA, increasing 
the intensity of fluorescence by over 1000-fold. This fluorescent can then be utilised as a molecule for 
calculation of the amount of DNA present in a sample, when comparing to a DNA standard of known 
concentration262. 
Cell seeded scaffolds were digested in a solution of CaCl2 and MgCl2 free PBS (Sigma), containing  2.5  
U/ml papain  extract  (Sigma)  5  mM cysteine-HCl  (Sigma)  and  5 mM EDTA  (Sigma)  and incubated 
overnight at 60°C. Picogreen solution was added to the digests and fluorescent intensity 
measurements read in a Modulus™ II microplate reader at an excitation wavelength of 480 nm and 
emission wavelength of 510-570 nm. A standard λ dsDNA curve of graded known concentrations was 
used to calibrate fluorescence intensity vs dsDNA concentration. 
2.15 Albumin assay 
Quantitation of albumin levels produced by hepatocyte cultures was undertaken using the 
commercially available bromocresol green (BCG) albumin quantitation kit (Sigma). The addition of 
samples containing albumin protein to a solution of BCG in a 0.075 M succinate buffer at a pH of 4.2 
produces an increase in absorbance at 628 nm. The absorbance-concentration relationship is linear 
for samples containing up to 6 g/dL of albumin. Bilirubin, moderate lipemia, and salicylate presence 
in the samples do not interfere with the analysis. The use of an anionic surfactant (sodium dodecyl 
sulphate) reduces the absorbance of the blank, prevents turbidity and improves linearity of the 
absorbance results263.  
53 
 
For each experiment, albumin production was established 24hr timescales at various time points, and 
results read at an absorbance of 620 nm in a Modulus™ II microplate reader. Results were quantified 
by comparison of absorbance with a calibration curve of known albumin concentration.   
2.16 Immunohistochemistry and cell imaging 
Imaging of cell/scaffold constructs was performed using fluorescently conjugated molecules. 
Phalloidin is used to image the cytoplasm of cells via its interaction with actin filaments. Phalloidin 
binds directly to actin subunits but does not bind to monomeric G-actin264, and was purchased 
conjugated with alexafluor-514 (Sigma) to allow for visualisation. 4’,6-diamidino-2-phenylindole 
(DAPI) binds to the A-T rich region of DNA increasing the DNA’s fluorescence intensity and allowing 
for visualisation265. A fluorescently conjugated E-Cadherin antibody (Abcam) was used to visualise cell 
membranes. E-Cadherin is a calcium-dependent cell-cell adhesion molecule with pivotal roles in 
epithelial cell behaviour, tissue formation, and suppression of cancer and is found in the cell 
membrane of healthy hepatocytes with appropriate phenotypes266. Fluorescently conjugated 
antibodies for Collagen I (Stratech), Laminin (Stratech) and Fibronectin (Sigma) were used to visualise 
the presence of these proteins in both ECM and in blended scaffolds, due to their significant roles in 
the human hepatic ECM53.  
Scaffolds seeded with cells, decellularized hybrid scaffolds and blended scaffolds were washed 3 times 
in TBS/PBS and fixed using 3.7% (v/v) formalin solution in TBS/PBS overnight, then washed again 3 
times in TBS/PBS. A 0.2% (v/v) TritonX-100 solution in TBS/PBS was used for permeabilization for 5 
minutes before washing 3 times in TBS/PBS. 
Cells lines were stained with primary antibodies overnight using 1µl per 1 ml PBS with 0.1 % bovine 
serum albumin at 4℃ and then washed 3 times in TBS/PBS. Nucleic acids were visualised using a 300 
nM DAPI solution in PBS for 20 minutes, then washed 3 times in TBS/PBS. Scaffolds were affixed to 
glass microscope slides (VWR) with mowiol mounting medium (Sigma) for imaging performed using a 
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Zeiss Axio Imager fluorescent microscope (COIL, University of Edinburgh) and post processed using 
ImageJ. 
The images in Chapter 4 were obtained using a custom multi-photon microscope. This system consists 
of a mode-locked ND:YVO4 laser source (PicoTrain, Spectra Physics) to generate both a Stokes pulse 
(6 ps, 1064 nm) and drive an optical parametric oscillator (OPO) (Levante Emerald, APE). The OPO 
provides a tuneable excitation pulse across 700-1000 nm allowing coherent anti- Stokes Raman 
scattering (CARS), second harmonic generation (SHG) and two-photon excitation fluorescence (TPEF) 
microscopy. The two pulse trains are coupled into an inverted microscope (Nikon BV ‘C1’, Amsterdam, 
Netherlands) and focused onto the sample with a 25 times water-immersion objective lens with a 
numerical aperture of 1.05 (XLPlan N, Olympus). Images from the CARS and TPEF signals were 
recorded on two photomultiplier tubes (R3896, Hamamatsu). The lateral and depth resolution of this 
objective was measured to be 0.25 and 1.1 µm, , respectively. The CARS signal was generated from 
the asymmetrical CH2 stretch of the scaffold at 812.5 nm (2911 cm-1 wavenumbers). The same OPO 
beam was used to excite the broad two-photon spectrum in the Phalloidin and DAPI. The signals were 
separated with two dichroic filter cubes at 649 nm, 570 nm, along with band pass filters with 
transmission peaks at 660 nm, 585 nm, 545 nm for the CARS, Phalloidin-iFluor™ and DAPI, 
respectively. 
All images are representative of scaffold conditions. 
2.17 Scanning electron microscopy 
Scanning electron microscopy (SEM) utilises a focused electron beam to scan the surface of 
microscopy samples. The signals generated reveal information regarding the topography of the 
material and generate an image for subsequent analysis. 
Glutaraldehyde is used as a fixative for SEM because it causes the rapid penetration of small HCHO 
molecules, which initiate the structural stabilization and thorough crosslinking of the tissue; 
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maintaining the ultrastructure of biological samples for SEM267. A secondary fixation with osmium 
tetroxide is undertaken to reduce charging of samples during imaging 268. Biological samples were 
fixed in 2.5% v/v glutaraldehyde (Fisher Scientific) in 0.1M phosphate buffer (PB) (pH 7.4) at 4℃ 
overnight. They were then rinsed three times in 0.1M PB before being post-fixed in 1% v/v osmium 
tetroxide (Electron Microscopy Supplies) buffered with 0.1M PB. Samples were again rinsed three 
times in 0.1M PB and dehydrated through an ethanol gradient (30-100%) and were dried by placing 
them in hexamethyldisilazane (HMDS, Sigma) which was allowed to evaporate off at room 
temperature overnight. Samples were mounted the samples onto SEM chucks using double sided 
carbon tape. 
A Hitachi S4700 fuelled emission scanning electron microscope (SEM) (Hitachi) with a 5kV accelerating 
voltage and a working distance of 12 mm was used to image scaffolds. Samples were coated using a 
Polaron splutter coater using gold-palladium (60:40). 
2.18 Mechanical testing 
Mechanical testing is used in this study to characterise polymer and protein:polymer scaffolds and 
elucidate any mechanical influences cells may be exposed to.  
Young’s modulus is a ratio of the force applied to a material against the change in its length. It is 
derived from the stress (σ) and strain (ε) measurements taken during the mechanical testing. Stress is 
defined as force (F) per unit area (A): 𝜎 = 
𝐹
𝐴
 and strain is the change in length (ΔL) divided by the original 
sample length (L): 𝜀 =  
∆𝐿
𝐿
 . Thus, Young’s modulus (E) is defined as 𝐸 = 
σ
ε
 . Young’s modulus is calculated 
before the elastic limit after which plastic deformation takes place; in a linear material Hooke’s law 
applies assuming a linear and elastic response.  
Non-linear materials have more complex properties and can be analysed using the tangential modulus 
at different values of strain. Dynamic (complex) modulus (E*) is used to calculate the properties of 
non-linear or viscoelastic materials and requires dynamic mechanical testing with an oscillatory force. 
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This is represented by a storage (E’) and loss (E’’) modulus where stress and strain possess a phase 
difference and as such the stress strain graph is non-linear 𝐸* = 𝐸 ′ + 𝑖𝐸′′.  
Ultimate tensile strength is the maximum stress that can be applied to a material before failure, 
although for polymers this is typically long after the elastic limit.  
Tension testing characterizes Young’s modulus and reveal elasticity of constructs. A uniaxial tensile 
load is applied to a specimen with known, uniform geometry, and the extension of the gage is recorded 
as a function of the applied load. Given the dimensions of the specimen, it is straightforward to obtain 
a stress-strain graph, and to extract E, σγ and σϝ269. The most common error in tensile testing is 
introduced when handling and mounting the samples. This is combatted my taking multiple 
measurements from multiple samples to reduce sample error, and by using a c-shaped mount to 
stabilise samples with a uniform support structure. Tensile testing was undertaken using Instron 3367 
dual column universal testing system with Bluehill 3 software.  The system was fitted with Instron 
biopulse submersible pneumatic side action grips and a 50N load cell.  A gauge length of 20mm and 
an extension rate of 20mm/min were used for all tensile tests. Analyses was conducted using the 
incremental modulus method as previously described 24,26. Samples were fixed to ‘C’ shaped card 
templates to allow consistent set up during tensile testing, and sizes were measured using digital 
callipers for accuracy. Samples were tested until failure. 
Nanoindentation was also used to characterise hybrid scaffolds. This is a powerful tool for testing small 
samples such as these scaffolds. A 100µm diameter flat diamond tip is projected into the sample, and 
the depth of penetration (δ) is measured as a function of the applied load (P)270. By estimating the 
area of contact under the indenter from the depth of indentation, Young's modulus is calculated271,272. 
Nanoindentation is limited by several factors including accidental indentation of ‘support’ structures, 
particularly when testing small, thin, non-homogenous samples. This is combatted again by testing 
multiple samples and by testing in a 12 x 12 array of nano-indentation points to represent the non-
homogenous samples more accurately. 
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Nanoindentation experiments were undertaken to 
establish the dynamic properties of scaffolds and 
decellularized ECM/scaffold constructs using the 
Keysight/Agilent G200 nano indenter testing system. 
During the  nanoindentation test, indentation load and 
displacement curves are recorded as the indenter tip is 
pressed into the test material's surface with a prescribed 
loading and unloading profile, allowing the determination of local mechanical properties. The 
displacement resolution of the DCM II is 0.2 picometer and produces noise levels < 1 angstrom, and 
as such is considered sensitive enough to measure changes 
in biological sample’s mechanical profiles. Scaffolds and 
constructs were subject to indentation by a DCM II actuator 
flat-ended cylindrical punch (D = 100µm) using a max load of 1g-f. All nanoindentation experiments 
were carried out on fresh, hydrated, unfixed samples which were adhered to the chuck using double 
sided tape. A total of 36 indentations were carried out on each sample, 50nm apart. Indent sites were 
selected using the high precision X-Y stage within the testing system (Agilent). Poisson’s ratio for 
biological materials and cells is assumed to be 0.5, as proteins of the ECM such as fibronectin and 
collagen act as ideal elastomers and thus a Poisson’s ratio of 0.5 was used 273–275. Allowable drift rate 
was 0.1nm/s. A NanoSuite (Keysight Technologies) test method “G-Series DCM CSM Flat Punch 
Complex Modulus” was used for all testing 271,272. 
Compression testing was undertaken to establish the dynamic properties of the hybrid polymer:ECM 
scaffolds using the Instron 3367 dual column universal testing system with Bluehill 3 software.  Each 
sample was compressed to 10% strain at a crosshead speed of 0.5% strain min−1. Incremental 
compressive moduli were calculated from 0%–2.5%, 2.5%–5%, 5%–7.5% and 7.5%–10%, adapted from 
previous methodology24,26. 
Figure 2.4; Schematic diagram of the 
actuating and sensing mechanisms of 




The reverse transcription real-time polymerase chain reaction (RT-qPCR) is used to quantify the levels 
of RNA expressed by a cell culture. The RNA is transcribed into complementary DNA (cDNA) using the 
reverse transcriptase reaction. This cDNA is then used as a template for real-time PCR (qPCR), 
producing DNA. 
qPCR requires 3 steps: denaturation, annealing, and elongation. These steps occur repeatedly in 
cycles; doubling the amount of DNA after each cycle. As each cycle takes place a fluorescent dye, 
SybrGreen, binds to newly formed DNA. The cycle in which fluorescence is first detected is designated 
the threshold cycle (Ct), and is used to quantify the amount of RNA present in the original sample. 
Quantification was performed using the 2−∆∆𝐶𝑡 method 276. The 2−∆∆𝐶𝑡 method compares the Ct 
values of a gene of interest in both a reference sample (𝑇𝐺𝑅) and a subject sample (𝑇𝐺𝑆), with a 
housekeeping reference gene used as a normaliser (𝐻𝐾𝑅 , 𝐻𝐾𝑆). Equations used are as follows; 
Difference in Ct value between the target gene and the housekeeping gene.  
∆𝐶𝑡 = 𝑇𝐺 − 𝐻𝐾 
Difference between ΔCt of the subject sample and ΔCt of the reference sample. 
∆∆𝐶𝑡 =  ∆𝐶𝑡𝑆 −  ∆𝐶𝑡𝑅 
Relative expression of the gene of interest compared to a reference sample. The reference sample is 
taken to be 1.  
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 2−∆∆𝐶𝑡 
















To further clarify, in the 2−∆∆𝐶𝑡 method identical expression would be 1, any number between 0 - 1 
represents a decrease in expression and any number larger than 1 represents an increase in 
expression. By representing results graphically on log axis equal representation is given to both up and 
down regulation of genes. Errors in data can arise from 𝑇𝐺𝑅 , 𝑇𝐺𝑠, 𝐻𝐾𝑅 and 𝐻𝐾𝑆, thus it is therefore 
important to calculate the standard deviation of each of these means and propagate errors correctly. 
If standard deviation (SD) is calculated following data manipulation, then the propagation of errors 
throughout the manipulation is not accounted for. SD therefore must be propagated using the 2−∆∆𝐶𝑡 
equation to represent graphically, as either standard error (SE) or confidence interval (CI). This method 
ensures error in each measured data set is properly accounted for and represented accurately 276. 
Standard error of the 2−∆∆𝐶𝑡 method 
𝑈𝑝𝑝𝑒𝑟 =  2−(∆∆𝐶𝑡−𝐶𝐼) 
𝐿𝑜𝑤𝑒𝑟 =  2−(∆∆𝐶𝑡+𝐶𝐼) 
RT-qPCR was performed in a two-step process. Cells and scaffolds were homogenised using Trizol® 
(Life Technologies) and subjected to phase separation 277 using chloroform (Sigma Aldrich). RNA was 
isolated by harvesting the clear supernatant and purified using the commercially available silica 
membrane/chaotropic agent based 278 RNeasy kit (Qiagen) as per the manufacturer’s instructions. The 
cDNA was synthesised from a reverse transcription reaction using an ImProm-II kit (Promega), 
according to the manufacturer’s instructions, and a PCR machine (Applied Biosystems Proflex PCR 
system) using Cycle 1. 
Cycle 1 
Anneal – 5 minutes @ 25°C 
Extend – 60 minutes @ 42°C 
Inactivation – 15 minutes @ 70°C 
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cDNA was used in a qPCR reaction with the SensiFAST™ SYBR®Hi-ROX kit (Bioline) according to the 
manufacturer’s protocol using Cycle 2. 
Cycle 2 
Initial denaturation – 2 minutes @ 95°C 
40 cycles of; 
Denaturation – 15 seconds @ 95°C 
Annealing/Extension – 1 minute @ 60°C (or 5°C below lowest primer TM) 
Gene expression levels were normalised using expression of the housekeeping gene Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and presented as a relative expression. The 2−∆∆𝐶𝑡 method was 
used to calculate relative RNA levels of Albumin (Alb), Cytochrome P450 Family 1 Subfamily A 
Polypeptide 1 (Cyp1A1), Cytochrome P450 Family 1 Subfamily A Polypeptide 2 (Cyp1A2), Cytochrome 
P450 Family 2 Subfamily B Polypeptide 6 (Cyp2B6), Cytochrome P450 Family 3 Subfamily A Polypeptide 
4 (Cyp3A4), Collagen Type I alpha 1 (Col1A1), Collagen Type 4 alpha 1 (Col4A1) and Fibronectin Type 
1 (FN1) were investigated. Forward and reverse primers (Sigma) were designed using the free to 
access NCBI PrimerBLAST 279 and are detailed in Table 7. Errors in graphs were calculated from a 
magnitude of the standard deviations of both the housekeeping gene and the target gene of both the 
sample and the control to ensure errors were carried forward. Data was presented on a logarithmic 
scale to give equal relevance in terms of graphical representation to both increases and decreases in 
expression. As ΔΔCt was manipulated by a log factor, the values represented by the error bar 
represented also underwent the same manipulation, thus maintaining their relevance to the 
manipulated dataset. 
Table 2.1; Primer Sequences 
Albumin (Alb) 
For - CCTGTTGCCAAAGCTCGATG 
Rev - GAAATCTCTGGCTCAGGCGA 
Cytochrome P450 Family 1 Subfamily A 
Polypeptide 1 (Cyp1A1) 
For - AATTTCGGGGAGGTGGTTGG 
Rev - GATGTGGCCCTTCTCAAAGGT 
61 
 
Cytochrome P450 Family 1 Subfamily A 
Polypeptide 2 (Cyp1A2) 
For - CTTCGCTACCTGCCTAACCC 
Rev - GTCCCGGACACTGTTCTTGT 
Cytochrome P450 Family 2 Subfamily B 
Polypeptide 6 (Cyp2B6) 
For - TGCCCCTTTTGGGAAACCTT 
Rev - ATGAGGGCCCCCTTGGATTT 
Cytochrome P450 Family 3 Subfamily A 
Polypeptide 4 (Cyp3A4) 
For-  TTTTTGGATCCATTCTTTCTCTCAA 
Rev- TCCACTCGGTGCTTTTGTGT 
Collagen Type I alpha 1 (Col1A1) 
For - GGACACAGAGGTTTCAGTGGT 
Rev - GCACCATCATTTCCACGAGC 
Collagen Type 4 alpha 1 (Col4A1) 
For - GACCCCCGGGAGAAATAGGT 
Rev - TTTGAAAAAGCAATGGCACTCC 
Fibronectin Type 1 (FN1) 
For - GAACAAACACTAATGTTAATTGCCC 
Rev - TCTTGGCAGAGAGACATGCTT 
Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) 
For – GTCTCCTCTGACTTCAACAG 
Rev - GTTGTCATACCAGGAAATGAG 
 
2.20 Statistical analysis 
All statistical analyses were performed in Origin and Minitab software. Where n is used n = number of 
biological replicates. All experiments were performed with a minimum of 3 biological replicates to 
allow for statistical analysis.  Multiple comparisons tests have been used following the Ryan Joiner test 
for normality and Bartlett’s test for the homogeneity of variances; a test which tells us if populations 
have similar variances. ANOVA and some Design of Experiments (DOE) tests rely upon underlying data 
possessing similar variance. Selecting the correct multiple comparison/post hoc test avoids errors 
caused by α inflation induced by performing multiple t-tests upon groups with unequal variance.  
The Tukey post hoc test tests each experimental group against each control group while maintaining 
the experiment wise error rate (αE) at the pre-established α level. The Tukey test relies upon equal 
population variance, and so is used where Bartlett’s test result is not significantly different i.e. the null 
hypothesis of population variances being equal is not rejected.  
The Games-Howell test does not assume equal variances and sample sizes. The test was designed 
based on Welch’s degrees of freedom correction and uses Tukey’s studentised range distribution. The 
Games-Howell test is performed on the ranked variables similar to other nonparametric tests, and is 
used where Bartlett’s test result is significantly different i.e. the null hypothesis of population 
variances being equal is rejected. 
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Fisher’s LSD test is the least robust of the post hoc tests, and performs pairwise comparisons between 
<3 groups, as unlike Tukey and Games Howell, the Fisher’s LSD test does not while maintaining the 
experiment wise error rate (αE) at the pre-established α level for over 3 groups of comparisons280–282. 
2.21 Ethical approval for donor human liver work 
All human tissue used in this study was provided by NHS Organ Donation and Transplant and NHS 
Blood and Transplant. No organs/tissues were procured from prisoners. Ethical approval was granted 
for the project from the North of Scotland Research Ethics Committee, ref 16/NS/0083. Informed 
consent for organ donation for research purposes was obtained in accordance with the Helsinki 
Declaration. A total of 6 donor livers were obtained over the duration of this project and tissue from 
one donor was used for the study detailed in Chapter 4, and tissue from one donor was used for the 



















Drug induced hybrid protein:polycaprolactone 










The extracellular matrix (ECM) is a non-cellular component of all tissues which provides essential 
support for the cells of the tissue or organ. Each tissue type has its own specific ECM ‘recipe’, 
composed of water, proteins and polysaccharides, driven by a dialogue between various cellular 
components and the microenvironment within the tissue283,284. Additionally, the ECM is a dynamic 
structure, subject to constant modification in response to environmental influences such as 3D cell 
culture73 and which varies massively between tissues285. <sup>30</sup>  
Multiple methods have been employed in an attempt to provide hepatocytes with an optimal 
environment; in particular decellularization of whole livers and novel 3D tissue engineered scaffolds. 
Decellularization provides a whole organ ECM based bioscaffold with the potential to maintain the 3D 
site-specific architecture and highly conserved sinusoidal ECM gradient required for hepatocyte 
function upon their repopulation of the organ30. Several studies have repopulated decellularized 
organs with hepatocytes and endothelial cells which subsequently survive and exhibit some level of 
function31–35,286. However, this approach still requires precious donor organs, whether human or 
animal and with all of their immunogenic potential and methods used are not without their 
drawbacks287,288. Detergents such as sodium dodecyl sulphate (SDS), Triton-X100 and sodium 
deoxycholate (SDOC) are employed to strip the ECM of cells. These detergents disrupt native tissue 
ultrastructure, decrease glycosaminoglycan (GAG) content and reduce collagen integrity38,39 as well as 
disrupt lipid-lipid, lipid-protein and protein-protein interactions40. Scaffold manufacture employs 
engineering technologies to create a synthetically derived structure which mimics the characteristics 
of the native ECM. There are several different methods of creating a scaffold, and they can be made 
from a myriad of substances; both natural and synthetic29. Hydrogels have been of particular interest 
to liver tissue engineers, gels biofunctionalized with collagen I enhance P450 (Cyp450) activity, cell 
adhesion markers and innate hepatocyte fibronectin production41. Gels biofunctionalized with 
galactose increase albumin production and promoted the proliferation of hepatocytes42. Viability and 
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hepatic functions of primary hepatocytes are improved by culturing them in hydrogels made with liver 
extracellular matrix43, and when encapsulated in collagen-alginate composite hydrogels44. PEG 
hydrogels have been shown to augment cell-cell interactions of bipotential mouse embryonic liver 
(BMEL) cells, subsequently improving their survival and function45, however incorporating ECM 
components into scaffolds at the manufacturing stage has proved challenging, with the harsh solvents 
require to solubilize major components of ECM alter their microstructure and functionality46,47. 
Ongoing research is showing great promise, however to date no scaffold has been created which 
allows hepatocytes to function as well as in vivo36,37.  
Both ECM components and scaffolds have shown great promise in tissue engineering 12,26,48.  With 
these considerations in mind,  decellularization and scaffold engineering were combined to create a 
novel environment in which hepatocytes thrive (Fig 3.1).  Two different histone deacetylase inhibitors 
(iHDACs) were used to manipulate the cellular environment and alter the ECM production; sodium 
butyrate (NaBut) is widely used in industry to increase yield recombinant protein yields in mammalian 
cells. Valproic acid (ValA) is an FDA approved anti-convulsant which also functions as an iHDAC to 
increase recombinant protein yields 289. Histone deacetylase inhibitors (iHDACs) can influence gene 
expression via their role in deacetylation; the process by which DNA renders itself less transcriptionally 
active. Inhibiting this process in cells results in hyperacetylation of histones and subsequently and 
increase in transcriptional activity 290. By manipulating ECM production using pharmaceuticals and 
exploiting polymer characteristics a novel hybrid polymer-ECM platform for liver tissue engineering 
was produced. To validate the platform cells representative of the liver (HepG2s) were used.  






All methods were performed according to protocols laid out in Chapter 2. Specific details are 
described forthwith. 
3.2.1 Electrospinning 
A 12% wt/vol solution of poly-capro-lactone (Sigma-Aldrich) and hexafluoroisopropanol (Manchester 
Organics) was used to electrospin scaffolds according to the following parameters;  














1.8ml 8ml 21 cm 12kV -2kV 250rpm 100mm/s 
 
3.2.2 Oxygen plasma surface treatment 
10mm discs of scaffold were subjected to oxygen plasma surface treatment (Harrick Plasma) at 10.2W 
for 30 seconds. Scaffolds were removed from the plasma chamber and placed into 
antibiotic/antimycotic treatment solution for 1 hour prior to initial seeding. 
3.2.3 Initial Layer Cell Seeding and Culture 
Scaffolds were removed from the antibiotic/antimycotic treatment solution and rinsed three times for 
15 minutes each in complete media; Eagles Minimal Essential Media supplemented with 10% foetal 
bovine serum, 2mM L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin (Gibco). They were 
then placed into a fresh 48 well tissue culture plate. 
5637 human urinary bladder epithelials (ATCC) were trypsinized using standard methods from tissue 
culture flasks and counted using the trypan blue exclusion method. 1 x 104 cells at passage 23 were 
suspended in 100µl of complete media and seeded directly on to the scaffolds. The cells were allowed 
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to incubate in this small volume on the scaffolds for 2 hours, before an additional 400µl of complete 
media was added.  
Media was changed after 24 hours to either 750µM Valproic Acid (VA) or 750µM Sodium Butyrate 
(NaB) (Sigma-Aldrich) in complete media and subsequently changed every 48 hours. Controls were 
scaffold only, i.e. not seeded with an initial cell layer and no drug treatment i.e. the initial layer 
cultured in drug free complete media only. Drug concentrations and initial layer cells were chosen 
following results of a drug response curve for each iHDAC (data not shown). Valproic acid and sodium 
butyrate are used as epigenetic control mechanisms of gene transcription. They function by inhibiting 
histone deacetylases (as iHDACs) to modulate chromatin structure, creating an open, transcriptionally 
active euchromatin configuration at gene coding and regulatory regions of the chromosome. This 
renders the chromatin accessible to transcription factors, and facilitates gene transcription 290. 
Valproic acid and sodium butyrate are both commonly used in industry, particularly antibody 
production due to their ability to upregulate protein production in such a manner 289,291. This initial 
layer of cells was cultured for 7 days at 37ºC and 5% CO2 in a humidified incubator. 
3.2.4 Decellularization  
Decellularization was performed using methods adjusted from Lu et al. (2012), under sterile conditions 
at room temperature (19 - 22ºC) and agitation. Scaffolds were washed in phosphate buffered saline 
(PBS) for 15 minutes and then rinsed in 10mM tris buffered saline (TBS) for 15 minutes.  
The scaffolds were submerged in a 0.1% vol/vol Triton X-100 (Sigma-Aldrich) 1.5M potassium chloride 
(Acros Organics) 50mM TBS for 4 hours. They were rinsed for 15 minutes in 10mM TBS before being 
submerged in fresh 10mM TBS overnight. 
Scaffolds were given a final rinse in 10mM TBS for 15 minutes before being incubated in complete 




3.2.5 Functional layer Cell Seeding and Culture 
HepG2 cells were trypsinized using standard methods from tissue culture flasks and counted using the 
trypan blue exclusion method. 3 x 105 cells at passage 17 were suspended in 100µl of complete media 
and seeded directly on to the scaffolds. The cells were allowed to incubate in this small volume on the 
scaffolds for 2 hours, before an additional 400µl of complete media was added. 
Media was changed after 24 hours and changed every 48 hours after the initial 24 hour adherence 
and recovery period. This functional layer (FL) of cells was cultured using standard methods for either 
3 or 5 days at 37ºC and 5% CO2 in a humidified incubator. 
3.2.6 Live/Dead® Viability/Cytotoxicity assay 
To determine cellular viability, cell/scaffold constructs were incubated with 10µm calcein and 2µm 
ethidium ho-modimer-1 (Ethd-1) for 30 minutes as part of the two colour live/dead assay (Molecular 
Probes). Calcein is actively converted to calcein-AM in living cells, which then appear green when 
excited during fluorescence microscopy. Ethd-1 only accumulates in dead cells, which subsequently 
appear red. The method allows differentiation between dead and viable cells. The scaffolds were 
rinsed three times in CaCl2/MgCl2 free PBS to remove excess dye and placed onto a standard 
microscope slide with a 25mm glass coverslip (VWR). All images were captured using a Zeiss Axio 
Imager fluorescent microscope (COIL, University of Edinburgh) at 40x magnification and post 
processed using ImageJ. 
3.2.7 CellTiter-Blue® Cell viability assay 
The assay was performed according to manufacturer’s instruction (Promega). For each condition 
group, n = 3. Importantly, cell/scaffolds constructs were moved into fresh 48 well plates to prevent 
reading activity from tissue culture plastic bound cells. Measurements were read in a Modulus™ II 
microplate reader at an excitation wavelength of 525 nm and emission wavelength of 580-640 nm and 
reported as fluorescence.  
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3.2.8 Picogreen DNA quantification 
The Quant-IT™ Picogreen® dsDNA assay kit (Life Technologies™) was employed to establish the 
efficiency of the decellularization method in removing cellular material and to estimate cell number 
on the cell/scaffold constructs. The assay was performed according to manufacturer instructions. In 
brief, constructs (n = 6) were digested in a solution of CaCl2 and MgCl2 free PBS (Sigma),  containing  
2.5  U/ml papain  extract  (Sigma)  5  mM cysteine-HCl  (Sigma)  and  5 mM EDTA  (Sigma)  and incubated 
overnight at 60°C. Picogreen solution was added to the digests and fluorescent intensity 
measurements read in a Modulus™ II microplate reader at an excitation wavelength of 480 nm and 
emission wavelength of 510-570 nm. A standard λ dsDNA curve of graded known concentrations was 
used to calibrate fluorescence intensity vs dsDNA concentration. 
3.2.9 Sectioning and staining 
The samples were rinsed three times in PBS (Gibco) for 15 minutes each, then fixed in 4% v/v formalin 
buffered in saline for 15 minutes at room temperature. After rinsing with fresh PBS, constructs were 
embedded in low melting temperature polyester wax (Electron Microscopy Supplies) using methods 
adapted from Steele et al. (2014). In brief, samples are dehydrated through 70-100% ethanol, then 
incubated in 50:50 ethanol:wax overnight at 45ºC overnight with agitation. The samples were moved 
into 100% wax for 3 hours at 45ºC and then fresh 100% wax for 1 hour at 45ºC. Samples were 
embedded and allowed 72 hours to fully cure before sectioning. Immunohistochemical staining was 
undertaken using antibodies for Collagen I (Stratech), Laminin (Stratech) and Fibronectin (Sigma).  All 
images were captured using a Coherent Anti-Stokes Raman Scattering (CARS) system (Bioimaging 






3.2.10 Scanning Electron Microscopy 
SEM was used to characterise the scaffold architecture. Samples were rinsed three times in PBS for 15 
minutes each, then fixed in 2.5% v/v glutaraldehyde (Fisher Scientific) in 0.1M phosphate buffer (PB) 
(pH 7.4) at 4ºC overnight. They were then rinsed three times in 0.1M PB before being post-fixed in 1% 
v/v osmium tetroxide (Electron Microscopy Supplies) buffered with 0.1M PB. Samples were again 
rinsed three times in 0.1M PB and dehydrated through an ethanol gradient (30-100%). They were 
dried by placing them in hexamethyldisilazane (HMDS, Sigma) which was allowed to evaporate off at 
room temperature overnight. The samples were mounted onto SEM chucks using double sided carbon 
tape and coated them with a thin layer of gold and palladium alloy (Polaron Sputtercoater). 
All images were captured at 5 kV using a Hitachi S-4700 SEM (BioSEM, University of Edinburgh). 
3.2.11 Mechanical Testing 
Nanoindentation experiments were undertaken to establish the dynamic properties of scaffolds and 
decellularized ECM/scaffold constructs using the Keysight/Agilent 5200 nano indenter testing system. 
Scaffolds and constructs were subject to indentation by a DCM II actuator flat-ended cylindrical punch 
(D = 100µm) using a max load of 1g-f. All nanoindentation experiments were carried out on fresh, 
hydrated, unfixed samples which were adhered to the chuck using double sided tape. A total of 36 
indentations were carried out on each sample, 50nm apart. Indent sites were selected using the high 
precision X-Y stage within the testing system (Agilent). Poissons ratio was assumed to be 0.5 for each 
sample 273,274. Allowable drift rate was 0.1nm/s. A NanoSuite (Keysight Technologies) test method “G-
Series DCM CSM Flat Punch Complex Modulus” was used for all testing 271,272. 
3.2.12 Gene Expression analysis 
RNA was extracted from constructs using standard Trizol (Fisher Scientific) methods and purified using 




Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the LightCycler® 480 
Instrument II (Roche Life Science) and Sensifast™ SYBR® High-ROX (Bioline) system. Results were 
normalized to HepG2s of the same passage number grown on tissue culture plastic and compared to 
the housekeeping gene Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH). Analysis was 
performed using the 2–[delta][delta] Ct method 276, n = 4. Albumin (Alb), Cytochrome P450 Family 1 
Subfamily A Polypeptide 1 (Cyp1A1), Cytochrome P450 Family 1 Subfamily A Polypeptide 2 (Cyp1A2), 
Cytochrome P450 Family 3 Subfamily A Polypeptide 4 (Cyp3A4), Collagen Type I alpha 1 (Col1A1), 
Collagen Type 4 alpha 1 (Col4A1) and Fibronectin Type 1 (FN1) were investigated, forward and reverse 
primers (Sigma) are detailed in Table 3.2. 
Table 3.2; QRT-PCR Primers  
 
Albumin (Alb) 
For - CCTGTTGCCAAAGCTCGATG 
Rev - GAAATCTCTGGCTCAGGCGA 
Cytochrome P450 Family 1 Subfamily A 
Polypeptide 1 (Cyp1A1) 
For - AATTTCGGGGAGGTGGTTGG 
Rev - GATGTGGCCCTTCTCAAAGGT 
Cytochrome P450 Family 1 Subfamily A 
Polypeptide 2 (Cyp1A2) 
For - CTTCGCTACCTGCCTAACCC 
Rev - GTCCCGGACACTGTTCTTGT 
Cytochrome P450 Family 3 Subfamily A 
Polypeptide 4 (Cyp3A4) 
For-  TTTTTGGATCCATTCTTTCTCTCAA 
Rev- TCCACTCGGTGCTTTTGTGT 
Collagen Type I alpha 1 (Col1A1) 
For - GGACACAGAGGTTTCAGTGGT 
Rev - GCACCATCATTTCCACGAGC 
Collagen Type 4 alpha 1 (Col4A1) 
For - GACCCCCGGGAGAAATAGGT 
Rev - TTTGAAAAAGCAATGGCACTCC 
Fibronectin Type 1 (FN1) 
For - GAACAAACACTAATGTTAATTGCCC 
Rev - TCTTGGCAGAGAGACATGCTT 
Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) 
For – GTCTCCTCTGACTTCAACAG 
Rev - GTTGTCATACCAGGAAATGAG 
 
3.2.13 Statistical Analysis 
One-way ANOVAs and Tukey post-hoc testing were performed and graphs generated using Origin 
software (OriginLab, Northampton, MA). A minimum of n = 3 and max of n = 6 was used for all analysis. 
Study groups were as follows; Scaffold only, No drug treatment, treatment with Valproic acid and 





3.3.1 Scaffold production 
Scaffold imaging was performed using scanning electron microscopy and fibres assessed for average 
diameter using DiameterJ230. The average fibre size was 1.14µm. Analyses was also performed post 
oxygen plasma surface treatment. The average fibre size following oxygen plasma surface treatment 










Figure 3.2; Electrospun fibres pre and post oxygen plasma surface treatment 
The scaffolds were assessed for consistency and fibre size via scanning electron microscopy and 
subsequent image analysis. n = 4. 200x (Pre) and 400x (Post) magnification. 
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3.3.2  Decellularization 
Decellularization was confirmed using Picogreen DNA quantitation. Remnant DNA falls well below the 
threshold remnant DNA concentration of 50ng/mg212, thus scaffolds are considered successfully 
decellularized. 







Figure 3.3; Decellularization of initial layer 
Decellularization was confirmed using the Quant-IT™ Picogreen® dsDNA assay and scanning 
electron microscopy (not shown). Additionally, CellTiter-Blue® Cell viability assay was performed 
on the decellularized scaffolds and showed no activity, and staining with DAPI (4′,6-diamidino-2-




3.3.3 Cell attachment and survival on scaffolds 
When compared to N-ECM, a lower number of HepG2s adhered to each of the drug induced scaffold-
ECM constructs, and to the scaffold alone (Fig. 3.4); demonstrating that ‘normal’ ECM is efficient for 
cell seeding purposes. SO, VA-ECM and NaB-ECM conditions demonstrate longer term maintenance 
or the HepG2s however (Fig. 3.4) and results are confirmed by both CellTiter-Blue® viability (Fig. 3.4B) 
and Picogreen® DNA quantitation (Fig. 3.4A). Live/Dead® Viability/Cytotoxicity images (Fig. 3.5) further 
demonstrates the metabolic viability of the functional HepG2 cell layer (FL), although it should be 
noted that imaging reveals the FL was not yet confluent at 5 days culture, as further confirmed by SEM 
images (Fig. 3.6).  
Figure 3.4; Seeding efficiency/viability on scaffolds 
Cell adherence was assessed by Quant-IT™ Picogreen® dsDNA assay (A) and further confirmed by CellTiter-
Blue® Cell viability assay (B). One-way ANOVA with Tukey post hoc testing. * = p <0.05 ** = p<0.01. Error 





















Figure 3.5; Live/Dead® Viability/Cytotoxicity assay 
Viability of the FL was assessed by Live/Dead® Viability/Cytotoxicity staining assay. Results 

















3.3.4 Mechanical characterisation of scaffolds 
Interestingly, mechanical differences between the scaffold construct were negligible (Fig. 3.7). No 
significant differences in storage (Fig. 3.7A) or loss (Fig. 3.7B) modulus between the four conditions 
(Tables 3.3 and 3.4).  
Figure 3.6; SEM of Scaffold-ECM constructs and functional cell layers 
Scanning electron microscopy images of the decellularized scaffold-ECM constructs and 
functional cell layers at three and five days culture. Topographical differences are clearly evident 
on decellularized constructs. 500x magnification. 
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Testing was performed at frequencies experienced by the human liver in vivo292. Storage modulus (G’) 
ranged from 3.58±0.12 to 4.64±0.43 MPa and loss modulus (G’’) from 0.55±0.03 to 1.17±0.07 at the 
frequencies detailed in tables 3.3 and 3.4. This reassures us that differences in cell attachment, 
viability and function are due to differences in the biochemical and topographical profile of the hybrid 
scaffolds, as opposed to potential dynamic differences to which cells are known to be so sensitive293–
296. 
Table 3.3; Storage modulus G’ at mechanical excitation frequencies 
Frequency 
(Hz) 
Storage modulus, G’ (MPa) 



















































































Table 3.4; Loss modulus G’’ at mechanical excitation frequencies 
Frequency 
(Hz) 
Loss modulus, G’’ (MPa) 






















































































3.3.5 Biochemical characterisation of the hybrid polymer-ECM scaffolds 
Differences in the biochemical profile of the different ECMs were demonstrated by 
immunohistochemistry performed on the hybrid scaffold sections (Fig. 3.8). Hepatic phenotype has 
long been known to be influenced by ECM proteins; particularly Collagen I, Laminin and 
Fibronectin12,53,179, all of which are present on the scaffolds to varying degrees. Laminin is of particular 
importance in the regenerating liver and for cell adhesion, and is increased in injured or developing 
states6,297. Laminin is present in each construct, but appear to be most prevalent in NaB-ECM scaffolds 
(Fig. 3.8J). These constructs demonstrate higher ‘maintenance’ of the HepG2s; that is cell number and 
viability increases between 3 days and 5 days (Fig. 3.3). Collagen I is one of the major components of 
normal liver ECM53,179. Collagen I is most prevalent on NaB-ECM scaffold constructs (Fig. 3.8I), followed 
by VA-ECM (Fig. 3.8E) and N-ECM (Fig. 3.8A) scaffold constructs. When compared to the N-ECM 
scaffold constructs, these demonstrate improved maintenance of the HepG2 cell layer (Fig. 3.3), 
although not in comparison to the SO conditions. Fibronectin is also ubiquitous in healthy liver 
ECM53,298 and is present under each of the conditions, but is most prevalent on NaB-ECM scaffolds 
Figure 3.7; Mechanical characterization of decellularized scaffolds 
Decellularized ECM/scaffold constructs were subject to nanoindentation experiments to assess 
their dynamic properties. Results demonstrate no significant differences in storage (A) or loss (B) 
modulus between the four conditions (Tables 3.3 and 3.4). 
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(Fig. 3.8K). Scanning electron microscopy of the hybrid scaffolds appears to confirm the fibrillary 
nature of the Collagen I enriched NaB (Fig. 3.6J) and VA-ECMs (Fig. 3.6G) and the smoother 
morphology of the Laminin enriched N-ECM (Fig. 3.6D). The ECMs present have penetrated the 
scaffold in each case, and each protein is present on each scaffold, indicating the robustness and 
reproducibility of the method (Supplementary Fig. 1 n = 3). 
 
3.3.6 Gene expression of HepG2s in response to hybrid polymer-ECM scaffolds 
Multiple genes associated with liver function were assayed for gene expression (Fig. 3.9). Albumin 
expression is a marker of liver cell differentiation and function and Cytochrome P450 (CYP) are 
involved in metabolism of toxic compounds and products of endogenous metabolism such as bilirubin 
in the liver 150,155. Albumin mRNA expression increases between day 3 and day 5 as expected, but at 
day 5 is upregulated in comparison to HepG2s grown on tissue culture plastic in all conditions; with 
the highest levels observed in SO and N-ECM conditions. Additionally, albumin mRNA expression is 
downregulated at day 3 in SO and NaB-ECM conditions (Fig. 3.9A). Cyp1A1 mRNA expression is 
consistently upregulated in comparison to tissue culture plastic (Fig. 3.9B). Cyp1A2 mRNA expression 
is hugely upregulated in comparison to tissue culture plastic (~1000 – 38,000-fold), with the highest 
levels observed at 3 days on VA-ECM scaffold constructs, and levels at day 5 consistently lower than 
Figure 3.8; Immunohistochemical investigation 
Immunohistochemistry staining of the decellularized ECM/scaffold constructs revealed significant 
differences in ECM components. Stains were performed for Collagen I, Laminin and Fibronectin, 
post processed using ImageJ . 10x and 100x magnification. 
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those at day 3 (Fig. 3.9C). Cyp3A4 mRNA expression follows a similar pattern, barring the NaB-ECM 
scaffolds; where expression levels at day 5 are higher than those of day 3. Additionally, the highest 
levels of expression are observed on SO at day 3 of culture (Fig. 9D). Additionally, three ECM genes 
were analysed, as key components of the liver microenvironment; Fibronectin (Fig. 3.9E), Collagen I 
(Fig. 3.9F) and Collagen IV (Fig. 3.9G). While hepatocytes are not the major producers of ECM proteins 
in the liver53, the expression of such genes are of interest with regards to the cells further modulation 
of its environment considering the plastic nature of the ECM283.   
Fibronectin mRNA levels are higher in each condition than in that of HepG2s grown on tissue culture 
plastic, and highest levels are observed at day 3 on VA-ECM scaffold constructs, subsequently 
dropping to less than a third of day 3 levels by day 5. This may be in response to fibronectin levels 
observed in Figure 3.6, where the highest fibronectin levels observed (Fig. 3.6K) correspond with the 
lowest mRNA expression in the HepG2s. Collagen I mRNA expression is upregulated in every condition. 
Levels increase at day 5 in SO and NaB-ECM conditions; N-ECM and VA-ECM conditions follow the 
opposite trend with lowest levels observed in NaB-ECM conditions at day 3. The highest level of gene 
expression is observed on the scaffold with correspondingly increased Collagen I levels; NaB-ECM (Fig. 
3.7I). Collagen IV mRNA levels are decreased in comparison to tissue culture plastic. While the authors 
refrain from speculation without further analysis, the alterations in mRNA levels indicate that the drug 









Figure 3.9; Q-PCR analysis of functional cell layer 
Quantitative analysis of gene expression was undertaken on the functional cell layer at three and 
five days culture, compared to that of HepG2s of the same passage and culture periods grown on 
tissue culture plastic.  mRNA levels of Albumin (A), Cyp1A1 (B), Cyp1A2 (C), CYP3A4 (D), Fibronectin 
(E) Collagen I (F), and Collagen IV (G) are represented as fold difference relative to tissue culture 
plastic controls and relative to the housekeeping gene GAPDH. One-way ANOVA with Tukey-post 




Fabrication of a hybrid polymer-ECM scaffold is an important avenue for liver tissue engineering, 
addressing the need for donor organs and combatting issues regarding animal-sourced biomaterials 
and creating a platform which can produce consistent, bioactive scaffolds for liver cell survival and 
function.  
In this chapter, an electrospun fibre approach was taken in the study to mimic the morphology of 
healthy fibrillary collagen 24,299, which may explain cells favouring environments observed to contain 
more Collagen I. PCL was used for the fabrication of electrospun scaffolds as it possesses FDA approval 
for use in medical devices due to its biodegradable nature and elasticity 26.  Oxygen plasma surface 
treatment altered the hydrophilicity of the PCL to allow cell adhesion. 
These results indicate not only that the iHDACs used significantly alter the production and consistency 
of the ECM, but that this technique is robust and reproducible and the ECM it produces, when 
harnessed in combination with 3D scaffolding technologies, creates a biofuctionalized scaffold which 
significantly alters the behaviour of liver cells. These results address the aims of this thesis to assess 
the response of hepatocytes to novel liver tissue engineering scaffolds. 
While the ECM produced by a bladder epithelial may be different to that of a liver cell; several 
decellularized ECM products on the market are in clinical use to regenerate tissues from which they 
are not derived, including ALLOPATCH HD™, MatriStem® and Tutoplast® Pericardium300. Hepatocytes 
are regularly cultured on ‘ECM’ surfaces which are not derived from liver, commonly using Matrigel®, 
a product derived from murine sarcoma which is as yet undefined and experiences batch to batch 
variability12,154,301–303. Ass discussed in the justification for this research, the promising field of whole 
organ decellularization is hampered by the availability of human livers, and researchers are 
subsequently investigating alternative organ and cells sources, such as spleen, bone marrow 
mesenchymal stem cells174,304 174and various animal sources of livers36. One of the main advantages of 
using decellularized native liver ECM is conservation of the highly conserved sinusoidal ECM gradient 
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required to allow hepatocytes to repopulate in their specific niches.  The complex extracellular matrix 
of the liver remains a topic of investigation in each of its states; diseased, regenerating and 
healthy6,53,54,124. 
To assess the performance of the hybrid scaffolds, the attachment and function of a commonly used 
liver cell line, HepG2s, at 3 and 5 day time points when cultured in vitro on the hybrid scaffolds versus 
scaffold alone was assessed. HepG2s were derived from the hepatocarcinoma of a 15 year old 
Caucasian male. They are often used because they are virus free, possess liver specific functions such 
as ammonia metabolism and albumin synthesis and secrete some growth factors such as insulin and 
insulin-like growth factor II138.  Cell attachment and viability was analysed, and gene expression of 
both liver function genes and ECM genes at both 3 and 5 day time points. Additionally, 
decellularization of the ECM producing cell layer was validated and immunohistochemical analyses of 
the hybrid scaffold-ECM constructs upon which the HepG2s were seeded was performed.  
While this work is a robust proof of principle regarding manipulation of ECM production, and has 
produced a novel hybrid polymer-ECM scaffold with great potential for liver tissue engineering, 
further work is required to analyse results and increase translatability. Although HepG2s are a highly 
valuable research resource, they are derived from a carcinoma and as such criticism of their in vitro 
relevance abounds within the scientific community. It is important to undertake future work using 
primary or stem cell derived hepatocytes to combat such criticism. Furthermore, while hepatocytes 
are the major parenchymal cell of the liver (making up more than 70% of the cellular mass), they do 
not exist in isolation and the non-parenchymal cells play an essential role in the in vivo liver124,305; 
future studies should look to include these cells. In addition, recognising the value of proteomic and 
functional assays (such as ELISAs) in analysing the function of the primary/stem cell derived 
hepatocytes will be important for future validation of the scaffolds, however at this time these were 
deemed unnecessary considering the critique of the HepG2 cell line. Additionally, care should be taken 
to ensure decellularization agents are completely removed from the scaffolds, due to their deleterious 
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effect on both cells and ECM 287. While such considerations are of importance, this study clearly 
demonstrates the potential of these hybrid polymer-ECM scaffolds for tissue engineering and provides 
a robust initial platform for further research. 
3.5 Conclusion 
This chapter developed a new method of creating hybrid polymer-ECM scaffolds by manipulating cells 
using electrospun scaffold technologies, clinically relevant iHDACs and methods easily modified to 
other organs in the human body. To do so, a sacrificial, ECM-producing cell layer was seeded onto a 
novel electrospun scaffold and then treated with valproic acid or sodium butyrate in order to 
biofuctionalize the scaffold with cell-derived ECM components. Scaffolds with untreated cells and no 
initial cell layer at all were used as controls. The initial cell layer was removed with a detergent based 
decellularization method, and the resulting hybrid polymer-ECM scaffolds seeded with a liver cell line 
for validation. The work was validated using robust methods such as Q-PCR, mechanical quantification 
and scanning electron microscopy. Drug induced hybrid polymer-ECM scaffolds had a significant 
positive influence on the gene expression profile, attachment and survival of liver cells. This data 
demonstrates promise as a unique method of inducing and altering the production of ECM and that 
the hybrid scaffolds exert influence upon cells in vitro, as well as future potential as an implantable 
treatment platform for liver disease patients.   
These scaffolds are a useful tool for the development of 3D liver cell platforms which can be used for 
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Strategies to mimic the in vivo ECM include decellularization of organs, use of recombinant and 
purified proteins and synthetic scaffolds such as hydrogels and electrospun polymers26,48,203,306. 
However, the use of these alone have proved insufficient for longer term maintenance, survival and 
optimisation of hepatocyte behaviour. Using such techniques has been beneficial to the field; 
scientists can maintain liver organoids; lab grown collections of hepatocytes and occasionally non-
parenchymal cells in the lab for a considerable amount of time and these organoids and spheroids 
maintain some semblance of hepatic function108. Unfortunately, to date no environment has been 
manufactured which allows hepatocytes to function as they do in vivo or provides a viable, clinically 
translatable alternative to whole organ transplant73. Equally, primary human hepatocytes are 
generally considered the gold standard for studying hepatocyte biology, however, they are a rare 
resource and as such are under-represented in the liver tissue engineering research field307. Yet, a 
minimum number of studies have been able to transition their promising early stage research into the 
next stage by undertaking further, translational studies using primary human hepatocytes.  
Drug-induced hybrid electrospun poly-capro-lactone:cell-derived ECM scaffolds for liver tissue 
engineering have been used previously11. These scaffolds were manufactured using a sacrificial, ECM-
producing cell layer which was seeded onto a novel electrospun scaffold and then treated with histone 
deacetylase inhibitors (iHDACs)290,291,308,309 to biofuctionalize the scaffold with ECM components. The 
initial cell layer was removed with a detergent-based decellularization method, and the resulting 
hybrid polymer-ECM scaffolds seeded with HepG2s for validation. Drug-induced hybrid polymer-ECM 
scaffolds had a significant positive influence on the gene expression profile, attachment, and survival 
of liver cells. These scaffolds represent a unique method of inducing and altering the production of 
ECM and of exerting an influence on phenotypic behaviour of cells, as well as future potential as an 
implantable treatment platform for liver disease patients. However, these scaffolds ECM layer was 
produced by a bladder epithelial cell line. An obvious improvement is to use a more hepatic relevant 
92 
 
cell line to biodecorate the scaffolds. Equally, use of a more clinically relevant cell; such as a primary 
or IPSC hepatocyte to validate the scaffolds adds to the robustness of the work and further highlights 
the translatability of the drug induced hybrid scaffold methods. 
With this background in mind the next generation of drug-induced hybrid electrospun scaffolds were 
manufactures; using poly-lactic-acid as a biocompatible and biodegradable polymer for the scaffolds 
and using sodium butyrate and valproic acid as previously described to alter the ECM biodecoration 
by a sacrificial liver cell line; THLE-3s. These scaffolds were decellularized and frozen until primary 
human liver cells, obtained from a donated cadaveric human liver were available. The scaffolds were 
defrosted and seeded with primary hepatocytes to validate the scaffolds. Results demonstrate that 
the ECM on the scaffolds is drastically altered by the drug treatment; displaying different mechanical 
and biochemical properties. Albumin production, cell survival and gene expression of the primary 
hepatocytes were all altered in response to the hybrid drug induced ECM:PLA scaffolds.  
This work further demonstrates the translatability of the hybrid protein:polymer scaffolds and further 
elucidates the impact of differing ECM profiles on the behaviour of primary human hepatocytes. 









4.2 Materials and Methods 
All methods were performed according to protocols laid out in Chapter 2. Specific details are 
described forthwith. 
4.2.1 Ethics and Governance 
All human tissue used in this chapter was provided by NHS Organ Donation and Transplant and NHS 
Blood and Transplant. No organs/tissues were procured from prisoners. Ethical approval was granted 
for the project from the North of Scotland Research Ethics Committee, ref 16/NS/0083. Informed 
consent for organ donation for research purposes was obtained in accordance with the Helsinki 
Declaration. Tissue from one donor liver was used for this chapter. 
4.2.2 Electrospinning 
A 22% wt/vol solution of poly-L-lactic acid (Goodman) and 10ml hexafluoroisopropanol (Manchester 
Organics) was used to electrospin scaffolds under the following parameters;  














2.5ml 7.5ml 23 cm 16kV -3kV 300rpm 100mm/s 
 
4.2.3 Scaffold Preparation 
10mm discs of scaffold were cut from the dry fibre sheet and sterilised using isopropyl alcohol for 10 
minutes, rinsed three times in phosphate buffered saline for 15 minutes each and were placed into 
antibiotic/antimycotic treatment for 1 hour. 
4.2.4 Initial Layer Cell Seeding and Culture 
Scaffolds were removed from the antibiotic/antimycotic treatment solution and rinsed three times for 
15 minutes each in complete media; Eagles Minimal Essential Media supplemented with 10% foetal 
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bovine serum, 2mM L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin (Gibco). They were 
then placed into a fresh 48 well tissue culture plate. 
THLE-3 immortalized normal human liver epithelials (ATCC) were trypsinized using standard methods 
from tissue culture flasks and counted using the trypan blue exclusion method. 3.5 x 104 cells at 
passage 4 were suspended in 100µl of complete media and seeded directly on to the scaffolds. The 
cells were allowed to incubate in this small volume on the scaffolds for 3 hours to allow attachment, 
before an additional 400µl of complete media was added.  
Media was changed after 24 hours to either 750µM Valproic Acid (VA-ECM) or 750µM Sodium 
Butyrate (NaB-ECM) (Sigma-Aldrich) in complete media and changed every 48 hours. Controls were 
polymer only (PO), i.e. not seeded with an initial cell layer at all and no drug treatment (N-ECM) i.e. 
the initial layer was cultured in drug free complete media only and never exposed to either iHDAC. 
Drug concentrations and initial layer cells were chosen following results of a drug response curve for 
each iHDAC (data not shown). Valproic acid and sodium butyrate are used as epigenetic control 
mechanisms of gene transcription. They function by inhibiting histone deacetylases (as iHDACs) to 
modulate chromatin structure, creating an open, transcriptionally active euchromatin configuration 
at gene coding and regulatory regions of the chromosome. This renders the chromatin accessible to 
transcription factors, and facilitates gene transcription 290. Valproic acid and sodium butyrate are both 
commonly used in industry, particularly antibody production due to their ability to upregulate protein 
production in such a manner 289,291. This initial layer of cells was cultured for 7 days at 37ºC and 5% 
CO2 in a humidified incubator. A control set of scaffolds was processed with the complete media, but 
with no initial layer cells and is referred to as the polymer only (PO) condition throughout. 
4.2.5 Decellularization  
Decellularization was performed using methods adjusted from Lu et al. (2012), under sterile conditions 
at room temperature (19 - 22ºC) and with agitation. 
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Scaffolds were given a final rinse in 10mM TBS for 15 minutes before being transferred to 500µl fresh, 
cell-culture grade PBS in new 48 well culture plates. Plates were sealed with parafilm and flash-frozen 
in a dry ice:ethanol bath. Samples were stored at -80ºC until use. 
4.2.6 Primary hepatocyte extraction 
The donor liver had been subject to ex situ normothermic perfusion as part of another groups ongoing 
research310 prior to collection. Upon receipt of the donated liver 8-10 small (2cm2) chunks of liver 
tissue were subjected to digestion and Percoll density centrifugation to obtain primary human 
hepatocytes. 
The hepatocytes plated onto tissue culture plastic or scaffolds as needed.  
4.2.7 Functional layer Cell Seeding and Culture 
The primary hepatocytes were seeded at 3 x 105 cells, suspended in 100µl of complete media and 
placed directly on to the scaffolds. The cells were allowed to incubate in this small volume on the 
scaffolds for 2 hours, before an additional 400µl of complete media was added. 
The primary hepatocytes were cultured in Williams E media with no phenol red (Gibco) containing 
10% Foetal Bovine Serum, 2mM glutamine, 1% Non-essential amino acids , 1% Sodium pyruvate (all 
Gibco), 2µg/ml Hydrocortisone (Sigma), 0.124 IU/ml Human insulin (Sigma) and 1µg/ml Human 
epidermal growth factor (Corning). They do not expand or split, and media was changed every 24 
hours. This functional layer (FL) of cells was cultured using standard methods for either 24, 72 or 120 
hours at 37ºC and 5% CO2 in a humidified incubator. 
4.2.8 Live/Dead® Viability/Cytotoxicity assay 
To determine cellular viability, cell/scaffold constructs were incubated with 10µm calcein and 2µm 
ethidium homodimer-1 (Ethd-1) for 30 minutes as part of the two colour live/dead assay (Molecular 
Probes). All images were captured using a Zeiss Axio Imager fluorescent microscope (COIL, University 
of Edinburgh) at 40x magnification and post processed using ImageJ. 
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4.2.9 MTT® Cell viability assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay 
(Sigma) was used to indicate cell viability.  
The primary hepatocyte functional cell layer was incubated with MTT for 2 hours at the 24, 72 and 
120-hour time points. Incubation time was limited because of the cytotoxic effect of reagents which 
utilize NADH from the cell to generate a signal. Thus, the formazan produced was solubilized prior to 
recording absorbance readings using acidic isopropanol (Sigma) and measurements were read in 
a Modulus™ II microplate reader at a wavelength of 570 nm and reported as absorbance. For each 
condition group, minimum n = 4. 
4.2.10 Albumin quantification 
A bromocresol green (BCG) albumin assay (Sigma) was used to quantify serum albumin produced by 
the primary hepatocyte functional cell layer over 24 hours at 24, 72 and 120 hours. The assay was 
performed according to manufacturer’s instructions and results read at an absorbance of 620 nm in a 
Modulus™ II microplate reader. For each condition group, minimum n = 5. 
4.2.11 Picogreen® DNA quantification 
The Quant-IT™ Picogreen® dsDNA assay kit (Life Technologies™) was employed to establish the 
efficiency of the decellularization method in removing cellular material and to estimate cell number 
on the cell/scaffold constructs. The assay was performed according to manufacturer instructions. For 
each condition group, minimum n = 5. 
4.2.12 Immunohistochemistry 
Constructs were stained using antibodies for Collagen I (Stratech), Laminin (Stratech) and Fibronectin 
(Sigma). Top down images of cells on the scaffolds were obtained by staining with DAPI (Sigma) and 
Phalloidin (Sigma). All images were captured using a custom multi-photon microscope at the Institute 
for Bioengineering Bioimaging Facility, University of Edinburgh. A mode-locked ND:YVO4 laser source 
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(PicoTrain, Spectra Physics) was used to generate both a Stokes pulse (6 ps, 1064 nm) and drive an 
optical parametric oscillator (OPO) (Levante Emerald, APE). The OPO provides a tuneable excitation 
pulse across 700-1000 nm allowing coherent anti- Stokes Raman scattering (CARS), second harmonic 
generation (SHG) and two-photon excitation fluorescence (TPEF) microscopy. 
4.2.13 Scanning Electron Microscopy 
SEM was used to characterise the scaffold architecture. The samples were mounted onto SEM chucks 
using double sided carbon tape and coated them with a thin layer of gold and palladium alloy (Polaron 
Sputter coater). 
All images were captured at 5 kV using a Hitachi S-4700 SEM (BioSEM, University of Edinburgh). 
4.2.14 Mechanical Testing 
Compression testing was undertaken to establish the dynamic properties of the hybrid polymer:ECM 
scaffolds using the Instron 3367 dual column universal testing system with Bluehill 3 software.  Each 
sample was compressed to 10% strain at a crosshead speed of 0.5% strain min−1. Incremental 
compressive moduli were calculated from 0%–2.5%, 2.5%–5%, 5%–7.5% and 7.5%–10%, adapted from 
previous methodology 24,26. 
4.2.15 Gene Expression analysis 
RNA was extracted from constructs using standard Trizol (Fisher Scientific) methods and purified using 
Qiagen’s RNeasy spin column system. cDNA was synthesised using the Promega’s ImProm-II™ Reverse 
Transcription System. 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the LightCycler® 480 
Instrument II (Roche Life Science) and Sensifast™ SYBR® High-ROX (Bioline) system. Results were 
normalized to primary hepatocytes of the same extraction grown on polymer only scaffolds and 
compared to the housekeeping gene Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH). Analysis 
was performed using the 2–[delta][delta] Ct method 276,311, n = 5. Albumin (Alb), Cytochrome P450 
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Family 1 Subfamily A Polypeptide 2 (Cyp1A2), Cytochrome P450 Family 2 Subfamily B Polypeptide 6 
(Cyp2B6), Cytochrome P450 Family 3 Subfamily A Polypeptide 4 (Cyp3A4), Collagen Type I alpha 1 
(Col1A1), Collagen Type 4 alpha 1 (Col4A1) and Fibronectin Type 1 (FN1) were investigated, forward 
and reverse primers (Sigma) are detailed in Table 4.2.  
Table 4.2; qRT-PCR primers used 
Albumin (Alb) 
For - CCTGTTGCCAAAGCTCGATG 
Rev - GAAATCTCTGGCTCAGGCGA 
Cytochrome P450 Family 1 Subfamily A 
Polypeptide 2 (Cyp1A2) 
For - CTTCGCTACCTGCCTAACCC 
Rev - GTCCCGGACACTGTTCTTGT 
Cytochrome P450 Family 2 Subfamily B 
Polypeptide 6 (Cyp2B6) 
For - TGCCCCTTTTGGGAAACCTT 
Rev - ATGAGGGCCCCCTTGGATTT 
Cytochrome P450 Family 3 Subfamily A 
Polypeptide 4 (Cyp3A4) 
For-  TTTTTGGATCCATTCTTTCTCTCAA 
Rev- TCCACTCGGTGCTTTTGTGT 
Collagen Type I alpha 1 (Col1A1) 
For - GGACACAGAGGTTTCAGTGGT 
Rev - GCACCATCATTTCCACGAGC 
Collagen Type 4 alpha 1 (Col4A1) 
For - GACCCCCGGGAGAAATAGGT 
Rev - TTTGAAAAAGCAATGGCACTCC 
Fibronectin Type 1 (FN1) 
For - GAACAAACACTAATGTTAATTGCCC 
Rev - TCTTGGCAGAGAGACATGCTT 
Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) 
For – GTCTCCTCTGACTTCAACAG 
Rev - GTTGTCATACCAGGAAATGAG 
 
4.2.16 Statistical Analysis 
One-way ANOVAs with Games-Howell and Tukey post-hoc testing was performed using Minitab 18 
Statistical Software. Multiple comparisons tests were used following the Ryan Joiner test for normality 
and Bartlett’s test for the homogeneity of variances. The Tukey post hoc test was used where Bartlett’s 
test result is not significantly different i.e. the null hypothesis of population variances being equal is 
not rejected. The Games-Howell test does not assume equal variances and sample sizes and was 
performed on the ranked variables similar to other nonparametric tests. The Games-Howell post hoc 
test is used where Bartlett’s test result is significantly different i.e. the null hypothesis of population 
variances being equal is rejected. Error bars indicate standard deviation. A minimum of n = 3 and max 
of n = 6 was used for all analysis. * = p value <0.05, ** = p value <0.01, *** = p value <0.001. 




4.3.1 Mechanical profiling of scaffolds 
The Young’s modulus at 0-40% strain analysis by one-way ANOVA and Games-Howell post hoc analysis 
(n=3, p = <0.05) showed a significant difference between V-ECM scaffolds and all other conditions; 
indicating that the use of valproic acid to alter ECM production has significantly altered the mechanical 
qualities and structure of the ECM and resulting in a stiffer environment for scaffolds. ND-ECM and 
NaB-ECM both exhibit lower Young’s modulus than both PO and V-ECM scaffolds, indicating that a 
‘normal’ , non-drug derived ECM and a NaB derived ECM are less stiff than a scaffold with no ECM 
‘PO’, as would be expected from a hydrated, protein-based ECM in comparison to an electrospun 
polymer mat. 
Table 4.3; Young’s modulus (MPa) of each scaffold. 
Strain Polymer only No drug treatment Valproic acid Sodium butyrate 
0-10% 0.00021 ± 0.00009 0.00011 ± 0.00007 0.00042 ± 0.00049 0.00017 ± 0.00005 
10-20% 0.00020 ± 0.00009 0.00021 ± 0.00009 0.01543 ± 0.01639 0.00016 ± 0.00006 
20-30% 0.00050 ± 0.00049 0.00024 ± 0.00015 0.07181 ± 0.06190 0.00023 ± 0.00011 












4.3.2 Scanning electron microscopy 






This phenomenon was also observed in previous studies; with each drug exerting a different effect on 
the visual appearance of the ECM. Equally, SEM imaging demonstrates a confluent initial cell layer and 
complete decellularization of the initial cell layer of THLE-3s. Decellularization was confirmed by use 
of Picogreen DNA analysis (Fig 4.3). Primary human hepatocytes are evident on the scaffolds at 24, 72 
and 120 hours on each scaffold. 
Figure 4.2; SEM of Scaffold-ECM constructs and functional cell layers 
Scanning electron microscopy images of the decellularized scaffold-ECM constructs and 
functional cell layers at 24, 72 and 120 hours culture. Topographical differences are clearly 














Figure 4.3; Decellularization of initial layer 
Decellularization was confirmed using the Quant-IT™ Picogreen® dsDNA assay and scanning 
electron microscopy (Fig 4.2).  
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4.3.3 Cell survival and metabolism 
As demonstrated in the SEM imaging (Fig 4.2) primary human hepatocytes have adhered to the 
scaffold successfully. This is confirmed by Picogreen DNA analysis of the scaffolds (Fig 4.4).  As 
expected, due to early cell death DNA levels drop off after 24 hours. They recover slightly, although 
not significantly, at 120 hours. MTT absorbance results (Fig 4.5) demonstrate that cells are 




Figure 4.4; Seeding efficiency/viability on scaffolds 
Cell adherence was assessed by Quant-IT™ Picogreen® dsDNA assay and further confirmed by MTT 
absorbance assay (Fig 4.5). One-way ANOVA with Tukey post hoc testing. * = p <0.05 ** = p<0.01. 










Differences in the biochemical profile of the different ECMs were demonstrated by 
immunohistochemistry performed on the hybrid scaffold sections (Fig 4.6). As discussed previously,  
hepatic phenotype and behaviour has long been known to be influenced by ECM composition; 
particularly Collagen I, Laminin and Fibronectin12,53,179, all of which are present on the scaffolds to 
varying degrees (stained in red). The PLA fibres are clearly visible in each. Laminin is of particular 
importance in the regenerating liver and for cell adhesion, and is increased in injured or developing 
states6,297. Laminin seem most prevalent on VA-ECM scaffold constructs (Fig 4.6H), followed by NaB-
ECM (Fig 4.6G) and N-ECM (Fig 4.6F) scaffold constructs. Collagen I is one of the major components of 
normal liver ECM53,179. Collagen I appears most prevalent on NaB-ECM scaffold constructs (Fig 4.6C), 
followed by VA-ECM (Fig 4.6D) and N-ECM (Fig 4.6B) scaffold constructs. These results were also seen 
in a previous iteration of this work11. When compared to the N-ECM scaffold constructs, these 
Figure 4.5; Seeding efficiency/viability on scaffolds 
Cell metabolism was confirmed by MTT absorbance assay. One-way ANOVA with Tukey post hoc 
testing. * = p <0.05 ** = p<0.01. Error bars represent SD. 
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demonstrate improved albumin production (Fig 4.6). Fibronectin is also ubiquitous in healthy liver 







Figure 4.6; Immunohistochemical investigation 
Immunohistochemistry staining of the decellularized ECM/scaffold constructs revealed 
differences in ECM components. Stains were performed for Collagen I, Laminin and 
Fibronectin,post processed using ImageJ. 
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Staining was also undertaken to visualise the hepatocytes adhered to the scaffolds (Fig 4.7). Cells are 
visible in each condition and at each time point, although spread far apart. This reflects the relatively 




Figure 4.7; Cell imaging 
Dapi and phalloidin staining of cell/scaffold constructs revealed cells present at each timepoint, 
post processed using ImageJ. 
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4.3.5 Albumin production 
Figure 4.8 reveals that albumin is being produced by the primary human hepatocytes in each condition 
and at each time point. Importantly, albumin levels are significantly higher than those produced on 
tissue culture plastic at 24 hours on every scaffold. On PO scaffolds, albumin production increases 
significantly between 72 and 120 hours. Importantly, the pattern of albumin production reassuringly 
tallies that of the MTT metabolic analyses (Fig 4.5), indicating an initial metabolic drop off and then 
recovery over the 120-hour culture period.  
 
Figure 4.8; Albumin production on scaffolds 
Cell function was assayed by checking for albumin protein production. One-way ANOVA with Tukey 
post hoc testing. * = p <0.05 ** = p<0.01. Error bars represent SD. 
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4.3.6 Gene expression 
Gene expression analysis demonstrates significant differences between conditions and time points 
(Fig 4.9). Albumin gene expression (Fig 4.9A) is altered between PO at 24 hours on ND-ECM and 72 
hours on V-ECM. Differences are also seen at 72 hours between ND-ECM, V-ECM and NaB-ECM as well 
as between each time point on N-ECM. Of not is that the gene expression follows a similar pattern to 
that of the albumin production; high at 24 hours then dropping off at 72 hours before recovering at 
120 hours in each condition. CYP1A2 expression (Fig 4.9B) is altered at 24 hours between PO-ECM, N-
ECM, V-ECM and NaB-ECM with changes also seen between time points on N-ECM. Col4A1 expression 
(Fig 4.9F) demonstrated changes between time points in the N-ECM condition, and FN1 (Fig 4.9G) 





Figure 4.9; Q-PCR analysis of functional cell layer 
Quantitative analysis of gene expression was undertaken on the functional cell layer 24, 72 and 
120 hours culture, compared to that of the polymer only condition at each time point.  mRNA levels 
of Albumin (A), CYP1A2 (B), CYP2B6 (C), CYP3A4 (D), Collagen I (E) Collagen IV (F), and Fibronectin 
(G) are represented as fold difference relative to tissue culture plastic controls and relative to the 
housekeeping gene GAPDH. One-way ANOVA with Games-Howell post hoc testing and minimum 




The production of an alternative to whole organ transplant for treatment of liver disease patients is a 
vital avenue for research in the face of increasing donor shortages, treatment costs and disease 
burden on national healthcare systems. Equally, the analysis of primary hepatocyte behaviour on 
manufactured culture environments is vital to the field of liver biology. A platform which can produce 
consistent, high quality scaffolds for liver cell survival and function would go some way to furthering 
knowledge of hepatocyte biology, liver disease and provide a potential treatment and drug testing 
bed without involving the use of animals and animal tissues.   
An electrospun fibre approach was taken in the study to mimic the morphology of healthy fibrillary 
collagen 24,299, a major constituent of the human liver extracellular matrix in vivo. PLA was used for the 
fabrication of electrospun scaffolds due to its biodegradable nature and elasticity 26, and it’s previous 
use in liver scaffolding studies 228,312, and favourable cell adhesion in initial tests.  
The hepatic ECM is a highly plastic biomaterial, subject to constant modification and varies massively 
between tissues 285, and between healthy and diseased livers 283,284. As the ECM is such a dynamic 
structure, it stands to reason that its production and maintenance will be influenced by its surrounding 
environment in 3D culture 73. Following on from the work presented in Chapter 3, which revealed that 
histone deacetylase inhibitors (iHDACs) do indeed alter ECM production in culture, iHDACs were used 
again to manipulate the cellular environment and alter the ECM production. Sodium butyrate (NaBut) 
is widely used in industry to increase yield recombinant protein yields in mammalian cells. Valproic 
acid (ValA) is an FDA approved anti-convulsant which also functions as an iHDAC to increase 
recombinant protein yields 289. Histone deacetylase inhibitors influence gene expression via their role 
in deacetylation; the process by which DNA renders itself less transcriptionally active. Inhibiting this 
process in cells results in hyperacetylation of histones and subsequently increases transcriptional 
activity 290. Once again, results indicate not only that the iHDACs significantly alter the production and 
consistency of the ECM, but that this technique is robust and reproducible and the ECM it produces, 
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when harnessed in combination with 3D scaffolding technologies, creates a biofuctionalized scaffold 
which significantly alters the behaviour of liver cells. Equally, these scaffolds can be simply stored by 
freezing and remain biologically active for subsequent seeding of primary human hepatocytes. 
Previous work took advantage of a bladder epithelial cell line for the initial ECM producing cell layer, 
however in this instance THLE-3 liver cells were used; a cell line derived from normal primary liver cells 
derived from the left lobe of a human liver. The cell line was immortalized via infection with SV40 large 
T antigen and expresses the phenotypic characteristics of normal adult liver epithelial cells. They are 
nontumorigenic when injected into athymic nude mice, have near-diploid karyotypes, and do not 
express alpha-fetoprotein. THLE-3 cells metabolize benzo(a)pyrene, N-nitrosodimethylamine, and 
aflatoxin B1 to their ultimate carcinogenic metabolites that adduct DNA, which indicates that they 
possess functional cytochrome P450 pathways 144,251. THLE-3s were used to address minor concerns 
that the ECM produced by the initial cell layer is not a ‘liver ECM’ and that this may have an influence 
on the functional cell layer. However, multiple studies and product continue to use inter-organ and 
even multi-animal sources of ECM. Several decellularized ECM products on the market are in clinical 
use to regenerate tissues from which they are not derived, including ALLOPATCH HD™, MatriStem® 
and Tutoplast® Pericardium300. Indeed, hepatocytes are often cultured on ‘ECM’ surfaces which are 
not derived from liver, commonly using Matrigel®, a product derived from murine sarcoma which is as 
yet undefined and experiences batch to batch variability 12,154,301–303. The promising field of whole 
organ decellularization is hampered by the availability of human livers, and researchers are 
subsequently investigating alternative organ and cells sources, such as spleen, bone marrow 
mesenchymal stem cells 174,304 174and various animal sources of livers 36. With this body of knowledge 
in mind, the hypothesis that hepatocytes may respond equally favourably to non-liver ECM and remain 
open to other sources of ECM for hybrid scaffold manufacture is not unwarranted. 
The use of primary human hepatocytes was undertaken to address concerns regarding the more 
commonly used cell lines. Previous work to assess the performance of the hybrid scaffolds, was 
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undertaken using HepG2s; derived from the hepatocarcinoma of a 15-year-old Caucasian male. They 
are often used because they are virus free, possess liver specific functions such as ammonia 
metabolism and albumin synthesis and secrete some growth factors such as insulin and insulin-like 
growth factor II 138, however they are limited in their translatability because they are derived from a 
carcinoma and are tumourigenic. By taking advantage of the rare resource provided by donor human 
livers, the clinical translatability of the hybrid scaffold platform is increased and further knowledge of 
the behaviour of primary human hepatocytes in engineered culture environment is elucidated. Cell 
attachment and metabolic viability, and gene expression of both liver function genes and ECM genes 
at both 24, 72 and 120-hour time points. Additionally, the decellularization of the ECM producing cell 
layer was validated and immunohistochemical analyses of the hybrid scaffold-ECM constructs upon 
which the HepG2s were seeded performed.  
This work is a robust body of ‘next stage’ research regarding manipulation of ECM production, and has 
produced a repeatable method of hybrid polymer-ECM scaffolds with great potential for liver tissue 
engineering and shown that these scaffolds can be stored frozen for future use and maintain 
bioactivity and sterility. Further work is required to analyse results and increase translatability. 
Primary human hepatocytes are a highly valuable research resource; however, the donors are derived 
from a pool of individuals whose organs are rejected for whole organ transplant into living recipients. 
This indicates that their livers, and therefore their hepatocytes are not in the utmost of health. Further 
work should ideally be undertaken using healthy human donor hepatocytes. Furthermore, while 
hepatocytes are the major parenchymal cell of the liver (making up more than 70% of the cellular 
mass), they do not exist in isolation and the non-parenchymal cells play an essential role in the in vivo 
liver 124,305; future studies should look to include a co-culture element. In addition, recognising the 
value of proteomic and functional assays (such as ELISAs) in analysing the function of the primary/stem 
cell derived hepatocytes will be important for future validation of the scaffolds, however at this time 
these were deemed unnecessary considering the health of the donor hepatocytes Additionally, care 
should be taken to ensure decellularization agents are completely removed from the scaffolds, due to 
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their deleterious effect on both cells and ECM 287. While such considerations are of importance, this 
chapter clearly demonstrates the potential of these hybrid polymer-ECM scaffolds for tissue 
engineering, provides a robust initial platform for further research and addresses the hypothesis and 
aims of this thesis to produce novel hybrid scaffolds which influence liver cell behaviour. 
4.5 Conclusion 
This chapter developed a new method of creating hybrid polymer-ECM scaffolds by manipulating cells 
using electrospun scaffold technologies, clinically relevant iHDACs and methods easily modified to 
fulfil good manufacturing practice (GMP) regulation. To do so, a sacrificial, ECM-producing cell layer 
was seeded onto a novel electrospun scaffold and then treated with valproic acid or sodium butyrate 
to biofuctionalize the scaffold with ECM components. Scaffolds with untreated cells and no initial cell 
layer at all were used as controls. The initial cell layer was removed with a detergent based 
decellularization method, and the resulting hybrid polymer-ECM scaffolds were stored at -80°C until 
a source of donor primary human hepatocytes was available for use as a functional cell layer. The work 
was validated using robust methods such as Q-PCR, mechanical quantification and scanning electron 
microscopy. Drug induced hybrid polymer-ECM scaffolds had a significant positive influence on the 
gene expression profile and albumin production of primary human hepatocytes. This data 
demonstrates promise as a unique method of inducing and altering the production of ECM and that 
the hybrid scaffolds exert influence upon cells in vitro, as well as future potential as an implantable 
treatment platform for liver disease patients and testing bed for development of novel 














The production of synthetically derived fibronectin 








Synthetic biology and genetic engineering are vital tools for tissue engineers and have been used to 
alter gene expression, enhance intracellular imaging and study fundamental processes in 
hepatocytes313–315. Recently, synthetic biology tools have been successfully employed to direct both 
stem cell lineage and fate in 3D constructs316,317, in the manipulation of biofilms for cell culture318 and 
in the production of therapeutic proteins in in vivo systems319,320 demonstrating the ability of synthetic 
biology techniques to manipulate 3D environments and thus their potential benefit to the field of 
tissue engineering.  Ground-breaking CRISPR321–323 and minicircle vector324–326  technologies have 
made the idea of therapeutic gene editing in humans a viable reality. However concerns exist 
regarding the safety and subsequently, the translatability of such tools with regards to patient 
treatment; particularly with the recent revelation that the much lauded CRISPR technology causes 
mass deletions and mutations in vivo165,327. Heavily publicised and tragic events such as the 1999 death 
of 18 year old Jesse Gelsinger328 and the 2002 clinical trial in which four children developed leukaemia 
following gene therapy for their Severe Combined Immune Deficiency disease329 have led to obvious 
worries regarding the safety of gene therapies. 
 The inflammatory and immune modulating effects of damage-associated molecular patterns (DAMPs) 
such as foreign DNA fragments330 are well documented, however clinical use of decellularized ECM in 
exogenic and allogenic form has demonstrated great promise, giving no immune response and 
showing regenerative potential, despite emerging evidence of remnant nucleic acid reservoirs and 







Table 5.1; the advantages of a combinatorial approach to tissue engineering of liver environments. 
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With the potential of synthetic biology for manipulation of protein production in mind, this chapter 
developed a novel bio-active hybrid scaffold which possesses the potential for customization of the 
ECM microenvironment. To date, this is the only work where synthetic biology and electrospinning 
have been combined. The scaffolds were successfully decellularized, and validated the platform using 
cells representative of the liver, HepG2s. 







5.2 Materials and Methods 
All methods were performed according to protocols laid out in Chapter 2. Specific details are 
described forthwith. 
5.2.1 Electrospinning 
A 10% wt/vol solution of poly-L-lactic acid (Goodman) and hexafluoroisopropanol (Manchester 
Organics) was used to electrospin the scaffolds under the following parameters;  














0.5ml 10ml 14 cm 16kV -3kV 250rpm 100mm/s 
 
The mandrel was coated in non-stick aluminium foil for collecting the electrospun fibres. The sheets 
of electrospun fibres were allowed to dry overnight in a fume hood when the electrospinning session 
was completed. The average fibre size was 1.48µm as calculated by ImageJ plugin ‘DiameterJ’ 230. 
5.2.2 Scaffold Preparation 
10mm discs of scaffold were cut from the dry fibre sheet and sterilised with isopropyl alcohol. 
Scaffolds were placed into an antibiotic/antimycotic treatment for 1 hour. 
5.2.3 Initial Layer Cell Seeding and Culture 
Scaffolds were removed from the antibiotic/antimycotic treatment solution and rinsed three times for 
15 minutes each in complete media; Dulbeccos Minimal Essential Media supplemented with 10% 
foetal bovine serum, 2mM L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin (Gibco). They 
were then placed into a fresh 48 well tissue culture plate. 
5637 human urinary bladder epithelials (ATCC) were cultured and expanded as per supplier 
recommendations, using the media described above. Cells for scaffold seeding were trypsinized using 
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0.25% Trypsin-EDTA (Gibco) from tissue culture flasks and counted using the trypan blue exclusion 
method. 1 x 105 cells at passage 23 were suspended in 100µl of complete media and seeded directly 
on to the scaffolds. The cells were allowed to incubate in this small volume on the scaffolds for 2 hours, 
before an additional 400µl of complete media was added.  
Media was changed after 24 hours using standard methods and subsequently changed every 48 hours. 
Controls were scaffold only, i.e. not seeded with an initial cell layer and a ‘normal’ initial layer i.e. 
untransfected cells. Initial layers of cells were cultured for 7 days at 37ºC and 5% CO2 in a humidified 
incubator. 
5.2.4 Fibronectin Vector 
Vectors were obtained from the DNASU plasmid repository. In brief, the human fibronectin gene (FN1) 
was placed into a retroviral expression vector, PJ1520. The insert sequence was verified by sequence 
analysis and restriction enzyme digest by DNASU. The vector was obtained in DH5-alpha T1 phage 
resistance Escheria coli glycerol stock. The E. coli were cultured under selective conditions; 100µg/ml 
ampicillin, 34µg/ml chloramphenicol and 7%wt/vol sucrose in LB media. Plasmid extractions were 
performed using Cambridge Bioscience’s Zyppy™ plasmid extraction kit following manufacturer’s 
methods. 
5.2.5 Transfections 
Transfections were performed using Invitrogen Lipofectamine 3000®. Following titration experiments, 
a concentration of 1µg plasmid DNA and 0.75µL lipofectamine reagent per scaffold was chosen. The 
initial layer of 5637 epithelials was cultured on the scaffolds under standard conditions for 7 days. 
Transfection was performed on the 7th day. Scaffold-cell constructs were then placed into selective 
media containing 150µg/ml puromycin. The cell-scaffold constructs were cultured under selection for 




5.2.6 Decellularization  
Decellularization was performed under sterile conditions at room temperature (19 - 22ºC) and with 
agitation and then transferred to new 48 well plates for seeding. 
5.2.7 Functional layer Cell Seeding and Culture 
HepG2 cells were trypsinized using standard methods from tissue culture flasks and counted using the 
trypan blue exclusion method. 1 x 105 cells at passage 17 were suspended in 100µl of complete media 
and seeded directly on to the scaffolds. The cells were allowed to incubate in this small volume on the 
scaffolds for 2 hours, before an additional 400µl of complete media was added. 
Media was changed after 24 hours and changed every 48 hours after the initial 24 hour adherence 
and recovery period. This functional layer (FL) of cells was cultured using standard methods for either 
3 or 5 days at 37ºC and 5% CO2 in a humidified incubator. 
5.2.8 Live/Dead® Viability/Cytotoxicity assay 
To determine cellular viability, cell/scaffold constructs were incubated with 10µm calcein and 2µm 
ethidium ho-modimer-1 (Ethd-1) for 30 minutes as part of the two colour live/dead assay (Molecular 
Probes). All images were captured using a Zeiss Axio Imager fluorescent microscope (COIL, University 
of Edinburgh) at 40x magnification and post processed using ImageJ. 
5.2.9 CellTiter-Blue® Cell viability assay 
The assay was performed according to manufacturer’s instruction (Promega). For each condition 
group, n = 5. Importantly, cell/scaffolds constructs were moved into fresh 48 well plates to prevent 
reading activity from tissue culture plastic bound cells. Measurements were read in a Modulus™ II 
microplate reader at an excitation wavelength of 525 nm and emission wavelength of 580-640 nm and 




5.2.10 Albumin quantification 
A bromocresol green (BCG) albumin assay (Sigma) was used to quantify serum albumin produced by 
the HepG2 functional cell layer over 24 hours at 3 and 5 day time points. The assay was performed 
according to manufacturer’s instructions and results read at an absorbance of 620 nm in a Modulus™ 
II microplate reader. For all groups, minimum n = 5. 
5.2.11 Picogreen® DNA quantification 
The Quant-IT™ Picogreen® dsDNA assay kit (Life Technologies™) was employed to establish the 
efficiency of the decellularization method in removing cellular material and to estimate cell number 
on the cell/scaffold constructs. Fluorescent intensity measurements were read in a Modulus™ II 
microplate reader at an excitation wavelength of 480 nm and emission wavelength of 510-570 nm. 
For all groups, minimum n = 5. 
5.2.12 Sectioning and staining 
The samples were rinsed three times in PBS (Gibco) for 15 minutes each, then fixed in 4% v/v formalin 
buffered in saline for 15 minutes at room temperature. After rinsing with fresh PBS, constructs were 
embedded in low melting temperature polyester wax (Electron Microscopy Supplies) using methods 
adapted from Steele et al. (2014). In brief, samples are dehydrated through 70-100% ethanol, then 
incubated in 50:50 ethanol:wax overnight at 45ºC overnight with agitation. The samples were moved 
into 100% wax for 3 hours at 45ºC and then fresh 100% wax for 1 hour at 45ºC. Samples were 
embedded and allowed 72 hours to fully cure before sectioning. Immunohistochemical staining was 
undertaken using antibodies for Collagen I (Stratech), Laminin (Stratech) and Fibronectin (Sigma).  All 
images were captured using a Zeiss Axio Imager system (Centre Optical Instrumentation Laboratory, 





5.2.13 Scanning Electron Microscopy 
SEM was used to characterise the scaffold architecture. Samples were mounted onto SEM chucks 
using double sided carbon tape and coated with a thin layer of gold and palladium alloy (Polaron 
Sputtercoater). All images were captured at 5 kV using a Hitachi S-4700 SEM (BioSEM, University of 
Edinburgh). 
5.2.14 Mechanical Testing 
Nanoindentation experiments were undertaken to establish the dynamic properties of scaffolds and 
decellularized ECM/scaffold constructs using the Keysight/Agilent 5200 nano indenter testing system. 
Scaffolds and constructs were subject to indentation by a DCM II actuator flat-ended cylindrical punch 
(D = 100µm) using a max load of 1g-f. All nanoindentation experiments were carried out on fresh, 
hydrated (suspended in PBS), unfixed samples in a stainless steel well chuck. A total of 36 indentations 
were carried out on each sample, 50nm apart. Indent sites were selected using the high precision X-Y 
stage within the testing system (Agilent). Poissons ratio was assumed to be 0.5 for each sample 273,274. 
Allowable drift rate was 0.1nm/s. A NanoSuite (Keysight Technologies) test method “G-Series DCM 
CSM Flat Punch Complex Modulus” was used for all testing 271,272. 
5.2.15 Gene Expression analysis 
RNA was extracted from constructs using standard Trizol (Fisher Scientific) methods and purified using 
Qiagen’s RNeasy spin column system. cDNA was synthesised using the Promega’s ImProm-II™ Reverse 
Transcription System. 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the LightCycler® 480 
Instrument II (Roche Life Science) and Sensifast™ SYBR® High-ROX (Bioline) system. Results were 
normalized to HepG2s of the same passage number grown on tissue culture plastic and compared to 
the housekeeping gene Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH). Analysis was 
performed using the 2–[delta][delta] Ct method 276,311, n = 5. Albumin (Alb), Cytochrome P450 Family 
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1 Subfamily A Polypeptide 1 (Cyp1A1), Cytochrome P450 Family 1 Subfamily A Polypeptide 2 (Cyp1A2), 
Cytochrome P450 Family 3 Subfamily A Polypeptide 4 (Cyp3A4), Collagen Type I alpha 1 (Col1A1), 
Collagen Type 4 alpha 1 (Col4A1) and Fibronectin Type 1 (FN1) were investigated, forward and reverse 
primers (Sigma) are detailed in Supplementary Table 1.  
5.2.16 Statistical Analysis 
One-way ANOVAs with Fishers, Games-Howell and Tukey280–282 post-hoc testing were performed using 
Minitab 17 Statistical Software and graphs generated using Origin software (OriginLab, Northampton, 

















5.3 Results  
5.3.1 Cell attachment and survival on scaffolds 
When compared to normal ECM derived from 
untransfected cells (N-ECM) and the scaffold 
alone (SO), a lower number of HepG2s 
adhered to the synthetically derived vector 
driven (SD-ECM) scaffold-ECM constructs (Fig. 
5.2). According to the CellTiter-Blue® results 
(Fig. 5.2A), the SD ECM layer maintained the 
growth of the HepG2s between days 3 and 5.  
However, this result is not concurrent with 
the Picogreen® DNA quantitation (Fig. 5.2B). 
This is most likely due to different data 
extraction methods and validation methods in 
the Picogreen and CellTiter-Blue assays. Both 
assays possess depth dependencies with 
regards to their efficiency and effectiveness in 
extracting data from fibrous scaffold 
constructs. Additionally, the assays were 
validated using 2D monolayer cell cultures. 
This would explain high standard deviations 
in the Picogreen® DNA quantitation dataset 
and slight different trends observed between the assays. These finding are corroborated by my recent 
published work of cells on electrospun scaffolds 28.  Live/Dead® Viability/Cytotoxicity images (Fig. 5.3) 
Figure 5.2; Cell titre blue and Picogreen results 
Cell titre blue assay indicating metabolic activity (A) 
and DNA quantitation of the functional layer (B). 
One way ANOVA with Games Howell post hoc 
testing, ** = p value <0.01. 
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demonstrate the metabolic viability of the functional HepG2 cell layer (FL), and that at day 5 the cells 
appear to be confluent and living, with low levels of cell death in each condition. 
5.3.2 Mechanical characterisation of scaffolds 
Reassuringly, both storage (G’) and loss (G”) modulus demonstrate significant differences between 
the three conditions (Fig. 5.4). Fibronectin is known to influence both the mechanical profile of the 
ECM85,332 and influence the maintenance and structure of other vital ECM proteins, such as collagen333. 
Equally, cells are known to respond to the mechanical and topographical influence a scaffold exerts296. 
Testing was performed at frequencies experienced by the human liver in vivo 292. Storage modulus (G’) 
Figure 5.3; Live/Dead® Viability/Cytotoxicity assay 
Viability of the FL was assessed by Live/Dead® Viability/Cytotoxicity staining assay. Results 
demonstrate the FL is metabolically viable at all assessed time points. 40x magnification. 
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ranged from 22.92±9.14 to 12.29±0.14 MPa and loss modulus (G’’) from 2.45±0.93 to 0.15±0.02 MPa 
at the frequencies detailed in tables 5.3 and 5.4.  
Table 5.3; Storage modulus G’ at mechanical excitation frequencies 
Frequency 
(Hz) 
Storage modulus, G’ (MPa) 
85.961 49.262 28.231 16.179 9.272 5.313 3.045 1.745 1 
Scaffold 
only 
22.92 22.84 22.72 22.60 22.48 22.38 22.34 22.82 23.04 
±9.14 ±9.10 ±9.05 ±9.00 ±8.95 ±8.91 ±8.86 ±9.11 ±9.20 
Normal 
12.36 12.37 12.36 12.33 12.31 12.29 12.29 12.33 12.43 
±0.14 ±0.14 ±0.14 ±0.14 ±0.14 ±0.14 ±0.14 ±0.14 ±0.14 
Synthetic 
14.64 14.78 14.77 14.73 14.67 14.61 14.56 14.58 14.68 
±0.61 ±0.59 ±0.59 ±0.59 ±0.61 ±0.62 ±0.65 ±0.71 ±0.65 
 
Table 5.4; Loss modulus G’’ at mechanical excitation frequencies 
Frequency 
(Hz) 
Loss modulus, G’’ (MPa) 
85.961 49.262 28.231 16.179 9.272 5.313 3.045 1.745 1 
Scaffold 
only 
2.45 1.60 1.12 0.85 0.68 0.61 0.58 0.70 0.69 
±0.93 ±0.62 ±0.45 ±0.35 ±0.30 ±0.28 ±0.27 ±0.34 ±0.35 
Normal 
1.05 0.64 0.41 0.28 0.20 0.16 0.15 0.18 0.16 
±0.16 ±0.10 ±0.06 ±0.04 ±0.03 ±0.02 ±0.02 ±0.02 ±0.02 
Synthetic 
1.46 0.90 0.61 0.45 0.37 0.33 0.33 0.38 0.35 
±0.22 ±0.11 ±0.06 ±0.04 ±0.03 ±0.03 ±0.05 ±0.04 ±0.04 
Figure 5.4; Mechanical characterization of decellularized scaffolds 
Decellularized ECM/scaffold constructs were subject to nanoindentation experiments to assess 
their dynamic properties. Results demonstrate significant differences in storage (A) or loss (B) 
modulus between the three conditions (Tables 3.3 and 3.4). One way ANOVA with Games Howell 
post hoc testing, ** = p value <0.01. 
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5.3.3 Biochemical characterisation of the hybrid polymer-ECM scaffolds 
Differences in the biochemical profile of the different ECMs were demonstrated by 
immunohistochemistry performed on decellularized hybrid scaffold sections (Fig. 5.5). Hepatic cells 
are very responsive to extracellular matrix proteins; particularly Collagen I, Laminin and Fibronectin 
Figure 5.5; Immunohistochemical investigation 
Immunohistochemistry staining of the decellularized ECM/scaffold constructs revealed significant 
differences in ECM components. Stains were performed for Collagen I, Laminin and Fibronectin, 
post processed using ImageJ . Staining demonstrates retention of major liver ECM proteins 
Collagen I (D, G), Fibronectin (E, H) and Laminin (F, I) following decellularization. Additionally, SO 
condition shows no positive staining as expected (A, B, C). 
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78,166,174. Fibronectin is ubiquitous in healthy liver 12,53, and antibody staining reveals altered levels of 
fibronectin in the synthetically derived ECM, as expected due to the introduction of the fibronectin 
vector (Fig. 5.5H).  ECM proteins do not exist in isolation, and fibronectin is known to influence the 
generation and laydown of other ECM proteins including collagen I and laminin 333,334, as evidenced in 
Fig. 5.5G and 5.5I when compared to N-ECM. The N-ECM is collagen I rich (Fig. 5.5D) with some 
fibronectin and laminin also present (Fig. 5.5E & 5.5F). Of note is that the SD-ECM appears to be 
concentrated on the outer layers of the electrospun scaffold. This could be due to the transfected cells 
being in fewer number than those which were not transfected (N-ECM), so they did not penetrate the 
scaffold to the same extent.  
5.3.4 Gene expression of HepG2s in response to hybrid polymer-ECM scaffolds 
Genes associated with both liver function and ECM production were assayed for gene expression (Fig. 
5.6). Albumin expression, a marker of appropriate liver cell differentiation and function, appears 
upregulated between day 3 and day 5 in each condition, confirming appropriate development of the 
cells. At day 5, expression is significantly upregulated in comparison to HepG2s grown on tissue culture 
plastic (TCP) on the SD-ECM constructs; with the highest levels of expression observed in SO and SD-
ECM conditions. Additionally, albumin mRNA expression is downregulated in comparison to TCP at 
day 3 in all conditions (Fig. 5.6A). Cytochrome P450s (CYP) are a family of enzymes involved in 
metabolism of xenobiotics and toxic compounds in the liver160,335,336. Cyp1A1 mRNA expression is 
significantly altered in comparison to TCP (Fig. 5.6B); upregulated at day 3 and downregulated at day 
5. Cyp1A2 mRNA expression is consistently significantly downregulated in all but one condition; day 3 
N-ECM (Fig. 5.6C). Cyp3A4 mRNA expression is upregulated in every condition, with a significant 
upregulation observed in response to SD-ECM (Fig. 5.6D). In addition, three ECM genes important for 
normal liver composition were assayed 53,77; Fibronectin (Fig. 5.6E), Collagen I (Fig. 5.6F) and Collagen 
IV (Fig. 5.6G). Considering the plastic nature of ECM, these genes are of interest with regards to 
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ongoing modification of the tissue microenvironment despite hepatocytes not being the main 
producers of ECM proteins in the liver 53,283.  
Collagen I is consistently upregulated, with significant upregulation observed at day 5 on SD-ECM. 
Equally, Fibronectin mRNA expression is significantly upregulated on day 5 SD-ECM constructs, though 
downregulated at day 3 on SO and N-ECM constructs. Collagen IV mRNA expression is consistently 
upregulated in each condition, with significant changes observed in all but day 3 N-ECM and SD-ECM. 
While such alterations in gene expression are promising, this chapter refrains from further assumption 
regarding cell response without further proteomic and functional analyses.  
Table 5.5; RT-PCR primers 
Albumin (Alb) 
For - CCTGTTGCCAAAGCTCGATG 
Rev - GAAATCTCTGGCTCAGGCGA 
Cytochrome P450 Family 1 Subfamily A 
Polypeptide 1 (Cyp1A1) 
For - AATTTCGGGGAGGTGGTTGG 
Rev - GATGTGGCCCTTCTCAAAGGT 
Cytochrome P450 Family 1 Subfamily A 
Polypeptide 2 (Cyp1A2) 
For - CTTCGCTACCTGCCTAACCC 
Rev - GTCCCGGACACTGTTCTTGT 
Cytochrome P450 Family 3 Subfamily A 
Polypeptide 4 (Cyp3A4) 
For-  TTTTTGGATCCATTCTTTCTCTCAA 
Rev- TCCACTCGGTGCTTTTGTGT 
Collagen Type I alpha 1 (Col1A1) 
For - GGACACAGAGGTTTCAGTGGT 
Rev - GCACCATCATTTCCACGAGC 
Collagen Type 4 alpha 1 (Col4A1) 
For - GACCCCCGGGAGAAATAGGT 
Rev - TTTGAAAAAGCAATGGCACTCC 
Fibronectin Type 1 (FN1) 
For - GAACAAACACTAATGTTAATTGCCC 
Rev - TCTTGGCAGAGAGACATGCTT 
Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) 
For – GTCTCCTCTGACTTCAACAG 










Figure 5.6; Q-PCR analysis of functional cell layer 
Quantitative analysis of gene expression was undertaken on the functional cell layer at three- and 
five-days culture, compared to that of HepG2s of the same passage and culture periods grown on 
tissue culture plastic. mRNA levels of Albumin (A), CYP1A1 (B), CYP1A2 (C), CYP3A4 (D), Collagen I 
(E) Collagen IV (F), and Fibronectin (G) are represented as fold difference relative to tissue culture 
plastic controls and relative to the housekeeping gene GAPDH. One-way ANOVA with post hoc 
testing and n = 4. * = p <0.05 ** = p<0.01. Error bars represent SD. 
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5.3.5 Albumin production 
Albumin levels are indicative of hepatocyte health and response to the microenvironment 78. Each 
condition results in differing levels of albumin production, with significant differences in protein levels 
observed between SO and SD-ECM at both 3 days and 5 days (Fig. 6), indicating that the N-ECM 





Figure 5.7; BCG albumin assay 
Albumin production between conditions, showing significant changes between SO and SD-ECM 
conditions at both time points. One way ANOVA with Games Howell post hoc testing, * = p value 
<0.05. ** = p value <0.01. 
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5.3.6 Confirmation of decellularization 
Decellularization was confirmed using Picogreen® DNA quantitation (Fig. 5.8G) and histological 
staining (Fig. 5.8A-F). A tenfold reduction in DNA combined with visual confirmation of an absence of 
DAPI nuclear staining and Phalloidin-514 actin staining on decellularized constructs, plus the presence 
of fibronectin antibody staining on both the N-ECM and SD-ECM decellularized constructs (Fig. 5.8E&F) 
provides evidence of efficient decellularization methods, and that synthetically derived fibronectin is 







Figure 5.8; Confirmation of decellularization  
 
Effectively decellularized constructs, with minimum remnant DNA detected by IHC (E,F) or 
picogreen (G). Scaffolds pre-decellularization shown in (A), (B) and (C). One way ANOVA with 





5.4 Discussion  
The extracellular matrix provides a microenvironment for cells which is not yet fully understood, nor 
replicable by existing manufacturing methods30,337–339. By manipulating human cells to produce a 
customizable blend of ECM components, and combining this with replicable electrospun scaffolds and 
decellularization methods the shortage of donor derived ECM bioscaffolds and the issues regarding 
animal-sourced biomaterials are negated30,287. Additionally, this platform has the potential to be used 
to model not only ‘healthy’ ECM microenvironments, but also those of disease and developing states. 
Fibrous electrospun scaffolds mimic the morphology of healthy fibrillary collagen24,25,340,341. PLA was 
used to fabricate the scaffolds, chosen for its compatibility with hepatocytes166 and its use in multiple 
types of medical device due to its predictable biodegradation rate and mechanical properties342,343.  
Fibronectin was chosen as the protein to synthetically overexpress due to its vital role in the liver85,344 
and its interaction with other ECM components such as collagen and laminin332,333. Fibronectin is a 
large dimeric adhesive glycoprotein which exists in both cellular and plasma forms, with roles in 
regenerating tissues, embryonic development and regulation of cell behaviours such as adhesion and 
migration345. The role of fibronectin in the liver is still unclear, with inhibition of fibronectin production 
or deposition improving fibrosis outcomes10,65. However, its vital role in the hepatic ECM is 
demonstrated by mutant mice who were specifically null in only the liver for both plasma and cellular 
fibronectin. The fibronectin-null livers not only develop highly disorganized/diffuse collagenous ECM 
networks, but when fibrogenesis was induced the null livers experienced more extensive fibrosis; 
thought to be due to fibronectins role in regulating TGF-β1 bioavailability344. Additionally, homozygous 
fibronectin null mutants display early embryonic lethality, while heterozygotes (with 50% of the 
normal plasma fibronectin levels) appear normal; suggesting a dose dependent role for fibronectin in 
development346. 
As an initial assessment of these novel hybrid scaffolds the attachment and function of a commonly 
used liver cell line, HepG2s was investigated, when cultured on the synthetically derived hybrid 
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scaffolds versus a wild type ‘normal’ hybrid scaffold and the scaffold alone. The HepG2 cell line was 
derived from the hepatocarcinoma of a 15 year old Caucasian male. They are often used because they 
are virus free, possess liver specific functions such as ammonia metabolism and albumin synthesis and 
secrete some growth factors138.  Cell attachment and viability, albumin production and gene 
expression of both liver function genes and ECM genes at 3 and 5 day time points were assayed. 
Additionally, the decellularization method was validated and both immunohistochemical and Raman 
spectrum analyses (data not shown) were undertaken of the hybrid scaffold-ECM constructs upon 
which the HepG2s were seeded.  
These results indicate not only that synthetically derived ECMs provide a viable method of 
biofunctionalising electrospun polymer scaffolds, but that the composition of the synthetically derived 
ECM-polymer hybrid scaffolds influences liver cells. That albumin production is significantly altered 
between SO and SD-ECM conditions, but not N-ECM conditions supports this assertion. Gene 
expression of key hepatic genes was altered on day 5 of SD-ECM conditions in every gene tested, 
whereas SO and N-ECM conditions only influence CYP1A2 and COL4A1 expression; demonstrating that 
the composition of the ECM is highly influential in tissue engineering. This in turn leads to questions 
regarding donor-donor variability of current decellularization work and its influence upon hepatic 
behaviour and a need for more reproducible hepatic microenvironments that this platform provides. 
While this study forms a robust initial proof of principle regarding the exploitation of synthetic biology 
for scaffold manufacture, and has produced a novel hybrid synthetically derived ECM- polymer 
scaffold with great potential for liver tissue engineering, further work is required to analyse results 
and increase translatability. Vector technologies and synthetic biology present obvious concerns with 
regards to patient safety319,347, and care should be taken to ensure all bacterial/ viral constructs are 
removed from the ECM layer. Detergent based methods used to strip the ECM of cells can be 
detrimental to the bioscaffold287,288, disrupting native tissue ultrastructure, decreasing 
glycosaminoglycan (GAG) content and reducing collagen integrity38,39 as well as disrupting lipid-lipid, 
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lipid-protein and protein-protein interactions40. Care should be taken to optimise this procedure in 
the future. HepG2s provide a convenient method of initial viability testing of the scaffolds, but they 
are derived from a carcinoma and as such criticism of their clinical relevance is well placed. Further 
studies will utilise primary or stem cell derived hepatocytes to combat such criticism. Additionally, 
recognition of the value of further proteomic and functional assays (such as ELISAs and Alkaline 
Phosphatase quantitation) in analysing the function of hepatocytes. Further, the importance of 
ensuring decellularization agents are removed from the constructs should not be underestimated, due 
to their influence upon cells and ECM35,287. While such criticisms are important to consider, this work 
clearly demonstrates the potential of synthetic biology for the design of bespoke ECMs and provides 
a robust initial platform upon which further, improved studies can be built. 
5.5 Conclusion 
This study demonstrates a novel method of creating a biologically bespoke hybrid ECM-polymer 
scaffold for liver tissue engineering, addressing the aims and hypothesis of this thesis. In order to 
achieve this, a sacrificial ECM-producing cell layer was transfected using a protein producing 
fibronectin vector on an electrospun scaffold, biofunctionalising the scaffold with a biologically 
bespoke ECM. Scaffolds with wild type untransfected cells and no initial cell layer at all were used as 
controls. The sacrificial cell layer was successfully removed with a detergent based method and the 
hybrid synthetically derived ECM-polymer scaffolds seeded with HepG2 liver cells for validation. 
Results were validated using multiple well characterized methods, including mechanical quantitation, 
Q-PCR and immunohistochemistry. The synthetically derived PLA-ECM scaffolds exert biological 
influence upon liver cells, manipulating their microenvironment and resulting in alterations in gene 
expression profile, protein synthesis and cell attachment and survival. These differences are not 
recapitulated in the polymer only scaffolds, indicating the ECM component of the hybrid scaffolds 
exerts a separate influence to the polymer alone. Such data demonstrates promise as a unique 
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method of creating biologically bespoke ECMs and exerting influence upon cell populations both in 
vivo and in vitro.  
These novel scaffolds exhibit great promise both as an implantable patient treatment for liver tissue 
engineering, for adaptation to other tissues and as a useful tool for development of 3D liver cell culture 
















Blended protein and decellularized human liver:poly-








In an effort to address the shortage of ECM like environments for hepatocytes, researchers have been 
incorporating bioactivity into scaffold environments for hepatocytes11,12,15. Decellularized extracellular 
matrix is the obvious avenue for such research30,348, and while results are promising a decellularized 
liver still requires a donor liver and recellularization. Obstacles such as necrosis, immune reaction and 
residual decellularization agents are all yet to be fully addressed for decellularized whole organs to be 
a truly viable option36,213,348,349. Individual ECM components in the form of gelatin298,350, collagen43,44,351, 
laminin77,83,297 and fibronectin65,80,352 have all been employed; each influencing the hepatocytes 
survival and function and providing insight into the complex cell-matrix interactions present in the 
hepatic microenvironment. However each protein individually represents a small fraction of the 
bioactive molecules present in the ECM and when used in isolation cannot recapitulate the healthy 
hepatic matrix77,78,353. 
With this work in mind this chapter develops a new scaffold for liver tissue engineering; for the first 
time incorporating human liver ECM (hLECM) directly into the fibres of electrospun polymer scaffolds. 
By combining the best of current scaffolding technology; reproducible polymeric scaffolds and 
efficiently decellularized human donor liver this work produced a niche bioinfluential 
microenvironment which influences the function of cultured human hepatocytes. 







All methods were performed according to protocols laid out in Chapter 2. Specific details are 
described forthwith. 
6.2.1 Ethics and Governance 
All human tissue used in this study was provided by NHS Organ Donation and Transplant and NHS 
Blood and Transplant. No organs/tissues were procured from prisoners. Ethical approval was granted 
for the project from the North of Scotland Research Ethics Committee, ref 16/NS/0083. Informed 
consent for organ donation for research purposes was obtained in accordance with the Helsinki 
Declaration. Tissue from one liver was used in this study. 
6.2.2 Decellularization 
Decellularization of human liver tissue was performed at room temperature (19 - 22ºC) in a custom 
made perfusion decellularization system (Fig 2.2, Chapter 2 Methods). Decellularized tissue was stored 
at -20ºC ant defrosted at room temperature prior to use. 
6.2.3 Preparation of hLECM  
Decellularization was confirmed using the Quant-IT™ Picogreen® dsDNA assay kit (Life Technologies™), 
performed according to manufacturer’s instructions. The ECM was lyophilized in a FreeZone® 4.5 
freeze-drier (Labconco®) before milling in a PM100® planetary ball mill (Retsch®).  
6.2.4 Preparation of proteins for electrospinning 
The powdered hLECM was solubilized in 0.25M acetic acid (Acros Organics) at a concentration of 25µg 
per ml. Bornstein and Traub Type I collagen (Sigma Type VIII), powder from human placenta (hBTC1), 
human recombinant laminin 521 (hRL521) (Biolamina), and human plasma fibronectin (hFN) (Merck) 
were all solubilized similarly and   incorporated into the electrospinning solutions using the same 
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methods. A control scaffold consisting of polymer only in the 9:1 HFIP:0.25M acetic acid was also 
incorporated into the study. 
6.2.5 Preparation of electrospinning solutions 
A 22% wt/vol solution of poly-L-lactic acid (Goodman) and 9ml hexafluoroisopropanol (Manchester 
Organics) was dissolved overnight at room temperature with agitation. 1ml of 0.25M acetic acid (Acros 
Organics) containing 25µg protein was added to the 22% poly-L-lactic acid:HFIP solution and combined 
at room temperature under agitation for 1 hour.   
6.2.6 Electrospinning 
Blended solutions were used to electrospin scaffolds under the following parameters;  














2.5ml 7.5ml 23 cm 16kV -3kV 300rpm 100mm/s 
 
The average fibre size of each scaffold is reported in Table 6.2; 
Table 6.2; Fibre sizes 
Scaffold Polymer only hBTC1 hFN hRL521 ECM 
Average fibre 
Size (µm) 
1.82 1.60 1.72 1.17 2.01 
 
6.2.7 Scaffold Preparation 
10mm discs of scaffold were cut from the dry fibre sheet and sterilized in 30% isopropyl alcohol then 
placed into an antibiotic/antimycotic treatment. 
6.2.8 Cell Seeding and Culture 
THLE-3 cells were trypsinized using standard methods from tissue culture flasks and counted using the 
trypan blue exclusion method. 1 x 105 cells at passage 14 were suspended in 100µl of complete media 
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and seeded directly on to the scaffolds. The cells were allowed to incubate in this small volume on the 
scaffolds for 2 hours, before an additional 400µl of complete media was added. 
Media was changed after 24 hours and changed every 48 hours after the initial 24 hour adherence 
and recovery period. This functional layer (FL) of cells was cultured using standard methods for either 
5, 10 or 16 days at 37ºC and 5% CO2 in a humidified incubator. 
6.2.9 Live/Dead® Viability/Cytotoxicity assay 
To determine cellular viability, cell/scaffold constructs were incubated with 10µm calcein and 2µm 
ethidium homodimer-1 (Ethd-1) for 30 minutes as part of the two colour live/dead assay (Molecular 
Probes). Calcein is actively converted to calcein-AM in living cells, which then appear green when 
excited during fluorescence microscopy. Ethd-1 only accumulates in dead cells, which subsequently 
appear red. The method allows differentiation between dead and viable cells. The scaffolds were 
rinsed three times in CaCl2/MgCl2 free PBS to remove excess dye and placed onto a standard 
microscope slide with a 25mm glass coverslip (VWR). All images were captured using a Zeiss Axio 
Imager fluorescent microscope (COIL, University of Edinburgh) at 40x magnification and post 
processed using ImageJ. 
6.2.10 CellTiter-Blue® Cell viability assay 
The assay was performed according to manufacturer’s instruction (Promega). For each condition 
group, minimum n = 5. Importantly, cell/scaffolds constructs were moved into fresh 48 well plates to 
prevent reading activity from tissue culture plastic bound cells. Measurements were read in a 
Modulus™ II microplate reader at an excitation wavelength of 525 nm and emission wavelength of 
580-640 nm and reported as fluorescence.  
6.2.11 Albumin quantification 
A bromocresol green (BCG) albumin assay (Sigma) was used to quantify serum albumin produced by 
the THLE-3 functional cell layer over 24 hours at 5, 10 and 16 day time points. The assay was performed 
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according to manufacturer’s instructions and results read at an absorbance of 620 nm in a Modulus™ 
II microplate reader. For each condition group, minimum n = 5. 
6.2.12 Picogreen® DNA quantification 
The Quant-IT™ Picogreen® dsDNA assay kit (Life Technologies™) was employed to establish the 
efficiency of the decellularization method in removing cellular material and to estimate cell number 
on the cell/scaffold constructs. The assay was performed according to manufacturer instructions. 
Fluorescent intensity measurements were read in a Modulus™ II microplate reader at an excitation 
wavelength of 480 nm and emission wavelength of 510-570 nm. Minimum n= 5 for each group. 
6.2.13 Sectioning and staining 
The samples were rinsed three times in PBS (Gibco) for 15 minutes each, then fixed in 4% v/v formalin 
buffered in saline for 1 hour at room temperature. After rinsing with fresh PBS, constructs were 
stained using antibodies for Collagen I (Stratech), Laminin (Stratech) and Fibronectin (Sigma). 
Additionally, top down images of cells on the scaffolds were obtained by staining with DAPI (Sigma), 
Phalloidin (Sigma) and E-Cadherin (Abcam). All images were captured using a Zeiss Axio Imager system 
(Centre Optical Instrumentation Laboratory, University of Edinburgh) at 40x magnification and post 
processed using ImageJ. 
6.2.14 Scanning Electron Microscopy 
SEM was used to characterise the scaffold architecture. Samples were mounted the samples onto SEM 
chucks using double sided carbon tape and coated them with a thin layer of gold and palladium alloy 
(Polaron Sputtercoater). All images were captured at 5 kV using a Hitachi S-4700 SEM (BioSEM, 
University of Edinburgh). 
6.2.15 Mechanical Testing 
Tensile testing was undertaken to establish the dynamic properties of scaffolds and hLECM using the 
Instron 3367 dual column universal testing system with Bluehill 3 software.  The system was fitted 
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with Instron biopulse submersible pneumatic side action grips and a 50N load cell.  A gauge length of 
20mm and an extension rate of 20mm/min were used for all tensile tests. Analyses was conducted 
using the incremental modulus method as previously described24,26. 
Six samples of each scaffold with a width of 10mm and a gauge length of 80mm were obtained from 
each sheet.  Samples were fixed to ‘C’ shaped card templates to allow consistent set up during tensile 
testing. Samples were tested until failure. N=6.  
6.2.16 Gene Expression analysis 
RNA was extracted from constructs using standard Trizol (Fisher Scientific) methods and purified using 
Qiagen’s RNeasy spin column system. cDNA was synthesised using the Promega’s ImProm-II™ Reverse 
Transcription System. 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the LightCycler® 480 
Instrument II (Roche Life Science) and Sensifast™ SYBR® High-ROX (Bioline) system. Results were 
normalized to THLE-3s of the same passage number grown on tissue culture plastic and compared to 
the housekeeping gene Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH). Analysis was 
performed using the 2–[delta][delta] Ct method 276,311, n = 5. Albumin (Alb), Cytochrome P450 Family 
1 Subfamily A Polypeptide 1 (Cyp1A1), Cytochrome P450 Family 1 Subfamily A Polypeptide 2 (Cyp1A2), 
Cytochrome P450 Family 3 Subfamily A Polypeptide 4 (Cyp3A4), Collagen Type I alpha 1 (Col1A1), 
Collagen Type 4 alpha 1 (Col4A1) and Fibronectin Type 1 (FN1) were investigated, forward and reverse 
primers (Sigma) are detailed in Supplementary Table 1.  
6.2.17 Statistical Analysis 
One-way ANOVAs with Games-Howell and Tukey post-hoc testing was performed using Minitab 18 
Statistical Software. Multiple comparisons tests were used following the Ryan Joiner test for normality 
and Bartlett’s test for the homogeneity of variances. The Tukey post hoc test was used where Bartlett’s 
test result is not significantly different i.e. the null hypothesis of population variances being equal is 
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not rejected. The Games-Howell test does not assume equal variances and sample sizes and was 
performed on the ranked variables similar to other nonparametric tests. The Games-Howell post hoc 
test is used where Bartlett’s test result is significantly different i.e. the null hypothesis of population 
variances being equal is rejected. Error bars indicate standard deviation. A minimum of n = 3 and max 
of n = 6 was used for all analysis. * = p value <0.05, ** = p value <0.01, *** = p value <0.001. 








































6.3 Results  
This chapter’s results demonstrate a method of incorporating proteins directly into a scaffold 
environment and of making impactful use of a valuable tissue resource which would otherwise be 
wasted. Protein:polymer scaffolds containing human liver ECM exert a significant positive influence 
on the gene expression profile, albumin production, attachment, and survival of liver cells which 
cannot be recapitulated by individual ECM components. These scaffolds show great potential not only 
for the future of liver tissue engineering and patient treatment and are easily adaptable for other 
organs and tissues. 
6.3.1 Mechanical characterization of scaffolds 
Tensile testing revealed significant increases in the Young’s Modulus between the ECM scaffold and 
every other scaffold (Fig 6.2), indicating that incorporating human liver ECM into the scaffold results 
in a significantly stiffer environment for hepatocytes. Interestingly, hRL521 scaffolds were significantly 
more elastic than both hBTC1 and hFN scaffolds (Table 3). Such results demonstrate that the 
mechanical influence of varying ECM compositions influence on cell behaviour and function cannot 
be discounted in studies and must be considered when analysing biological results.  
Table 6.3; Elasticity (0-10% strain) 

















6.3.2 Histological characterisation of the scaffolds 
The presence of the various proteins was demonstrated by immunohistochemistry performed on the 
scaffolds (Fig 6.3). Collagen I, Laminin and Fibronectin were chosen because of their long established 
influence on hepatic cells 78,149,166. Fibronectin is ubiquitous in healthy liver, collagen I is the largest 
component of the healthy liver extracellular matrix and laminin is of particular importance in the 
differentiation of liver cells as well as for cell adhesion and liver regeneration 12,53. Each is clearly 
present in their respective single protein scaffolds, as well as in varying degrees in the ECM scaffold, 
with no false positive staining observed in the control polymer only condition. Reassuringly, this 
indicates that the antigens to which the primary antibodies bind were not affected by the 
Figure 6.2; Mechanical testing 
Incorporating human liver ECM into the scaffold produces a significantly stiffer environment for 
hepatocytes. hRL521 scaffolds are significantly more elastic than both hBTC1 and hFN scaffolds. 
N= 6, Data shown as mean ± 95% confidence interval with statistics performed using One way 
ANOVA with Games Howell post hoc analyses 
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solubilisation or electrospinning process, and therefore that some bioactivity is maintained 
throughout the scaffold fabrication process. 
 
 
Figure 6.3; Immunohistochemistry  
Collagen I, Fibronectin and Laminin are all present in their respective single protein scaffolds, as 
well as in varying degrees in the ECM scaffold, with no false positive staining observed in the 
control polymer only condition. Stains were performed for Collagen I, Laminin and Fibronectin, 
post processed using ImageJ. 10x magnification. 
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6.3.3 Cell attachment and survival on scaffolds 
Every scaffold maintains the survival of the THLE-3 liver cells and the number of cells increases 
significantly between each time point (Fig 6.4A). Interestingly, between conditions the only significant 
difference observed is between the polymer only and hLECM scaffolds at day 5, with higher 
 
Figure 6.4; Cell viability – Cell titre blue and picogreen DNA quantitation 
Cell adherence was assessed by CellTiter-Blue® Cell viability assay (A) and further confirmed by 
Quant-IT™ Picogreen® dsDNA assay (B). Minimum n = 5. Data shown as mean ± 95% confidence 
interval with statistics performed using One-way ANOVA with Tukey post hoc testing. * = p <0.05 
** = p<0.01, *** = p<0.001. Each condition maintains cell survival and the number of cells increases 
significantly between each time point (Fig 4A). A significant increase in fluorescence is observed 
between the polymer only and hLECM scaffolds at day 5 indicating that the presence of human 
liver ECM has a positive influence on the early expansion and/or metabolic activity of hepatocytes. 
A consistent pattern is observed in the DNA concentration (Fig 4B) on the scaffolds. 
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fluorescence observed on the hLECM scaffolds indicating that the presence of human liver ECM in the 
scaffold has a positive influence on the early expansion and/or metabolic activity of hepatocytes.  
Reassuringly, a similar pattern is observed in the DNA concentration (Fig 6.4B) on the scaffolds, with 
a difference observed between polymer only and hLECM conditions once again; more DNA is present 
on the hLECM scaffolds indicating the presence of more cells. Live/dead viability/cytotoxicity images 
(Fig 6.5) further demonstrate the continuing metabolic viability of the hepatocytes at the latest time 
point (16d), with a confluent population of viable cells present on the scaffold and a low level of cell 
death on each scaffold. Presence of a dense cell layer is further confirmed by SEM imaging (Fig 6.6), 
with a carpet of cells visible in each condition at 16d. 
Figure 6.5; Cell viability – Live Dead 
Live/Dead® Viability/Cytotoxicity staining analyses demonstrates continuing metabolic viability of 
the hepatocytes at the latest timepoint (16d), with a confluent population of viable cells and a low 
level of cell death on each scaffold. Viability of the FL was assessed by. Results demonstrate the FL 
is metabolically viable at all assessed time points. 10x magnification. 
Figure 6.6; SEM analysis 
The scaffolds were assessed for consistency and fibre size via scanning electron microscopy and 
subsequent image analysis. Fibres diameter was determined by DiameterJ 34, n = 4. 250x 
magnification. Presence of a dense cell layer is further confirmed by SEM imaging with a carpet of 
cells visible in each condition at 16d. 
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6.3.4 Gene expression of THLE-3s in response to hybrid polymer-ECM scaffolds  
Genes associated with both liver function and ECM production were assayed for gene expression (Fig 
6.7). Albumin (Fig 6.7A), a marker of appropriate liver cell differentiation and function, and 
Cytochrome P450s (CYP1A1 Fig 6.7B, CYP1A2 Fig 6.7C and CYP3A4 Fig 6.7D), a family of enzymes 
involved in metabolism of xenobiotics and toxic compounds in the liver 160,335,336 were both studied. In 
addition, three ECM genes important in normal liver composition were assayed 53,77; Fibronectin (FN1 
Fig 6.7E), Collagen I (COL1A1 Fig 6.7F) and Collagen IV (COL4A1 Fig 6.7G). Considering the constantly 
altering and responsive nature of ECM, these genes are of interest with regards to ongoing 
modification of the tissue microenvironment despite hepatocytes not being the sole producers of ECM 
proteins in the liver 53,283. Results were normalised to the polymer only condition to assay the influence 
of the protein component of the scaffolds on gene expression. 
Only the human liver ECM scaffold maintains albumin expression in the expected pattern, increasing 
over time; as seen in primary hepatocytes and other liver cell lines 354. CYP1A1 is consistently 
downregulated in comparison to the polymer only scaffolds in every condition over the 16 days. 
CYP1A2 is down regulated in comparison to polymer only, with significant changes observed on 
hRL521 and hBTC1 scaffolds at day 16. CYP1A2 is upregulated at day 16 on liver ECM, indicating an 
improvement in metabolic capability for hepatocytes grown in the hLECM scaffolds. All the single 
protein environments increase the expression of CYP3A4 in comparison to the polymer only 
environment. These changes in metabolic genes demonstrate the importance of protein 
microenvironment for hepatocyte function. hLECM scaffolds caused an increase in COL1A1 expression 
over the 16 days, with expression 100 times higher at 16 days than on the polymer only environment. 
Significant changes were observed between days 5 and 10, and 10 and 16 of hFN and hRL521 scaffolds, 
and between days 5 and 16, and 10 and 16 on hBTC1 scaffolds. COL4A1 was downregulated over time 
on all the single protein scaffolds, but increases over time on the scaffolds which incorporate hLECM, 
although is overall reduced in comparison to polymer only. Significant changes were observed 
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between days 5 and 16 on hBTC1 and days 10 and 16 on hRL521 scaffolds in FN1 expression. Reduction 
in expression of FN1 was slight in comparison to polymer only scaffolds.  
 
Figure 6.7; Q-PCR of key hepatic genes 
Quantitative analysis of gene expression was undertaken on the functional cell layer at five, ten 
and sixteen days of culture, compared to that of the same culture periods grown on polymer only 
scaffolds. Results are represented as fold difference relative to tissue culture plastic controls and 
relative to the housekeeping gene GAPDH. One-way ANOVA with Games Howell and Tukey post 
hoc testing and minimum n = 5. * = p <0.05 ** = p<0.01, *** = p<0.001. Error bars = SD. 
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 6.3.5 Albumin production 
Albumin levels are indicative of hepatocyte health and response to the microenvironment 11,78. hBTC1, 
polymer only and liver ECM all exhibit increasing production of albumin over time (Fig 6.8), as 
expected in a healthy hepatocyte culture and correlating with gene expression patterns observed in 
Fig 6.7. Interestingly, a significant increase in albumin production is observed on liver ECM scaffolds 
when compared with hRL521 scaffolds at day 10, and compared to hBTC1 scaffolds at day 5; indicating 
that hLECM is important for the production of albumin and that individual ECM components are not 




Figure 6.8; Albumin production 
Serum albumin produced by the THLE-3 cells over 24 hours at 5, 10 and 16 day timepoints. n = 6. 
Data shown as mean ± 95% confidence interval with statistics performed using One-way ANOVA 




6.3.6 Validation of tissue decellularization 
Picogreen was employed to validate the decellularization process and ensure minimal DNA was 
present in the scaffolds. Results reassure us that our decellularization process is effective. 
Table 6.4; Remnant DNA in scaffolds 
Scaffold 
Native 





hBTC1 hFN hRL521 hLECM 
DNA (ng 
p/mg) 



















A bioactive scaffold for hepatocyte culture is an important avenue for tissue engineering, meeting the 
need for an environment which supports the behaviour and function of hepatocytes in as close to an 
in vivo like state as possible. An optimised environment for hepatocytes can address the need for 
appropriate in vitro models and the shortage of treatment options and donor livers for patients.  By 
combining a valuable and underused resource such as human liver tissue with the reproducibility of 
polymeric scaffold manufacture a platform that can produce consistent, bioinfluential scaffolds for 
liver cell survival and function is developed. 
An electrospun fibre was chosen as the basis of these scaffolds as their fibrous nature mimics the 
morphology of native fibrillary collagen I in the liver extracellular matrix. PLA was used for this study 
because of its history of use in medical devices due to its biodegradation profile and compatibility with 
cellular environments. It is of note that the fibre diameter of each scaffold varied between proteins 
despite being electrospun under identical parameters. This method was employed to ensure the 
proteins were exposed to the same levels of electrical charge, solvent concentration and spinning 
time. The influence of fibre size when culturing upon electrospun scaffolds is yet to be fully elucidated, 
with evidence that variations between 0.3-1.3µm do not  influence cell behaviour340,355. 
The livers used in this study are an underutilised resource. The donors are approved for transplant, 
but for varying reasons the liver may not be taken for transplant. In this situation, approved 
researchers are contacted and offered the tissue. The livers would otherwise be disposed of as clinical 
waste. This platform provides a method of using these livers to create niche, biologically active 
microenvironments for hepatocytes without the concerns that come with the more commonly used 
animal sourced tissue. Equally, the decellularization process developed as part of this work is effective 
and importantly, does not rely upon an intact vasculature for efficient decellularization unlike other 
successful work. This means that traumatically injured livers which are beyond surgical repair, those 
with occluded vasculature or partial lobes of liver. While the field of whole organ decellularization is 
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a promising avenue for tissue engineers, it remains that the field is hampered by a lack of suitable 
whole organs. This method circumvents the need for whole organs. The platform vastly enlarges the 
pool of tissue available for this avenue of research and makes use of a precious resource donated by 
bereaved families which would otherwise go to waste when unsuitable for transplant. 
These results indicate that hLECM has an influence on hepatocytes which cannot be recapitulated by 
individual ECM components, confirming that there is a complex and not fully understood relationship 
between cells and the native extracellular matrix. This method is robust, reproducible and by 
harnessing ECM protein in conjunction with 3D scaffolding technologies a bioactive scaffold which 
significantly alters the behaviour of liver cells was produced. 
ECM products are in clinical use, with products such as SIS, ALLO- PATCH HD®, MatriStem®, and 
Tutoplast® all being used in regenerative medicine for the benefit of patients. Equally, the 
decellularization method completely removed the potentially immunogenic DNA from the ECM, 
allaying translational concerns.  
To assess scaffold performance THLE-3 cells were used; a non-tumorigenic line derived from the left 
lobe of a normal adult human liver144. Their adherence, growth and performance was assessed at 5, 
10 and 16 days post-replating when cultured in vitro on the scaffolds containing hFN, hRL521, hBTC1 
and hLECM versus scaffolds containing no protein; polymer only. Cell attachment and viability was 
assayed, as was gene expression of both liver function genes and ECM genes at both 5, 10 and 16 day 
time points. Additionally, retention of ECM proteins in the scaffolds through the electrospinning 
process and the effective decellularization of the human liver ECM were validated. 
This work has resulted in a robust platform for the production of blended protein:polymer scaffolds 
and a reproducible method of liver decellularization which does not rely on obtaining an entire organ. 
This chapter developed bioactive scaffold for liver tissue engineering which influence the behaviour 
and function of THLE-3 human hepatocytes. There is vast potential for the application of these 
scaffolds and methodology in the field of liver tissue engineering and the wider tissue engineering 
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community however further work is required to analyse the scaffolds influence on the cells and further 
improve the translatability of this work. While cell lines such as THLE-3s are undisputedly a highly 
valuable research resource, criticism of cell lines behaviour in vitro and the translatability of such 
results abounds within the scientific community 144,251. It is important to undertake future work using 
primary or stem cell-derived hepatocytes22,155,356–358 and incorporate other important stimuli such as 
fluid flow to combat such criticism37,99,175. Furthermore, while the parenchymal hepatocytes make up 
more than 70% of the cellular mass, they do not exist in isolation and non-parenchymal and immune 
cells play an essential role in the in vivo liver; future studies should look to consider co-culture75,142,153.  
The value of proteomic and functional assays (such as enzyme-linked immunosorbent assays) in 
analysing the function of the hepatocytes will be vital in any future studies. At this juncture these tests 
were deemed unnecessary considering the critiques of cell lines. Additionally, while every care was 
taken to ensure the complete removal of decellularization agents in the manufacture of these scaffold, 
this should be validated to ensure further translatability of this work, considering the deleterious 
effects of remnant detergent on cells 213,246,287.  
While such concerns are valid, this work clearly demonstrates the potential of blended ECM scaffolds 
for liver tissue engineering, utilising an underused and valuable resource of human liver tissue rejected 
for transplant and provides an robust initial platform for further research. 
6.5 Conclusion 
This work established a robust platform for the production of reproducible blended protein:polymer 
scaffolds for liver tissue engineering by combining human liver ECM with electrospun polymer 
manufacturing technologies. To do so, this chapter develops a consistent and effective method of 
decellularizing the tissue using a pressurised flow device. The ECM was successfully solubilized and 
incorporated directly into the fibres via the electrospinning solution. Additional scaffolds for 
comparison containing hFN, hBTC1 and hRL521 were manufactured. These were all compared to a 
scaffold manufactured with no protein. The protein:polymer scaffolds were seeded with a liver cell 
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line to assess their biological influence. The work was validated using robust methods such as Q-PCR, 
mechanical quantification, and SEM. Liver ECM containing protein:polymer scaffolds exert a significant 
positive influence on the gene expression profile, albumin production, attachment, and survival of 
liver cells.  
The results presented here demonstrate great promise as a method of incorporating liver ECM and 
other proteins directly into a scaffold environment and of making impactful use of a valuable tissue 
resource which would otherwise be wasted. These scaffolds show great potential not only for the 
future of liver tissue engineering and patient treatment but are easily adaptable for other organs and 
tissues. Additionally, they are a useful tool for the development of 3D liver cell platforms, which can 


























The aim of this PhD project was to investigate the effect of bioengineered scaffolds on the behaviour 
and function of hepatocytes in culture; within the remit of the liver tissue engineering field. In each 
chapter I utilised different method of combining ECM components with an electrospun polymer 
scaffold and investigated the hybrid scaffold’s influence on cells representative of the human liver. 
Specifically, the aims and objectives of this project were as follows; 
1. The manufacture of electrospun polymer scaffolds capable of maintaining hepatocyte survival 
 2. Combine polymer scaffolds with cutting edge protein production techniques to manufacture 
practical, reproducible and translatable hybrid polymer:protein scaffolds for liver tissue engineering 
3. Assess the impact of polymer only and hybrid scaffolds on hepatocyte survival and behaviour. 
Each of these aims has been addressed via the development of novel hybrid scaffolds to influence 
hepatocyte cell behaviour, survival and function. 
Electrospun polymer scaffolds biodecorated with drug induced11 and synthetically derived228 ECMs 
influence on both cell lines and primary human hepatocytes have been studied. Blended electrospun 
scaffolds containing single ECM proteins and decellularized human ECM effect on cell line derived 
hepatocytes have also been investigated. 
Chapter 3 used histone deacetylase inhibitors to alter the ECM produced by a bladder cell epithelial 
line when cultured on an electrospun PCL scaffold. The constructs were decellularized, and displayed 
significant changes in their mechanical properties, as well as an altered biochemical profile. A HepG2 
cell line was cultured on the decellularized constructs, and displayed markedly altered survival, 
metabolic activity and gene expression between the conditions. With the critique of this work in mind, 
namely the use of tumour-derived cell lines, I proceeded to further the translatability of this work in 
Chapter 4. A non-cancer liver cell line was used to derive the ECM component of the hybrid scaffolds, 
and PLA was used due to its favourable biodegradable nature and superior cell adhesion properties. 
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These scaffolds were decellularized and subsequently stored until a source of primary human 
hepatocytes was available. These scaffolds also demonstrated altered mechanical properties and 
biochemical profiles. They were seeded with the primary hepatocytes and the differences in ECM 
proteins and mechanical changes induced a subsequent alteration in the behaviour of the 
hepatocytes. Albumin production demonstrated changes in each condition, as did gene expression 
data; with particular note taken of the correlation between albumin gene expression patterns and 
albumin production. 
Chapter 5 took advantage of synthetic biology techniques to introduce a protein producing vector into 
the ECM producing initial layer of cells. Mechanical changes were reassuringly present, as was a 
change in the biochemical profile of the ECM when assessed using immunohistochemistry. Hep-G2 
cells were subsequently cultured on the decellularized constructs and demonstrated changes in cell 
survival, gene expression and albumin production.  
Chapter 6 made use of decellularized human tissue to create a novel blended scaffold environment 
for THLE-3 liver cells. Scaffolds containing decellularized human liver, fibronectin, laminin-521 and 
collagen I were compared to elucidate the influence of single ECM proteins vs whole ECM. Drastic 
mechanical differences were observed between scaffolds, and immunohistochemistry demonstrated 
retention of the proteins in the electrospun scaffolds. Interestingly, Only the human liver ECM scaffold 
maintains albumin expression in the expected pattern, increasing over time; as seen in primary 
hepatocytes and other liver cell lines 354 with the same pattern observed in albumin production. Initial 
results indicate that hLECM has an influence on hepatocytes which cannot be recapitulated by 
individual ECM components, leading us to conclude that there is a complex and not fully understood 
relationship between cells and the native extracellular matrix. 
Electrospinning was chosen as the scaffold fabrication method because of its morphological similarity 
to collagen fibres359. PLA and PCL were used for the electrospinning process due to their 
biocompatibility360 and use in existing medical devices361,362. PLA in particular was chosen as cells grew 
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preferentially on PLA fibres in initial tests. However, other scaffold fabrication methods may be 
appropriate for combination with ECM proteins, including hydrogels193,194, phase-separated363 and 
hollow fibre364 scaffolds. Novel polymers which influence hepatic behaviour are also, of course, an 
option and some work is focussing on finding novel substrates for liver tissue engineering202,306,365,366. 
Immortal cell lines were used throughout this work. Critique of the use of cell lines is discussed in 
depth by multiple publications, however as a ‘proof-of-concept' tool, they are invaluable to 
researchers111,138,172. They allow us to assess biocompatibility and differences between experimental 
conditions without the need for ethical approval for use of animal or human tissue donors or the 
complexities or economic burden of primary cell extractions and culture. Where cell lines are used, 
this work is very conservative in its extrapolation to the in vivo condition and care is taken to use non-
cancer derived cell lines where possible. 
Primary human hepatocytes are considered the gold standard human liver cell model367; although 
availability of human liver tissue and difficulties in isolating viable cells limits their widespread use. 
Many factors influence the successful extraction of hepatocytes (I.e. their viability and yield), including 
donor age and gender, the presence of steatosis or fibrosis and levels of donor serum enzymes133,368. 
Two-step perfusion methods are said to give the highest yields of hepatocytes, however such methods 
require intact and unimpeded vasculature; not always a possibility in donated human tissue369. As 
such, a collagenase digestion method was utilised here, and iso-density percoll centrifugation used to 
separate viable parenchymal cells from cell aggregates, debris, and nonparenchymal cells258. By 
ensuring Ithe hepatocytes are separated from the non-parenchymal cells a homogenous cell 
population which can be used for qRT-PCR analyses is obtained, as opposed to a co-culture which 
could not be easily assayed for hepatocyte gene expression. Cell purity could be further analysed using 
flow cytometry and the expression of CD95 on hepatocytes, however data suggests these methods 
reliably result in >90% purity370. 
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qRT-PCR allows for the quantification of gene expression, however gene expression does not always 
equate production of proteins due to the complex post-translational mechanisms involved371,372. 
Contamination of RNA samples is also a concern during the process; primers were designed to 
encompass exon junctions to avoid gDNA amplification (if contamination was present). Following 
purification, optical density was used to determine the quantity of RNA and presence of contamination 
from phenol/DNA373. Using these methods increases reliability and reassures that RNA expression is 
truly being assayed, as opposed to DNA content.  Further work to assay cell function could confirm 
gene expression results, a next stage analysis would be an enzyme linked immunoabsorbant assay 
(ELISA) or mass spectrometry to quantify proteins produced. 
 Oxidation-reduction (redox) assays like MTT and CellTiter Blue are both stable, homogenous assays 
commonly used to indicate mitochondrial activity and therefore metabolic viability in cells. One of the 
disadvantages is optical interference. Additionally some culture additives can give false positive 
results374. However, by combining these assays with other indicators of cell life and metabolic activity 
such as LiveDead and the BCG Albumin production assay reliability Is increased. 
Cell and protein imaging were performed using immunohistochemical (IHC) staining and fluorescent 
imaging in the majority of cases. In addition to these techniques, in chapter 4, CARS and TPEF imaging 
were used. IHC staining is a qualitative technique; blocking with buffers such as gelatine or bovine 
serum albumin must be performed to prevent non-specific binding of proteins. Antigen retrieval may 
be required to allow antibody binding. Inappropriate fixation can limit the resolution of molecules of 
interest by masking or damaging antibody binding sites. Samples less than 3um thick may produce 
very weak staining. However IHC as a technique is commonly used as a qualitative technique and is 
considered, when used with appropriate negative and positive controls, to be indicative of antigen 
presence375. CARS is an effective technique for imaging and was utilised here to image polymer 
scaffolds and to assess the presence of ECM proteins and cells. Exploiting this technique in conjunction 
with TPEF allowed images of a single plane along the Z-axis, producing high quality images. Overall, it 
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is an effective qualitative method for determining the presence of particular markers and has been 
used here and previously to confirm the presence of desired cells376 
Liver tissue engineering is a rapidly evolving field, with multiple internationally renowned scientists 
focussing on the urgent need for an alternative to whole organ transplant. The need for a reliable cell 
source is possibly the most heavily researched field, with several groups focussing on the development 
of hepatocyte-like cells derived from iPSCs and progenitor cells with a view to producing an unlimited 
supply of functional human hepatocytes with minimal ethical concerns regarding their source. Co-
culture of parenchymal and non-parenchymal cells is the focus of several groups, with liver spheroid 
technology proving promising153; hepatocytes can be maintained for 100s of days in such conditions377, 
and early stage work is being undertaken using these in animal transplant studies and fluidic 
devices378. Decellularization of whole organs has become a major focus of the liver tissue engineering 
community, recognising the opportunity to combine expertise in deriving large numbers of 
hepatocyte-like cells from progenitors and iPSCs with which to recellularize an otherwise useless 
organ. Some work is being undertaken to elucidate the influence of 3D culture variables, such as shear 
and oxygen concentration on hepatocytes, with a view to combining this knowledge with scaffolding 
expertise to produce liver ‘devices’ which can be used to dialyse toxins from patients’ bloodstreams 
or implant in place of an organ. 
The field of hepatocyte biology has given us insight into the behaviour of liver cells in vivo, and of the 
progress and treatment options for liver disease. However, critics argue the field is heterogeneous 
and fractured. Historic use of products such as Matrigel and gelatin to grow cells in culture, as well as 
premature extrapolation of results gained from these cells to in vivo and 3D systems has led to an 
unclear picture of the true behaviour of primary parenchymal and non-parenchymal cells. Researchers 
are beginning to pull the field together, with molecular biologists, cell culture experts and 
bioengineers working together to gain a true picture of the hepatic niche, with projects like HepatoSys, 
a consortium of German research centres studying the physiology and pathophysiology of the human 
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liver using systems biology. As a result of this heterogeneous background, this thesis is particularly 
careful not to make assumptions about expected hepatocyte behaviour and aim to present all data as 
a valuable contribution to the field of liver tissue engineering with no comment made on ‘improving’ 
function or ‘preferred’ conditions for the hepatocytes used in these studies. 
The work demonstrated here combines scaffolding, synthetic biology and decellularization techniques 
to produce hybrid, bioactive environments for hepatocyte culture. Polymer scaffolds have been 
previously been utilised in liver tissue engineering studies, primarily via their use in fibre-based 
bioreactors and hydrogels. To date, research using electrospun polymers for liver tissue engineering 
has been minimal despite its advantages in manufacture, mechanical properties and collagen-like 
fibrillar nature. The polymers used in these studies are prevalent in the tissue engineering community 
due to their biocompatibility, biodegradation profile, mechanical properties, low cost and simplicity 
of manufacture. While other polymers may be more beneficial to hepatocytes, the lack of robust 
research into the influence of scaffolding materials and polymers on hepatocyte behaviour this 
research provides a basis upon which to perform further studies. Screening-methods for novel 
materials such as those used by the Hay group at University of Edinburgh may prove invaluable in 
finding an ideal polymer for liver tissue engineering196,365. 
While decellularization of whole organs is proving beneficial and providing a wealth of insight into liver 
biology and function, it none-the-less requires an ongoing source of whole, undamaged and healthy 
livers. By combining these techniques with novel ECM generating methods as has been achieved in 
this project, the need for whole organs is circumvented and provide a bioactive environment with a 
demonstrative influence on hepatocytes. By taking advantage of methods used by industrial protein 
production; drugs to alter protein yield/production and synthetic biology to derive extracellular matrix 
proteins, novel scaffold manufacturing methods and environments for hepatocyte culture were 
created without the use of rare whole organs. When the opportunity to obtain human liver tissue 
presented itself, the work within this thesis provided the advantage of knowledge in decellularization 
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to investigate for the first time the influence of single ECM components in comparison to ‘complete’ 
human ECM, providing insight into the interactions of ECM components and hepatocytes. 
7.2 Further work 
Critique of each study is present within their respective chapters; however, one major criticism is the 
lack of proteomic analyses of the scaffolds. Mass spectrometry (MS)-based high-throughput 
proteomics is the core technique for large-scale protein characterization303,379. Due to the extreme 
complexity of proteomes, sophisticated separation techniques and advanced MS instrumentation is 
required to conduct such studies, and these would most likely be outsourced to specialist centres such 
as the University of Dundee’s FingerPrint proteomics facility. For early-stage research such as this, this 
was not deemed an effective use of limited resources but remains a clear next step for future work. 
Equally, use of cell lines has limited the translatability of this research. Cell lines were used due to their 
ready availability and, particularly in the case of Chapter 5, survival of the transfection process. 
Wherever possible ‘normal’ cell lines such as the THLE-3s were used to address critique of cancer 
derived cell lines. Future work should address this issue with the use of cells such as HepaRGs, iPSCs 
and primary human hepatocytes.  
Co-culture with non-parenchymal cells of the liver and with circulating cells such as red blood cells is 
also key to understanding and improving hepatocyte function. Kupffer cells, hepatic stellate cells and 
sinusoidal endothelial cells have all been used in co-culture with hepatocytes and are found to induce 
improvement in hepatocyte function and maintenance of hepatic phenotype irrespective of the type 
of cell used for co-culture. Such work is a vital next step for promising liver tissue engineering such as 
these hybrid scaffolds. 
Further methods of analysing the hepatocytes response to the scaffold environments and hepatic 
characterisation should be included in the next round of experimentation. Analysis of hepatocyte 
polarization by analysis of the tight junction protein ZO-1143,380, apical export protein MRP219,381 and 
bile canalicular protein DPP4160 should be assessed. The functional ability of formed bile canaliculi 
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should be evaluated by accumulation of fluorescein within the cells21,160,382. Mature hepatic protein 
production in addition to that of albumin should also be assessed, namely prealbumin, α-fetoprotein, 
fibrinogen, haptoglobulin, α2‑macroglobulin and fibronectin150,160,301. Heatmap analysis of the 
metabolic functions of the hepatocytes could prove useful when comparing results to studies from 
other groups383. 
Functional studies would be invaluable for the ultimate aim of creating an environment which 
supports hepatic cell survival and function. Acetaminophen toxicity studies384 and analysis of the 
CYP450 reductase enzyme production using ELISA or western blotting44,142,149 would demonstrate the 
translatability of these platforms. The scaffolds could easily be incorporated into flow devices such as 
Kirkstall’s QuasiVivo221 or scaled up for larger systems similar to the Extracorporeal Liver Assist Device 
(ELAD)227 to assess the cells function and behaviour under flow and shear stress.  
Finally, now that these methods have been established within the group, future researchers could 
work towards a more directed ECM; recapitulating disease environments or specific regions of the 
liver such as the sinusoid to study the influence of disease ECM or cell location on the hepatocyte and 
investigate methods of manipulating such behaviour or creating benchtop disease systems. 
7.3 Conclusion 
The aims for this project were laid out as 
1. The manufacture of electrospun polymer scaffolds capable of maintaining hepatocyte survival 
 2. Combine polymer scaffolds with cutting edge protein production techniques to manufacture 
practical, reproducible and translatable hybrid polymer:protein scaffolds for liver tissue engineering 
3. Assess the impact of polymer only and hybrid scaffolds on hepatocyte survival and behaviour. 
Each of these aims has been addressed in this body of work. Novel methods have been employed to 
deliver scaffolds which can be used to influence the survival and behaviour of hepatocytes. Each study 
presented in this thesis represents the initial, ‘proof-of-concept’ stage of a new environment for liver 
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tissue engineering. Each condition tested exerted a differing influence on the survival, metabolic 
activity, gene expression and protein production of the hepatocytes cultured upon it.  
In Chapter 3 drug-derived ECM:PCL scaffolds displayed significant changes in their mechanical 
properties, as well as an altered biochemical profile. HepG2s cultures on the constructs displayed 
markedly altered survival, metabolic activity and gene expression between the conditions. This work 
represents this first use of pharmaceuticals to manipulate ECM production for liver tissue engineering. 
In Chapter 4, the work from chapter 3 was furthered by the use of a liver cell line to derive the ECM 
component of the hybrid scaffolds, and a switch to PLA for its favourable biodegradable nature and 
superior cell adhesion properties. The drug derived ECM:PLA scaffolds also demonstrated altered 
mechanical properties and biochemical profiles. They were seeded with primary human hepatocytes 
and the differences in ECM proteins and mechanical changes induced a subsequent alteration in 
albumin production and gene expression. 
Chapter 5 produced  a synthetically derived fibronectin enriched ECM:PLA scaffold which displayed 
mechanical and biochemical differences between conditions. Hep-G2 cells were subsequently 
cultured scaffolds and I observed changes in cell survival, gene expression and albumin production. 
This chapter represents the first combinatorial approach to synthetic biology and electrospun scaffold 
production for liver tissue engineering,  
Chapter 6 produced a to create a novel blended human ECM:PLA scaffold for THLE-3 liver cells. 
Scaffolds containing decellularized human liver, fibronectin, laminin-521 and collagen I were 
compared to elucidate the influence of single ECM proteins vs whole ECM. The drastic mechanical 
differences and immunohistochemical profiles of the scaffolds induced changes in THLE-3 cell 
behaviour. Results indicate that hLECM has an influence on hepatocytes which cannot be 
recapitulated by individual ECM components, raising questions regarding the relationship between 
cells and the native extracellular matrix. This study is the first time whole human licer ECM has been 
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combined with electrospinning and compared to its individual recombinant constituents at the same 
concentrations and with the same scaffold manufacturing method employed. 
The hybrid scaffolds developed in this work are a powerful platform for the future manipulation of 
liver cell behaviour. They provide a non-invasive, animal-free culture environment for hepatocytes 
which, with development, has the potential to contribute greatly to the fields of drug development, 
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Supplementary figure 1; Immunohistochemistry demonstrating penetration of ECM proteins into 
electrospun scaffold. Data taken from Chapter 3; a drug induced hybrid protein:polycaprolactone 






Supplementary figure 2; Raman spectra of decellularized constructs demonstrating changes in 
scaffolds ECM composition. Data taken from Chapter 5; the production of synthetically derived 
fibronectin scaffolds for liver tissue engineering 
 
Raman spectroscopy is a method used for label free characterisation of organic materials. It uses laser 
spectroscopy to measure a vibrational spectrum of covalent bonds, with each frequency being specific 
to part of a molecule (e.g., CH2 groups in lipids, beta‐sheet proteins, RNA). The relative proportions of 
each of such chemistries gives rise to a “fingerprint” spectrum specific to each material or collection 
of molecules e.g. to cell phenotype. Using raman spectroscopy allows us to analyse scaffolds woithout 
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damage being incurred by methods such as immunohistochemistry, and allows us to use minimal 
sample sizes. 
Supplementary figure 3; Full vector sequence. Data taken from Chapter 5; the production of 


























































































































































Supplementary figure 5; Example picogreen calibration curve 
 
















































Cell titre blue calibration curve
5637 bladder epithelial cells THLE3 cells HepG2 cells
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Supplementary figure 8; SEM of HepG2 cultures at 3/5 days on frozen drug derived ECM:PLA 
scaffolds vs non-frozen (normal) and scaffold only condition 
 
 
Supplementary figure 9; Cell titre blue of HepG2 cultures at 3/5 days on frozen drug derived 
ECM:PLA scaffolds vs non-frozen (normal) and scaffold only condition. N = 6, one way ANOVA with 







































Supplementary figure 10; Gene expression analyses of HepG2 cultures at 3/5 days on frozen drug 
derived ECM:PLA scaffolds vs non-frozen (normall) and scaffold only condition. N = 6, one way 
ANOVA with Games-Howell post hoc testing. * = p<0.05. Results normalised to GAPDH and relatice 








Supplementary figure 11; Cell titre blue analyses of 5637 cell cultures at varying concentrations of 
histone deacetylase inhibitors. 750uM chosen because of the similarity in cell titre blue results 
between drugs. 
 
Supplementary figure 12; Cell titre blue analyses of 5637 cell on different percentages of PCL and 
different coatings. 5637 cells were chosen because of their survival in histone deacetylase inhibitors 
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A Drug-Induced Hybrid 
Electrospun Poly-Capro-Lactone: Cell-Derived Extracellular 
Matrix Scaffold for Liver Tissue Engineering 
Rhiannon Grant, MSc,1 David C. Hay, PhD,2 and Anthony Callanan, PhD1 
Liver transplant is the only treatment option for patients with end-stage liver failure, however, there 
are too few donor livers available for transplant. Whole organ tissue engineering presents a 
potential solution to the problem of rapidly escalating donor liver shortages worldwide. A major 
challenge for liver tissue engineers is the creation of a hepatocyte microenvironment; a niche in 
which liver cells can survive and function optimally. While polymers and decellularized tissues pose 
an attractive option for scaffold manufacturing, neither alone has thus far proved sufficient. This 
study exploited cell’s native extracellular matrix (ECM) producing capabilities using two different 
histone deacetylase inhibitors, and combined these with the customizability and reproducibility of 
electrospun polymer scaffolds to produce a ‘‘best of both worlds’’ niche microenvironment for 
hepatocytes. The resulting hybrid poly-capro-lactone (PCL)-ECM scaffolds were validated using 
HepG2 hepatocytes. The hybrid PCL-ECM scaffolds maintained hepatocyte growth and function, as 
evidenced by metabolic activity and DNA quantitation. Mechanical testing revealed little significant 
difference between scaffolds, indicating that cells were responding to a biochemical and 
topographical profile rather than mechanical changes. Immunohistochemistry showed that the 
biochemical profile of the drug-derived and nondrugderived ECMs differed in ratio of Collagen I, 
Laminin, and Fibronectin. Furthermore, the hybrid PCL-ECM scaffolds influence the gene expression 
profile of the HepG2s drastically; with expression of Albumin, Cytochrome P450 Family 1 Subfamily A 
Polypeptide 1, Cytochrome P450 Family 1 Subfamily A Polypeptide 2, Cytochrome P450 Family 3 
Subfamily A Polypeptide 4, Fibronectin, Collagen I, and Collagen IV undergoing significant changes. 
Our results demonstrate that drug-induced hybrid PCL-ECM scaffolds provide a viable, translatable 
platform for creating a niche microenvironment for hepatocytes, supporting in vivo phenotype and 
function. These scaffolds offer great potential for tissue engineering and regenerative medicine 
strategies for whole organ tissue engineering. 
Keywords: liver tissue engineering, electrospun scaffolds, acellular biological matrices, drug induced, 
3D liver cell culture 
Introduction biology, medicine, and engineering and encompasses a wide range of scientific disciplines, 
including polymer chemistry, 
s a result of rapidly increasing incidence and mor- using different polymers and manufacturing 
techniques to tality, a chronic shortage of liver donors, and a lack of support cell growth and 
differentiation;7–10 fluid dynamics, 
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viable new pharmaceuticals there is an urgent need for 
a solution for patients with liver disease.1–4 A significant 
proportion of research focuses on working toward a 
liver ‘‘organoid’’; organs created in a laboratory that 
can function as a liver in vivo.5,6 Such tissue engineering 
lies at the interface of 
designing bioreactors and micro-fluidic devices in 
which to grow cells;11–14 and molecular biology, 
manipulating the molecular environment and 
response of cells15–17 in an attempt to recapitulate an 
environment in which hepatocytes, the functioning 
cells of the liver, can function long term. 
1 
While scientists can maintain liver organoids 
within a laboratory environment, decades worth 
of scientific research has failed to translate this 
into an organ that could be used for patient 
transplant.5,6 This in part is due to the 
complexities of recapitulating a vital part of the 
in vivo multicellular environment, the 
extracellular matrix (ECM).18 
Multiple methods have been employed in an 
attempt to provide hepatocytes with an optimal 
environment; in particular decellularization of 
whole livers and novel threedimensional (3D) 
tissue-engineered scaffolds. Decellularization 
provides a whole organ ECM-based bioscaffold 
with the potential to maintain the 3D site-
specific architecture and highly conserved 
sinusoidal ECM gradient required for hepatocyte 
function upon their repopulation of the organ.18 
Several studies have repopulated decellularized 
organs with hepatocytes and endothelial cells, 
which subsequently survive and exhibit some 
level of function.19–23 However, this approach still 
requires precious donor organs, sourced from 
potentially immunogenic human or animal 
donors, and methods used are not without their 
drawbacks. 
Detergents such as sodium dodecyl sulfate, 
Triton-X100, and sodium deoxycholate are 
employed to strip the ECM of cells. These 
detergents disrupt native tissue ultrastructure, 
decrease glycosaminoglycan content, and reduce 
collagen integrity26,27 and disrupt lipid–lipid, 
lipid–protein, and protein–protein interactions.28 
Scaffold manufacture employs engineering 
technologies to create a synthetically derived 
structure, which mimics the characteristics of 
the native ECM. There are several different 
methods of creating a scaffold, and they can be 
made from a myriad of substances; both natural 
and synthetic.29 
Hydrogels have been of particular interest to 
liver tissue engineers, gels biofuctionalized with 
collagen I enhance P450 (Cyp450) activity, cell 
adhesion markers, and innate hepatocyte 
fibronectin production.30 Gels biofunctionalized 
with galactose increased albumin (Alb) 
production and promoted the proliferation of 
hepatocytes.31 Viability and hepatic functions of 
primary hepatocytes are improved by culturing 
them in hydrogels made with liver ECM,32 and 
when encapsulated in collagen-alginate 
composite hydrogels.33 Polyethylene glycol 
hydrogels have been shown to augment cell–cell 
interactions of bipotential mouse embryonic 
liver cells, subsequently improving their survival 
and function,34 however, incorporating ECM 
components into scaffolds at the manufacturing 
stage has proved challenging, with the harsh 
solvents require to solubilize major components 
of ECM alter their microstructure and 
functionality.35,36 Ongoing research 
demonstrates great promise, however to date 
no scaffold has been created which allows 
hepatocytes to function as well as they do in 
vivo.11,37 
Both ECM components and scaffolds have 
shown great promise in tissue engineering.9,10,15 
With these considerations in mind, we combined 
decellularization and scaffold engineering to 
create a novel environment in which 
hepatocytes thrive (Supplementary Fig. S1; 
Supplementary Data are available online at 
www.liebertpub.com/tea). By manipulating ECM 
production using pharmaceuticals and exploiting 
polymer characteristics we created a novel 
hybrid polymer-ECM platform for liver tissue 
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engineering. To validate the platform we used 
cells representative of the liver (HepG2s). 
Materials and Methods 
Electrospinning 
A 12% wt/vol solution of poly-capro-lactone 
(PCL; SigmaAldrich) and hexafluoroisopropanol 
(Manchester Organics) was dissolved overnight 
at room temperature with agitation. Solutions 
were placed into a 10mL syringe and pumped 
using syringe pump EP-H11 (Harvard Apparatus) 
into the EC-DIG electrospinning system (IME 
Technologies) via a 27G bore needle under the 
following parameters Table 1. 
The mandrel was coated in nonstick aluminium 
foil for collecting the electrospun fibers. The 
sheets of electrospun fibers were allowed to dry 
overnight in a fume hood when the 
electrospinning session was completed. The 
average fiber size was 1.14mm as calculated by 
ImageJ plugin 
‘‘Diameter J’’ (Fig. 1).38 
Plasma coating 
Ten millimeter discs of scaffold were cut from 
the dry fiber sheet. The scaffolds were soaked in 
70% ethanol for 30min, rinsed three times in 
phosphate-buffered saline (PBS) for 15min each, 
and allowed to dry completely at room 
temperature. We then freeze dried the scaffolds 
overnight in a FreeZone 4.5 freeze-drier 
(Labconco) before plasma coating (Harrick 
Plasma) at 10.2 W for 30s. Scaffolds were 
removed from the plasma chamber and placed 
into an antibiotic/antimycotic treatment solution 
of Eagles Minimal Essential Media supplemented 
with 10% fetal bovine serum (FBS),2mMl-
glutamineand100U/mLpenicillin,100mg/mL 
streptomycin, and 0.25mg/mL Fungizone 
(amphotericin B) Anti-Anti solution (Gibco) for 
1h. 
Initial layer cell seeding and culture 
Scaffolds were removed from the 
antibiotic/antimycotic treatment solution and 
rinsed three times for 15min each in complete 
media; Eagles Minimal Essential Media 
supplemented with 10% FBS, 2mM l-glutamine, 
100U/mL penicillin, and 100mg/mL streptomycin 
(Gibco). They were then placed into a fresh 48-
well tissue culture plate. 
5637 human urinary bladder epithelials (ATCC) 
were trypsinized using standard methods from 
tissue culture flasks and counted using the 
trypan blue exclusion method. About 1·104 cells 
at passage 23 were suspended in 100mL 
 
FIG. 1. Characterization of electrospun scaffolds. The 
scaffolds were assessed for consistency and fiber size 
via SEM and subsequent image analysis. Fibers 
consistently displayed a meandiameter 
of1.14mmasdeterminedbyDiameterJ,34 n=4. 
200·magnification. SEM, scanning electron 
microscopy. 
Table 1. Electrospinning Parameters 
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Conditions under which the electrospun poly-capro-lactone scaffold was fabricated. 




FIG. 2. Confirmation of decellularization. 
Decellularization was confirmed using the Quant-IT 
Picogreen dsDNA assay and SEM (not shown). 
Additionally, CellTiter-Blue cell viability assay was 
performed on the decellularized scaffolds (data not 
shown). 
of complete media and seeded directly on to the 
scaffolds. The cells were allowed to incubate in 
this small volume on the scaffolds for 2h, before 
an additional 400mL of complete media was 
added. 
Media was changed after 24h to either 750mM 
valproic acid (VA) or 750mM sodium butyrate 
(NaB; SigmaAldrich) in complete media and 
changed every 48h. Controls were scaffold only, 
that is, not seeded with an initial cell layer and 
no drug treatment that is, the initial layer 
cultured in drug-free complete media only. Drug 
concentrations and initial layer cells were chosen 
following results of a drug response curve for 
each histone deacetylase inhibitor (iHDAC) (data 
not shown). VA and NaB are used as epigenetic 
control mechanisms of gene transcription. They 
function by inhibiting HDACs (as iHDACs) to 
modulate chromatin structure, creating an open, 
transcriptionally active euchromatin 
configuration at gene coding and regulatory 
regions of the chromosome. This renders the 
chromatin accessible to transcription factors, 
and facilitates gene transcription.39 
VA and NaB are both commonly used in industry, 
particularly antibody production due to their 
ability to upregulate protein production in such a 
manner.40,41 This initial layer of cells was cultured 
for 7 days at 37C and 5% CO2 in a humidified 
incubator. 
Decellularization 
Decellularization was performed using methods 
adjusted from Lu et al.,42 under sterile conditions 
at room temperature (19–22C) and agitation 
(Fig. 2). Scaffolds were washed in PBS for 15min 
and then rinsed in 10mM Trisbuffered saline 
(TBS) for 15min. 
The scaffolds were submerged in a 0.1% vol/vol 
Triton X-100 (Sigma-Aldrich), 1.5M potassium 
chloride (Acros Organics), and 50mM TBS for 4h. 
They were rinsed for 15min in 10mM TBS before 
being submerged in fresh 10mM TBS overnight. 
Scaffolds were given a final rinse in 10mM TBS 
for 15min before being incubated in complete 
media for 15min and then transferred to new 
48-well plates for seeding. 
Functional layer cell seeding and culture 
HepG2 cells were trypsinized using standard 
methods from tissue culture flasks and counted 
using the trypan blue exclusion method. About 
3·105 cells at passage 17 were suspended in 
100mL of complete media and seeded directly 
on to the scaffolds. The cells were allowed to 
incubate in this small volume on the scaffolds for 
2h, before an additional 400mL of complete 
media was added. 
Media was changed after 24h and changed every 
48h after the initial 24h adherence and recovery 
period. This functional layer (FL) of cells was 
cultured using standard methods for either 3 or 
5 days at 37C and 5% CO2 in a humidified 
incubator. 
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Live/Dead viability/cytotoxicity assay 
To determine cellular viability, cell/scaffold 
constructs were incubated with 10mm calcein 
and 2mm ethidium ho-modimer-1 (Ethd-1) for 
30min as part of the two color live/dead assay 
(Molecular Probes). Calcein is actively converted 
to calcein-AM in living cells, which then appear 
green when excited during fluorescence 
microscopy. Ethd-1 only accumulates in dead 
cells, which subsequently appear red. The 
method allows differentiation between dead and 
viable cells. The scaffolds were rinsed three 
times in CaCl2/MgCl2-free PBS to remove excess 
dye and placed onto a standard microscope slide 
with a 25mm glass coverslip (VWR). All images 
were captured using a Zeiss Axio Imager 
fluorescent microscope (COIL; University of 
Edinburgh) at 40 ·magnification and 
postprocessed using ImageJ. 
CellTiter-Blue Cell viability assay 
The assay was performed according to 
manufacturer’s instruction (Promega). For each 
condition group, n=3. Importantly, cell/scaffolds 
constructs were moved into fresh 48-well plates 
to prevent reading activity from tissue culture 
plastic bound cells. Measurements were read in 
a Modulus II microplate reader at an excitation 
wavelength of 525nm and emission wavelength 
of 580–640nm and reported as fluorescence. 
Picogreen DNA quantification 
The Quant-IT Picogreen dsDNA assay kit (Life 
Technologies) was employed to establish the 
efficiency of the decellularization method in 
removing cellular material and to estimate cell 
number on the cell/scaffold constructs. The 
assay was performed according to manufacturer 
instructions. In brief, constructs (n=6) were 
digested in a solution of CaCl2 and MgCl2-free 
PBS (Sigma), containing 2.5U/mL papain extract 
(Sigma), 5mM cysteine-HCl (Sigma), and 5mM 
ethylenediaminetetraaceticacid (Sigma) and 
incubated overnight at 60C. Picogreen solution 
was added to the digests and fluorescent 
intensity measurements read in a Modulus II 
microplate reader at an excitation wavelength of 
480nm and emission wavelength of 510– 
570nm. A standard l dsDNA curve of graded 
known concentrations was used to calibrate 
fluorescence intensity versus dsDNA 
concentration. 
Sectioning and staining 
The samples were rinsed three times in PBS 
(Gibco) for 15min each, then fixed in 4% v/v 
formalin buffered in saline for 15min at room 
temperature. After rinsing with fresh PBS, 
constructs were embedded in low melting 
temperature polyester wax (Electron Microscopy 
Supplies) using methods adapted from Steele et 
al.9 In brief, samples are dehydrated through 70–
100% ethanol, then incubated in 50:50 
ethanol:wax overnight at 45C overnight with 
agitation. The samples were moved into 100% 
wax for 3h at 45C and then fresh 100% wax for 
1h at 45C. Samples were embedded and allowed 
72h to fully cure before sectioning. 
Immunohistochemical staining was undertaken 
using antibodies for Collagen I (Stratech), 
Laminin (Stratech), and Fibronectin (Sigma). All 
images were captured using a Coherent Anti-
Stokes Raman Scattering system (Bioimaging 
Facility, University of Edinburgh) at 10· and 100· 
magnification and postprocessed using ImageJ. 
Scanning electron microscopy 
Scanning electron microscopy (SEM) was used to 
characterize the scaffold architecture. Samples 
were rinsed three times in PBS for 15min each, 
then fixed in 2.5% v/v glutaraldehyde (Fisher 
Scientific) in 0.1M phosphate buffer (PB) (pH 7.4) 
at 4C overnight. They were then rinsed three 
times in 0.1M PB before being postfixed in 1% 
v/v osmium tetroxide (Electron Microscopy 
Supplies) buffered with 0.1M PB. Samples were 
again rinsed three times in 0.1M PB and 
dehydrated through an ethanol gradient (30–
100%). They were dried by placing them in 
hexamethyldisilazane (Sigma), which was 
allowed to evaporate off at room temperature 
overnight. We mounted the samples onto SEM 
chucks using double-sided carbon tape and 
coated them with a thin layer of gold and 
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palladium alloy (Polaron Sputtercoater). All 
images were captured at 5kV using a Hitach S-
4700 SEM (BioSEM; University of Edinburgh). 
Mechanical testing 
Nanoindentation experiments were undertaken 
to establish the dynamic properties of scaffolds 
and decellularized ECM/scaffold constructs using 
the Keysight/Agilent 5200 nano indenter testing 
system. 
Scaffolds and constructs were subject to 
indentation by a DCM II actuator flat-ended 
cylindrical punch (D=100mm) using a max load 
of 1 gf. All nanoindentation experiments were 
carried out on fresh, hydrated, unfixed samples 
that were adhered to the chuck using double-
sided tape. A total of 36 indentations were 
carried out on each sample, 50nm apart. Indent 
sites were selected using the high precision X–Y 
stage within the testing system (Agilent). 
Poissons ratio was assumed to be 0.5 for each 
sample.43,44 Allowable drift rate was 0.1nm/s. A 
NanoSuite (Keysight Technologies) test method 
‘‘G-Series DCM CSM Flat Punch Complex 
Modulus’’ was used for all testing.45,46 
Gene expression analysis 
RNA was extracted from constructs using 
standard TRIzol (Fisher Scientific) methods and 
purified using Qiagen’s RNeasy spin column 
system. cDNA was synthesized using the 
Promega’s ImProm-II Reverse Transcription 
System. 
Quantitative real-time polymerase chain 
reaction was performed using the LightCycler 
480 Instrument II (Roche Life Science) and 
Sensifast SYBR High-ROX (Bioline) system. 
Results were normalized to HepG2s of the same 
passage number grown on tissue culture plastic 
and compared to the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase. 
Analysis was performed using the 2-DDCt 
method,47 n=4. Alb, Cytochrome P450 Family 1 
Subfamily A Polypeptide 1 (Cyp1A1), 
Cytochrome P450 Family 1 Subfamily A 
Polypeptide 2 (Cyp1A2), Cytochrome P450 
Family 3 Subfamily A Polypeptide 4 (Cyp3A4), 
Collagen Type I alpha 1, Collagen Type 4 alpha 1, 
and Fibronectin Type 1 were investigated, 
forward and reverse primers (Sigma) are 
detailed in Supplementary Table S1. 
Statistical analysis 
One-way analysis of variance and Tukey post hoc 
testing were performed and graphs generated 
using Origin software (OriginLab). A minimum of 
n=3 and max of n=6 was used for all analysis. 
Study groups were as follows; Scaffold only, No 
drug treatment, treatment with VA, and 
treatment with NaB. HepG2 cells were grown on 
each scaffold for 3 and 5 day time points. 
Results 
Cell attachment and survival on scaffolds 
When compared to normal ECM (N-ECM), a 
lower number of HepG2s adhered to each of the 
drug-induced scaffold-ECM constructs, and to 
the scaffold alone (Fig. 3); demonstrating that 
‘‘normal’’ ECM is efficient for cell seeding 
purposes. Scaffold only (SO), valproic acid ECM 
(VA-ECM) and sodium butyrate ECM (NaB-ECM) 




FIG. 3. Seeding efficiency/viability on scaffolds. Cell 
adherence was assessed by Quant-IT Picogreen 
dsDNA assay (A) and further confirmed by CellTiter-
Blue Cell viability assay (B). One-way ANOVA with 
Tukey post hoc testing. *p<0.05, **p<0.01. Error bars 
represent SD. SD, standard deviation; ANOVA, 
analysis of variance. 
conditions demonstrate longer term 
maintenance or the HepG2s, however, (Fig. 3) 
and results are confirmed by both CellTiter-Blue 
viability and Picogreen DNA quantitation. 
Live/dead viability/cytotoxicity images (Fig. 4) 
further demonstrates the metabolic viability of 
the functional HepG2 cell layer (FL), although it 
should be noted that imaging reveals the FL was 
not yet confluent at 5 days culture, as further 
confirmed by SEM images (Fig. 5). 
Mechanical characterization of scaffolds 
Interestingly, mechanical differences between 
the scaffold construct were negligible (Fig. 6). No 
significant differences in storage (Fig. 6A) or loss 
(Fig. 6B) modulus between the four conditions 
(Supplementary Tables S2 and S3). 
Testing was performed at frequencies 
experienced by the human liver in vivo.48 Storage 
modulus (G¢) ranged from 
3.58–0.12 to 4.64–0.43MPa and loss modulus 
(G¢¢) from 0.55–0.03 to 1.17–0.07 at the 
frequencies detailed in Supplementary Tables S2 
and S3. This reassures us that differences in cell 
attachment, viability, and function are due to 
differences in the biochemical and topographical 
profile of the hybrid scaffolds, as opposed to 
potential dynamic differences to which cells are 
known to be so sensitive.49–52 
Biochemical characterization of the hybrid polymer-ECM 
scaffolds 
Differences in the biochemical profile of the 
different ECMs were demonstrated by 
immunohistochemistry performed on the hybrid 
scaffold sections (Fig. 7). Hepatic phenotype has 
long been known to be influenced by ECM 
proteins; particularly Collagen I, Laminin, and 
Fibronectin,15,53,54 all of which are present on the 
scaffolds to varying degrees. 
Laminin is of particular importance in the 
regenerating liver and for cell adhesion, and it is 
increased in injured or developing states.55,56 
Laminin is present in each construct, but it 
appears to be most prevalent in NaB-ECM 
scaffolds (Fig. 7J). These constructs demonstrate 
higher ‘‘maintenance’’ of the HepG2s; that is cell 
number and viability increases between 3 and 5 
days (Fig. 3). 
Collagen I is one of the major components of 
normal liver ECM.53,54 Collagen I is most 
prevalent on NaB-ECM scaffold constructs (Fig. 
7I), followed by VA-ECM (Fig. 7E) and N-ECM 
(Fig. 7A) scaffold constructs. When compared to 
the N-ECM scaffold constructs, these 
demonstrate improved maintenance of the 
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HepG2 cell layer (Fig. 3), although not in 
comparison to the SO conditions. 
Fibronectin is also ubiquitous in healthy liver 
ECM53,57 and is present under each of the 
conditions, but is most prevalent on NaB-ECM 
scaffolds (Fig. 7K). SEM of the hybrid scaffolds 
appears to confirm the fibrillary nature of the 
Collagen I-enriched NaB (Fig. 5J) and VA-ECMs 
(Fig. 5G) and the smoother morphology of the 
Lamininenriched N-ECM (Fig. 5D). 
The ECMs present have penetrated the scaffold 
in each case, and each protein is present on each 
scaffold, indicating the robustness and 
reproducibility of the method (Supplementary 
Fig. S2 n=3). 
Gene expression of HepG2s in response to hybrid polymer-
ECM scaffolds 
Multiple genes associated with liver function 
were assayed for gene expression (Fig. 8). Alb 
expression is a marker of liver cell differentiation 
and function and Cytochrome P450 (Cyp) are 
involved in metabolism of toxic compounds and 
products of endogenous metabolism such as 
bilirubin in the liver.6,17 
Alb mRNA expression increases between day 3 
and 5 as expected, but at day 5 is upregulated in 
comparison to HepG2s grown on tissue culture 
plastic in all conditions; with the highest levels 
observed in SO and N-ECM conditions. 
Additionally, Alb mRNA expression is 
downregulated at day 3 in SO and NaB-ECM 
conditions (Fig. 8A). 
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Cyp1A1 mRNA expression is consistently 
upregulated in comparison to tissue culture 
plastic (Fig. 8B). Cyp1A2 mRNA expression is 
hugely upregulated in comparison to tissue 
culture plastic (*1000–38,000-fold), with the 
highest levels observed at 3 days on VA-ECM 
scaffold constructs, and levels at day 5 
consistently lower than those at day 3 (Fig. 8C). 
Cyp3A4 mRNA expression follows a similar 
pattern, barring the NaB-ECM scaffolds; where 
expression levels at day 5 are higher than those 
of day 3. Additionally, the highest levels of 
expression are observed on SO at day 3 of 
culture (Fig. 8D). 
Additionally, we assayed for three ECM genes, 
key components of the liver microenvironment; 
Fibronectin (Fig. 8E), Collagen I (Fig. 8F), and 
Collagen IV (Fig. 8G). While hepatocytes are not 
the major producers of ECM proteins in the 
liver,53 the expression of such genes are of 
interest with regards to the cells further 
modulation of its environment considering the 
plastic nature of the ECM.58 Fibronectin mRNA 
levels are higher in each condition than in that of 
HepG2s grown on tissue culture plastic, and 
FIG. 4. Live/Dead viability/ 
cytotoxicity assay. Viability of the 
FL was assessed by live/dead 
viability/cytotoxicity staining assay. 
Results demonstrate the FL is 
metabolically viable at all assessed 
time points. 40· magnification. FL, 
functional layer. 
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highest levels are observed at day 3 on VA-ECM 
scaffold constructs, subsequently dropping to 
less than a third of day 3 levels by day 5. This 
may be in response to fibronectin levels 
observed in Figure 7, where the highest 
fibronectin levels observed (Fig. 7K) correspond 
with the lowest mRNA expression in the HepG2s. 
Collagen I mRNA expression is upregulated in 
every condition. Levels increase at day 5 in SO 
and NaB-ECM conditions; N-ECM and VA-ECM 
conditions follow the opposite trend with lowest 
levels observed in NaB-ECM conditions at day 3. 
The highest level of gene expression is observed 
on the scaffold with correspondingly increased 
Collagen I levels; NaB-ECM (Fig. 7I). Collagen IV 
mRNA levels are decreased in comparison to 
tissue culture plastic. 
While the authors refrain from speculation 
without further analysis, the alterations in mRNA 
levels indicate that the drug-induced ECMs have 
a profound effect on liver cellular behavior. 
Discussion 
Fabrication of a hybrid polymer-ECM scaffold is 
an important avenue for liver tissue engineering, 
overcoming the shortage of donor organs and 
 
FIG. 5. SEM of scaffold-ECM constructs and functional cell layers. SEM images of the decellularized scaffold-ECM 
constructs (A, D, G, and J) and functional cell layers at 3 (B, E, H, and K) and 5 (C, F, I, and L) days culture. 
Topographical differences are clearly evident on decellularized constructs. 500· magnification. 
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issues regarding animal-sourced biomaterials 
and creating a platform that can produce 
consistent, clinically translatable scaffolds for 
liver cell survival and function. An electrospun 
fiber approach was taken in the study to mimic 
the morphology of healthy fibrillary collagen,59,60 
which may explain cells favoring environments 
with more Collagen I. We selected PCL for the 
fabrication of electrospun scaffolds as it 
possesses FDA approval for use in medical 
devices due to its biodegradable nature and 
elasticity.9 
The ECM is highly plastic, subject to constant 
modification and varies massively between 
tissues,61 with each tissue possessing its own 
specific ECM ‘‘recipe’’, composed of water, 
proteins, and polysaccharides, driven by a dialog 
between various cellular components and the 
microenvironment within the tissue.58,62 As the 
ECM is such a dynamic structure, it stands to 
reason that its production and maintenance will 
be influenced by its surrounding environment in 
3D culture.63 
We used two different iHDACs to manipulate the 
cellular environment and alter the ECM 
production; NaB is widely used in industry to 
increase yield recombinant protein yields in 
mammalian cells. VA (ValA) is an FDA-approved 
anticonvulsant, which also functions as an iHDAC 
to increase 
recombinant protein yields.40 By using iHDACs 
we can influence gene expression via their role 
in deacetylation, the process by which DNA 
renders itself less transcriptionally active. 
Inhibiting this process in cells results in 
hyperacetylation of histones and subsequently 
an increase in 
transcriptional activity.39 
Our results indicate not only that the iHDACs 
significantly alter the production and consistency 
of the ECM, but also that this technique is robust 
and reproducible and the ECM it produces, when 
harnessed in combination with 3D scaffolding 
technologies, creates a biofuctionalized scaffold, 
which significantly alters the behavior of liver 
cells. 
The ECM produced by a bladder epithelial may 
be different to that of a liver cell; however, 
several decellularized ECM products on the 
market are in clinical use to regenerate tissues 
from which they are not derived, including 
 
FIG. 6. Mechanical characterization of decellularized scaffolds. Decellularized ECM/scaffold constructs were subject to 
nanoindentation experiments to assess their dynamic properties. Results demonstrate no significant differences in 
storage (A) or loss (B) modulus between the four conditions (Supplementary Tables S2 and S3). ECM, extracellular 
matrix. 
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ALLOPATCH HD, MatriStem, and Tutoplast 
Pericardium.64 Indeed, hepatocytes are often 
cultured on ‘‘ECM’’ surfaces that are not derived 
from liver, commonly using Matrigel, a product 
derived from murine sarcoma, which is as yet 
undefined and experiences batch to batch 
variability.15,65–68 
The promising field of whole organ 
decellularization is hampered by the availability 
of human livers, and researchers are 
subsequently investigating alternative organ and 
cells sources, such as spleen, bone marrow 
mesenchymal stem cells,69,70 and various animal 
sources of livers.37 One of the main advantages 
of using decellularized native liver ECM is 
conservation of the highly conserved sinusoidal 
ECM gradient required to allow hepatocytes to 
repopulate in their specific niches. The complex 
ECM of the liver remains a topic of investigation 
in each of its states, diseased, regenerating, and 
healthy.53,55,71,72 
To assess the performance of the hybrid 
scaffolds, we investigated the attachment and 
function of a commonly used liver cell line, 
HepG2s, at 3 and 5 days post-replating when 
cultured in vitro on the hybrid scaffolds versus 
scaffold alone. 
HepG2s were derived from the hepatocarcinoma 
of a 15-yearold Caucasian male. They are often 
used because they are virus-free, possess liver-
specific functions such as ammonia metabolism 
and albumin synthesis, and secrete some growth 
factors such as insulin and insulin-like growth 
factor II.73 We analyzed cell attachment and 
viability, and gene expression of both liver 
function genes and ECM genes at both 3 and 5 
day time points. Additionally, we validated the 
decellularization of the ECM producing cell layer 
and performed 
immunohistochemicalanalysesofthe 
hybridscaffold-ECMconstructsupon which the 
HepG2s were seeded. 
While this work is a robust proof of principle 
regarding manipulation of ECM production, and 
has produced a novel hybrid polymer-ECM 
scaffold with great potential for liver tissue 
engineering, further work is required to analyze 
results and increase translatability. While 
HepG2s are a highly valuable research resource, 
they are derived from a carcinoma and as such 
criticism of their in vitro relevance abounds 
within the scientific community. It is important 
to undertake future work using primary or stem 
cell-derived hepatocytes and incorporate other 
stimuli such as fluid flow to combat such 
criticism. Furthermore, while hepatocytes, the 
major parenchymal cell of the liver, make up 
more than 70% of the cellular mass, they do not 
exist in isolation and the nonparenchymal cells 
play an essential role in the in vivo liver71,74; 
future studies should look to include these cells. 
In addition, recognizing the value of proteomic 
and functional assays (such as enzyme-linked 
immunosorbent assays) in analyzing the function 
of the primary/stem cellderived hepatocytes will 
be important for future validation of the 
scaffolds, however, at this time these were 
deemed unnecessary considering the critique of 
the HepG2 cell line. Additionally, care should be 
taken to ensure decellularization agents are 
completely removed from the scaffolds, due to 
their deleterious effect on both cells and ECM.24 
While such considerations are of importance, 










FIG. 8. Quantitative polymerase chain reaction analysis of functional cell layer. Quantitative analysis of gene 




the same passage and culture periods grown on tissue culture plastic (Fig. 7). mRNA levels of Albumin (A), 
Cyp1A1 (B), Cyp1A2 (C), CYP3A4 (D), Fibronectin (E) Collagen I (F), and Collagen IV (G) are represented as 
fold difference relative to tissue culture plastic controls and relative to the housekeeping gene GAPDH. One-
way ANOVA with Tukey-post hoc testing and n=4. *p<0.05, **p<0.01. Error bars represent SD. GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase. 
10 




demonstrates the potential of these hybrid polymer-ECM scaffolds for tissue engineering and 
provides a robust initial platform for further research. 
Conclusion 
This study developed a new method of creating hybrid polymer-ECM scaffolds by manipulating cells 
using electrospun scaffold technologies, clinically relevant iHDACs and methods easily modified to 
fulfill good manufacturing practice regulation. To do so, a sacrificial, ECM-producing cell layer was 
seeded onto a novel electrospun scaffold and then treated with VA or NaB to biofuctionalize the 
scaffold with ECM components. Scaffolds with untreated cells and no initial cell layer at all were 
used as controls. The initial cell layer was removed with a detergent-based decellularization method, 
and the resulting hybrid polymer-ECM scaffolds seeded with a liver cell line for validation. The work 
was validated using robust methods such as Q-PCR, mechanical quantification, and SEM. Drug-
induced hybrid polymer-ECM scaffolds had a significant positive influence on the gene expression 
profile, attachment, and survival of liver cells. 
Our data demonstrates promise as a unique method of inducing and altering the production of ECM 
and that the hybrid scaffolds exert influence upon cells in vitro, as well as future potential as an 
implantable treatment platform for liver disease patients. 
These scaffolds show great potential not only for the future of liver tissue engineering and patient 
treatment, but are easily adaptable for other organs and tissues. Additionally, they are a useful tool 
for the development of 3D liver cell platforms, which can be used for in vivo cell analysis and novel 
pharmaceutical research. 
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Liver transplant is the only curative treatment option for patients with end - stage liver failure,  
however there  are few  donor livers  available  for transplant.  T issue engineering of a human  
liver would potentially solve the problem of escalating donor shortages. A major challenge  
presents itself in the form of the  hepatic extracellular matrix (ECM) ; a finely controlled  in vivo  
niche whic h supports  hepatocytes  and plays a critical role in the development of liver disease .  
Polymers and decellularized tissues each provide some of the necessary biological cues for  
the hepatocytes, however, neither alone has proved sufficient. Equally,  the abi lity to fine tune  
the microenviro n ment using bioactive molecules presents researchers with the opportunity to  
create personalised niches for hepatocytes , representing both normal and diseased  
phenotypes . This study  combines cell derived ECM with a  fibronectin vector and electrospun  
scaffolding techniques to produce a platform for creating customisable ECM  
microenvironments for hepatocytes   ( Abstract image ) . The resulting poly - L - lactic acid - 
extracellular matrix   PLA ( - ECM) scaffolds were validated using   HepG2 hepatocytes.   
  
As expected,   statistically  significant mechanical differences were observed between the  
synthetically derived ECM (SD - ECM)  scaffolds  and normal ECM (N - ECM) scaffolds ,  
confirming that the ECM has been altered by the fibronectin produci ng vector.  The PLA - ECM  
scaffolds maintained hepatocyte growth and function  and  influence the gene expression  of  
key hepatic genes.  Furthermore,  immunohistochemistry showed SD and N - ECMs differed in  
ratios of Collagen I, Laminin and Fibronectin .  
Our results  demonstrate that hybrid PLA - ECM scaffolds  and the synthetic production of ECM  
provide a viable, translatable platform for customising microenvironments for hepatocytes.  
Abstract image .  Methodology used to biofuctionalize electrospun scaffolds with  






This technology offers a potential solution to current obstacles in regenerative medic ine ,  


























In the US alone, as of August 20 th   2017 , the Organ Procurement and Transplantation Network  
( OPTN) estimates 14,158 patients are waiting for a donor liver.  With a  lack of viable new  
pharmaceuticals, liver transplant remains the sole treatment option for end - stage disease  
patients  1 .  Liver disease is an increasing burden on the health of the Western world, with both  
incidence and mortality increasing rapidly since 1970  2 .    Demand for donor livers far outstrips  
supply, and the incidence of liver disease shows no signs of slowing down  3 .   
Tissue engineers seek to solve this problem by engineering liver ‘organoids’; l aboratory  
created organs which can function as a liver in vivo  4 – 7 .  The 3D environment exerts  extensive  
influence on the behaviour and function of hepatocytes  6 , 8 . With this in mind, tissue engineers  
employ scaffold manufactur ing  technologies to create structure s which encompass key  
characteristics of the native 3D ECM  9 – 14 . Several different methods of creating a scaffold are  
in use, and they can be made from a myriad of substances; both natural and synthetic  15 , and  
enhanced with bio - decoration methods  8 . There has been particular focus on decellularization,  
which provides an ECM bioscaffold with the 3D s ite - specific vasculature required for  
hepatocyte function upon their repopulation of the organ  16 . Decellularized organs have been  
r epopulated with hepatocytes and endothelial cells which subsequently survive and exhibit  
some level of function, clearly demonstrating the importance of the ECM in supporting  
hepatocyte survival and phenotype  17 – 21 . However, decellularization requires a human or  
animal source of  whole , undamaged organs and  while research is showing great promise,  
the field is fragmented and to date no scaffold has been created which allows hepatocytes to  
function as well as in vivo  23 22 , .  
Synthetic biology and genetic engineering are vital tools for tissue engineers and have been  
used to alter gene expression, enhance intracellular imaging and stu dy fundamental  
processes in hepatocytes  24 – 26 . Recently, synthetic biology tools have been successfully  
employed to direct both stem cell lineage and fate in 3D constructs  27 , 28 , in the manipulation of  






demonstrating the ability of synthetic biology techniques to manipulate 3D environments and  
thus their potential benefit to the field of tissue engineering.   Groundbreaking  CRISPR  32 – 34   
and minicircle   vector  35 – 37    technologies have made the idea of therapeutic gene editing in  
humans a viable reality, however concerns exist regarding the safety and subsequently, the  
translatability of such tools with regards to patient treatment. Heavily publicised and tragic  
ev ents such as the 1999 death of  18 year old  Jesse Gelsinger  38   and the 2002  clinical trial in  
which four children developed leukaemia following gene therapy for their Severe Combined  
Immune Deficiency disease   39   have led to obvious worries regarding the safety of gene  
therapies.  The inflammatory and immune modulating effects of  damage - associated molecular  
patterns (DAMPs) such as foreign DNA fragments  40   are well documented, however clinical  
use of decellularized ECM in exogenic and allogenic form has demonstrated great promise,  
giving no immune response and showing regenerative potential. This paves the way for using  
synthetic biology to t issue engineer the ideal ECM environment. The ideal ECM would utilise  
synthetic biology and genetic technologies to their utmost, considerable, potential but remove  
any risk from the tools used; such as the genetically modified cells themselves.  
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With the potential of synthetic biology for manipulation of protein pr oduction in mind, we set  
out to  address this problem; developing a novel bio - active hybrid scaffold   which  possesses  
the potential for customizatioon of  the  ECM microenvironment .  To date, no bioengineers have  
combined the promising fields of scaffold manufacture, decellularized tissue and synthetic  
biology.  Here we report the  first  use of  a sacrificial , t ransfected  cell line to bio - functionalise an  
electrospun polymer scaffold for liver tissue engineering.   We have successfully decellularized  
the  bio - functionalised scaffold, and validated the platform using  cells representative of the  
liver, HepG2s.  
Materials and Methods  
Electrospinning  
A 10% wt/vol solution of poly -L - lactic acid (Goodman) and hexafluoroisopropanol (Manchester  
Organics) was dissolved overnight at room temperature with agitation. Solutions were placed  
into a 10ml syringe and pumped usi ng syringe pump EP - H11 (Harvard Apparatus) into the  
EC - DIG electrospinning system (IME technologies) via a 27G bore needle under the following  
parameters;   
Table 2 ; Electrospinning parameters  














ml 0.5  10 ml   cm 14  kV 16  - kV 3  rpm 250  mm/s 100  
  
The mandrel was coated in non - stick aluminium foil for collecting the electrospun fibres. The  
sheets of electrospun fibres were allowed to dry overnight in a fume hood when the  
electrospinning session was completed. The average fibre size was 1.48µm as cal culated by  
ImageJ plugin ‘DiameterJ’  41 .  
Scaffold Preparation  
10 mm discs of scaffold were cut from the dry fibre sheet. The scaffolds were soaked in 70%  


































































minutes each and allowed to dry completely at room temperature. Scaffolds were placed into  
an antibiotic/antimycotic treatment solution of Dulbeccos Minimal Essential Media  
supplemented with 100U/ml  penicillin, 100µg/ml streptomycin, 0.25µg/ml Fungizone ®   
( amphotericin B) Anti - Anti solution (Gibco) for 1 hour.  
Initial Layer Cell Seeding and Culture  
Scaffolds were removed from the antibiotic/antimycotic treatment solution and rinsed three  
times for 15 m inutes each in complete media; Dulbeccos Minimal Essential Media  
supplemented with 10% foetal bovine serum, 2mM L - glutamine, 100U/ml penicillin and  
100 µg/ml streptomycin (Gibco). They were then placed into a fresh 48 well tissue culture plate.   
5637 human u rinary bladder epithelials (ATCC) were cultured and expanded as per supplier  
recommendations, using the media described above. Cells for scaffold seeding were  
trypsinized using 0.25% Trypsin - EDTA (Gibco) from tissue culture flasks and counted using  
the try pan blue exclusion method. 1 x 10 5   cells at passage 23 were suspended in 100µl of  
complete media and seeded directly on to the scaffolds. The cells were allowed to incubate in  
this small volume on the scaffolds for 2 hours, before an additional 400µl of co mplete media  
was added.   
Media was changed after 24 hours using standard methods and subsequently changed every  
48 hours. Controls were scaffold only, i.e. not seeded with an initial cell layer and a ‘normal’  
initial layer i.e. untransfected cells. Initial   layers of cells were cultured for 7 days at 37ºC and  
% CO 5 2  in a humidified incubator.  
Fibronectin Vector  
Vectors were obtained from the DNASU plasmid repository. In brief, the human fibronectin  
gene (FN1) was placed into a retroviral expression vector, P J1520. The insert sequence was  
verified by sequence analysis and restriction enzyme digest by DNASU. The vector was  
obtained in DH5 - alpha T1 phage resistance  Escheria coli  glycerol stock. We cultured the E.  






sucrose in LB media. Plasmid extractions were performed using Cambridge Bioscience’s  
Zyppy™ plasmid extraction kit following manu facturer’s methods.  
Transfections  
Transfections were performed using Invitrogen Lipofectamine 3000 ® . Following titration  
experiments, a concentration of 1µg plasmid DNA and 0.75µL lipofectamine reagent per  
scaffold was chosen. The initial layer of 5637 epi thelials was cultured on the scaffolds under  
standard conditions for 7 days. Transfection was performed on the 7 th   day. Scaffold - cell  
constructs were then placed into selective media containing 150µg/ml puromycin. The cell - 
scaffold constructs were cultured   under selection for a further 7 days to allow production of  
the vector derived fibronectin before being decellularized.   
Decellularization   
Decellularization was performed under sterile conditions at room temperature (19  -  22 ºC) and  
with agitation. Scaffo lds were placed into 50ml falcon tubes and placed on a rotator at 20RPM.  
Scaffolds were washed with phosphate buffered saline (PBS) for 15 minutes and then rinsed  
in 10mM tris buffered saline (TBS) for 15 minutes.   
The scaffolds were submerged in a 0.1% vo l/vol Triton X - 100 ( Sigma - Aldrich) 1.5M potassium  
chloride (Acros Organics) 50mM TBS for 4 hours. They were rinsed for 15 minutes in 10mM  
TBS before being submerged in fresh 10mM TBS overnight.  
Scaffolds were given a final rinse in 10mM TBS for 15 minutes  before being incubated in  
complete media for 15 minutes and then transferred to new 48 well plates for seeding.  
Functional layer Cell Seeding and Culture  
HepG2 cells were trypsinized using standard methods from tissue culture flasks and counted  
using the  trypan blue exclusion method. 1 x 10 5   cells at passage 17 were suspended in 100µl  






in this small volume on the scaffolds for 2 hours, before an additional 400µl of   complete media  
was added.  
Media was changed after 24 hours and changed every 48 hours after the initial 24 hour  
adherence and recovery period. This functional layer (FL) of cells was cultured using standard  
methods for either 3 or 5 days at 37ºC and 5% CO 2  in a humidified incubator.  
Live/Dead ®   Viability/Cytotoxicity assay  
To determine cellular viability, cell/scaffold constructs were incubated with 10µm calcein and  
2 µm ethidium ho - modimer - 1 (Ethd - 1) for 30 minutes as part of the two colour live/dead assay  
( Molecular Probes). Calcein is actively converted to calcein - AM in living cells, which then  
appear green when excited during fluorescence microscopy. Ethd - 1 only accumulates in dead  
cells, which subsequently appear red. The method allows differentiation be tween dead and  
viable cells. The scaffolds were rinsed three times in CaCl 2 /MgCl 2  free PBS to remove excess  
dye and placed onto a standard microscope slide with a 25mm glass coverslip (VWR). All  
images were captured using a Zeiss Axio Imager fluorescent mi croscope (COIL, University of  
Edinburgh) at 40x magnification and post processed using ImageJ.  
CellTiter - Blue ®   Cell viability assay  
The assay was performed according to manufacturer’s instruction (Promega). For each  
condition group, n = 5. Importantly, cel l/scaffolds constructs were moved into fresh 48 well  
plates to prevent reading activity from tissue culture plastic bound cells. Measurements were  
read in a Modulus™ II microplate reader at an excitation wavelength of 525 nm and emission  
wavelength of 580 - 640 nm and reported as fluorescence.   
Albumin quantification  
A bromocresol green (BCG) albumin assay (Sigma) was used to quantify serum albumin  






assay was performed acc ording to manufacturer’s instructions and results read at an  
absorbance of 620  nm in a Modulus™ II microplate reader.  
Picogreen ®   DNA quantification  
The Quant - IT™ Picogreen ®   dsDNA assay kit (Life Technologies™) was employed to establish  
the efficiency of th e decellularization method in removing cellular material and to estimate cell  
number on the cell/scaffold constructs. The assay was performed according to manufacturer  
instructions. In brief, constructs (n = 5) were digested in a solution of CaCl 2  and MgCl 2  free  
PBS (Sigma),  containing  2.5  U/ml papain  extract  (Sigma)  5  mM cysteine - HCl  (Sigma)   
and  5 mM EDTA  (Sigma)  and incubated for 48 hours at 60°C. Picogreen solution was added  
to the digests and fluorescent intensity measurements read in a Modu lus™ II microplate  
reader at an excitation wavelength of 480 nm and emission wavelength of 510 - 570 nm. A  
standard λ dsDNA curve of graded known concentrations was used to calibrate fluorescence  
intensity vs dsDNA concentration.  
Sectioning and staining  
The  samples were rinsed three times in PBS (Gibco) for 15 minutes each, then fixed in 4%  
v/v formalin buffered in saline for 15 minutes at room temperature. After rinsing with fresh  
PBS, constructs were embedded in low melting temperature polyester wax (Electr on  
Microscopy Supplies) using methods adapted from  Steele et al. (2014 ) . In brief, samples are  
dehydrated through 70 - 100 % ethanol, then incubated in 50:50 ethanol:wax overnight at 45ºC  
overnight with agitation. The samples were moved into 100% wax for 3 hours at 45ºC and  
then fresh 100% wax for 1 hour at 45ºC. Samples were e mbedded and allowed 72 hours to  
fully cure before sectioning. Immunohistochemical staining was undertaken using antibodies  
for Collagen I (Stratech), Laminin (Stratech) and Fibronectin (Sigma).  All images were  
captured using a Zeiss Axio Imager system (Ce ntre Optical Instrumentation Laboratory,  







Scanning Electron Microscopy  
SEM was used to characterise the scaffold architecture. Samples were rinsed three times in  
PBS for 15 minu tes each, then fixed in 2.5% v/v glutaraldehyde (Fisher Scientific) in 0.1M  
phosphate buffer (PB) (pH 7.4) at 4ºC overnight. They were then rinsed three times in 0.1M  
PB before being post - fixed in 1% v/v osmium tetroxide (Electron Microscopy Supplies)    
bu ffered with 0.1M PB. Samples were again rinsed three times in 0.1M PB and dehydrated  
through an ethanol gradient (30 - 100%) . They were dried by placing them in  
hexamethyldisilazane (HDMS, Sigma) which was allowed to evaporate off at room  
temperature overnig ht. We mounted the samples onto SEM chucks using double sided carbon  
tape and coated them with a thin layer of gold and palladium alloy (Polaron Sputtercoater).  
All images were captured at 5 kV using a Hitach S - 4700 SEM (BioSEM, University of  
Edinburgh).  
M echanical Testing  
Nanoindentation experiments were undertaken to establish the dynamic properties of  
scaffolds and decellularized ECM/scaffold constructs using the Keysight/Agilent 5200 nano  
indenter testing system.  
Scaffolds and constructs were subject to  indentation by a DCM II actuator flat -ended cylindrical  
punch (D = 100µm) using a max load of 1g - f. All nanoindentation experiments were carried  
out on fresh, hydrated (suspended in PBS), unfixed samples in a stainless steel well chuck. A  
total of 36 inde ntations were carried out on each sample, 50nm apart. Indent sites were  
selected using the high precision X - Y stage within the testing system (Agilent). Poissons ratio  
was assumed to be 0.5 for each sample  42 43 , . Allowable drift rate was 0.1nm/s. A NanoSuite  
( Keysight Technologies) test method “G - Series  DCM CSM Flat Punch Complex Modulus” was  







Gene Expression analysis  
RNA was extracted from const ructs using standard Trizol (Fisher Scientific) methods and  
purified using Qiagen’s RNeasy spin column system. cDNA was synthesised using the  
Promega’s ImProm - II™ Reverse Transcription System.  
Quantitative real - time polymerase chain reaction (qRT - PCR) was  performed using the  
LightCycler ®   480 Instrument II (Roche Life Science) and Sensifast™ SYBR ®  High - ROX  
( Bioline) system. Results were normalized to HepG2s of the same passage number grown on  
tissue culture plastic and compared to the housekeeping gene Glyce raldehyde - 3 - Phosphate  
Dehydrogenase (GAPDH). Analysis was performed using the 2 – delta][delta] Ct method  [ 46 , 47 ,  
n = 5. Albumin (Alb), Cytochrome P450 Family 1 Subfamily A Polypeptide 1 (Cyp1A1),  
Cytochr ome P450 Family 1 Subfamily A Polypeptide 2 (Cyp1A2), Cytochrome P450 Family 3  
Subfamily A Polypeptide 4 (Cyp3A4), Collagen Type I alpha 1 (Col1A1), Collagen Type 4  
alpha 1 (Col4A1) and Fibronectin Type 1 (FN1) were investigated, forward and reverse  
primer s (Sigma) are detailed in Supplementary Table 1.    
  
Statistical Analysis  
One - way ANOVAs with Fishers, Games - Howell and Tukey   48 – 50   post - hoc testing were  
performed using Minitab 17 Statistical Software and graphs generated using  Origin software  
( OriginLab, Northampton, MA). Error bars indicate standard deviation. A minimum of n = 3  











Results   
Cell attachment and survival on scaffolds  
When compared to normal ECM derived  
from untransfected cells (N - ECM) and the  
scaffold alone (SO), a lower number of  
He pG2s adhered to the synthetically  
derived vector driven (SD - ECM) scaffold - 
ECM constructs  Fig.  ( 1 ) . According to the  
CellTiter - Blue ®   results (Fig. 1 A), the  SD  
ECM layer maintained the growth of the  
HepG2s between days 3 and 5.  However,  
this result is not concurrent with the  
Picogreen ®  DNA quantitation   ( Fig.  1 B).  
This is most likely due to different data  
methods  extraction  and  validation  
methods in the Picogr een and CellTiter - 
Blue assays. Both assays possess depth  
dependencies with regards to their  
efficiency and effectiveness in extracting  
data from fibrous scaffold constructs.  
Additionally, the assays were validated  
using 2D monolayer cell cultures. This  
wou ld explain high standard deviations in the Picogreen ®   DNA quantitation dataset and slight  
different trends observed between the assays. These finding are corroborated by our recent  
published work of cells on electrospun scaffolds  14 .  Live/Dead ®   Viabi lity/Cytotoxicity images  
( Fig.  2 ) demonstrate the me tabolic viability of the functional HepG2 cell layer (FL), and that at  
day 5 the cells appear to be confluent and living, with low levels  of cell death in each condition.  
Figure 1. Cell titre blue assay indicating  
metab olic activity (A) and DNA quantitation of  
the functional layer (B). One way ANOVA with  








Mechanical characterisation of scaffolds  
Reassuringly, both storage (G’) and loss (G”)  
modulus  demonstrate  significant  differences  
between the three conditions  Fig.  ( 3 ) . Fibronectin is  
known to influence both the mechanical profile of the  
ECM  51 , 52   and influence the maintenance and  
structure of o ther vital ECM proteins, such as  
collagen  53 . Equally, cells are known to respond to  
the mechanical and topographical influenc e a  
scaffold exerts  54 .   
Testing was performed at frequencies experienced  
by the human liver in vivo  55 . Storage modulus (G’)  
ranged from 22.92±9.14 to 12.29±0.14 MPa and  
loss modulus (G’’) from 2.45±0.93 to 0.15±0.02 MPa  
at the frequencies detaile d in supplementary tables  




Figure 2. Live Dead imaging demonstrating the  
living functional layer present at each time  
point, with minimal cell death.  
Figure 3. Significant mechanical differences  
were observed between  all  scaffold conditions.  
One way ANOVA with Games H owell post hoc  






Biochemical characterisation of the hybrid polymer - ECM scaffolds  
Differences in the biochemical profile of  
the different ECMs were demonstrated by  
on  immunohistochemistry  performed  
decellularized  hybri d scaffold  sections  
( Fig.  4 . Hepatic cells are very responsive  ) 
to extracellular matrix proteins; particularly  
Collagen I, Laminin and Fibronectin  56 – 58 .  
Fibronectin is ubiquitous in healthy liver  
59 , 60 , and antibody staining reveals  altered  
levels  of fibronectin in the synthetically  
derived ECM, as expected due to the  
introduction of the fibronectin vector (Fig.  
4 H).  ECM proteins do not exist in  
isolation, and fibronectin is known to  
influence the generation and laydown of other ECM  proteins including collagen I and laminin  
61 53 , , as evidenced in Fig. 4G and 4 I when compared to N - ECM. The N - ECM is collagen I rich  
( Fig.  4 D) with some fibronectin   and laminin also present (Fig.  4 E &  4 F). Of note is that the SD - 
ECM appears to be concentrated on the outer layers of the electrospun scaffold. This could  
be due to the transfected cells being in fewer number than those which were not transfected  
( N - ECM), so they did not  penetrate the scaffold to the same extent.   
Gene expression of HepG2s in response to hybrid polymer - ECM scaffolds  
Genes associated with both liver function and ECM production were ass ayed for gene  
expression (Fig. 5 ) . Albumin expression, a marker of approp riate liver cell differentiation and  
function,  appears  upregulated between day 3 and day 5   in each condition , confirming  
appropriate development of the cells. At day 5, expression is significantly upregulated in  
comparison to HepG2s grown on tissue culture   plastic (TCP) on the SD - ECM constructs; with  
Figure 4. IHC staining showing the retention of  
major liver ECM proteins Collagen I (D, G),  
Fibronectin (E, H) and Laminin (F, I) following  
decellularization. Additionally, SO condition  







the highest levels of expression observed in SO and SD - ECM conditions. Additionally, albumin  
mRNA expression is downregulated in comparison to TCP at day 3 in all  conditions (Fig. 5 A).  
Cytochrome P450s (Cyp) ar e a family of enzymes involved in metabolism of xenobiotics and  
toxic compounds in the liver  62 – 64 . Cyp1A1 mRNA expression is significantly altered in  
comparison to TCP   ( Fig.  5 B); upregulated at day  3 and downregulated at day 5. Cyp1A2  
mRNA expression is consistently significantly downregulated in all but one condition; day 3 N -
ECM  ( Fig.  5 C). Cyp3A4 mRNA expression is upregulated in every condition, with a significant  
upregulation observed in response  to SD - ECM  ( Fig.  5 D).  
In addition, we assayed for three ECM genes important for normal liver composition  59 , 65 ;  
Fibronectin (Fig. 5 E), Collagen I (Fig.   5 F) and Collagen IV (Fig.  5 G). Considering the plastic  
nature of ECM, these genes are o f  
regards  to  ongoing  interest  with  
of  the  tissue  modification  
microenvironment despite hepatocytes  
not being the main producers of ECM  
proteins in the liver  59 , 66 .   
Collagen I is consistently upregulated,  
with significant upregulation observed at   
day 5 on SD - ECM. Equally, Fibronectin  
expression  is  significantly  mRNA  
upregulated  on  day  5  SD - ECM  
constructs, though downregulated at day  
3 on SO  and N - ECM constructs. Collagen  
IV  mRNA expression is consistently  
upregulated in each condition, with  
signif icant changes observed in all but day  
3 N - ECM and SD - ECM. While such  
Figure 5. Q - PCR results showing significant  
changes in expression of major liver genes  
when compared to TCP, Albumin (A), CYP1A1  
B), CYP1A2 (C), CYP3A4 (D) an ECM genes  ( 
Col 1A1 (E), Col 4A1 (F) and Fibronectin (G)  
between the hybrid scaffolds and tissue  culture  
plastic.  ( A, C, D, E, F, G) = One way ANOVA  
with Games Howell post hoc testing, * = p  
value <0.05. (B) = One way ANOVA with Tukey  






alterations in gene expression are promising, we refrain from further assumption regarding  
cell response without further proteomic and functional analyses.  
Albumin production  
levels  Albumin  are  indicative  of  
hepatocyte health and response to the  
microenvironment  57 . Each condition  
results in   differing levels of albumin  
production , with significant differences in  
protein  levels observed between SO and  
SD - ECM a t both 3 days and 5 days (Fig.  
6 ) , indicating that the  N - ECM encouraged  
albumin production more than  SD - ECM.   
Confirmation of decellularization  
Decellularization was confirmed using  
Picogreen® DNA quantitation   ( Fig.  7 G)  
a nd histological staining (Fig. 7 A - F). A tenfold reduction in DNA combined with visual  
confirmation of an absence of DAPI nuclear staining and Phalloidin -  actin staining on  514
Figure  6.  production  between  Albumin  
changes  conditions,  showing  significant  
between SO and SD - ECM condi tions at both  
time points.   One way ANOVA with Games  
Howell post hoc testing, * = p value <0.05. **  
= p value  <0.01.  
Figure 7. Effectively decellularized constructs, with minimum remnant  DNA detected by  
IHC (E,F) or picogreen (G). Scaffolds pre - decellularization shown in (A), (B) and (C). One  
way ANOVA with Games Howell post hoc testing, ** = p value <0.05. Scaffold only (A, D),  






dece llularized constructs, plus the presence of fibronectin antibody staining on both the N - 
ECM and SD - ECM decellularized constructs (Fig.  7 E&F) provides evidence of efficient  
decellularization methods, and that synthetically derived fibronectin is present on  the hybrid  
scaffolds.   
Discussion   
The extracellular matrix provides a microenvironment for cells which is not yet fully  
understood, nor replicable by existing manufacturing methods  16 , 67 – 69 . By manipulating human  
cells to produce a  customizable  blend of ECM components, and combining this with replicable  
electrospun scaffolds  and decellularization methods  we overcome the shortage of donor  
derived ECM bioscaffolds   and the issues regarding animal - sourced biomaterials  16 , 70 .  
Additionally, this platform has the potential to be used to model not only ‘healthy’ ECM  
microenvironments, bu t also those of disease and developing states.  
By using fibrous electrospun scaffolds we mimic the morphology of healthy fibrillary collagen  
,11,71, 72 10 . PLA was used to fabricate the sc affolds, chosen for its compatibility with hepatocytes  
56   and its use in multiple   types of medical device due to its predictable biodegradation rate and  
mechanical properties  , 73 74 .   
Fibronectin was chosen as our protein to synthetically overexpress due to its vital role in the  
liver  5 75 , 1   and its interaction with other ECM components such as collagen and laminin  52 , 53 .  
Fibronectin is a large dimeric adhesive glycopro tein which exists in both cellular and plasma  
forms, with roles in regenerating tissues, embryonic development and regulation of cell  
behaviours such as adhesion and migration  76 . The role of fibronectin in the liver is st ill unclear,  
with inhibition of fibronectin production or deposition improving fibrosis outcomes  77 , 78 .  
However its vital role in the hepatic ECM is demonstrated by mutant mice who were  
specifically null in only the liver for both plasma and cellular fibronectin. The fibronectin - null  
livers not only de velop highly disorganized/diffuse collagenous ECM networks, but when  






due to fibronectin s role in regulating TGF - β1 bioavailability  75 . Additionally, homozygous  
fibronectin null mutants display early embryonic lethality, while heterozygotes (with 50% of the  
normal plasma fibronectin levels) appear normal; suggesting a dos e dependent role for  
fibronectin in development  79 .  
As an initial assessment of these novel hybrid scaffold s we investigated the attachment and  
function of a commonly used liver cell line, HepG2s, when cultured on the synthetically derived  
hybrid scaffolds versus a wild type ‘normal’ hybrid scaffold and the scaffold alone. The HepG2  
cell line was derived from t he hepatocarcinoma of a 15 year old Caucasian male. They are  
often used because they are virus free, possess liver specific functions such as ammonia  
metabolism and albumin synthesis and secrete some growth factors  80 .  We analysed cell  
attachment and viability, albumin production and gene expression of both liver function genes  
and ECM genes at 3 and 5   day time points. Additionally, we validated our decellularization  
method and performed both immunohistochemical and raman spectrum analyses (data not  
shown) of the hybrid scaffold - ECM constructs upon which the HepG2s were seeded.   
Our results indicate not   only that synthetically derived ECMs provide a viable method of  
biofunctionalising electrospun polymer scaffolds,  but  that the composition of the synthetically  
derived ECM - polymer hybrid scaffolds influences liver cells.   That albumin production is  
signifi cantly altered between SO and SD - ECM  conditions , but not N - ECM conditions supports  
this assertion. Gene expression of key hepatic genes was altered on day 5 of SD - ECM  
conditions in every gene tested, whereas SO and N - ECM conditions only influence CYP1A2  
an d COL4A1 expression; demonstrating that the  composition  of the ECM is highly influential  
in tissue engineering.  This in turn leads to questions regarding donor - donor variability of  
current decellularization work and its influence upon hepatic behaviour and   a need for more  
reproducible hepatic microenvironments that this platform provides.  
The researchers responsible recognise that, while this study forms a robust initial proof of  
principle regarding the exploitation of synthetic biology for scaffold manufac ture, and has  






liver tissue engineering, further work is required to analyse results and increase translatability.  
Vector technologies and synthetic biology present   obvious concerns with regards to patient  
safety  30 , 81 , and care should be taken to ensure all bacterial/ viral constructs are removed from  
the ECM layer.  Deterge nt based methods used to strip the ECM of cells can be detrimental to  
the bioscaffold  82 70 , , disrupting native tissue ultrastructure, decreasing glycosaminoglycan  
( GAG) content and reducing collagen integrity  83 , 84   as well as disrupting lipid - lipid, lip id - protein  
and protein - protein interactions  85 . Care should be taken to optimise this procedure in t he  
future.  HepG2s provide a convenient method of initial viability testing of the scaffolds, but they  
are derived from a carcinoma and as such criticism of their clinical relevance is well placed.  
Further studies will utilise primary or stem cell derived h epatocytes to combat such criticism.  
Additionally, recognition of the value of further proteomic and functional assays (such as  
ELISAs and Alkaline Phosphatase quantitation) in analysing the function of hepatocytes will  
be vital for expanding this work, ho wever at this time these were deemed unnecessary  
considering the obvious critiques of the use of the HepG2 cell line. Further, the importance of  
ensuring decellularization agents are removed from the constructs should not be  
underestimated, due to their in fluence upon cells and ECM  21 , 70 . While  such criticisms are  
important to consider, this work clearly demonstrates the potential of synthetic biology for the  
design of bespoke ECMs and provides a robust initial platform upon which further, improved  
studies can be built.  
Conclusion  
This study demo nstrates a novel method of creating a biologically bespoke hybrid ECM - 
polymer scaffold; utilising clinically translatable electrospun scaffold technologies and  
synthetic biology methods both easily modified to fulfil Good Manufacturing Practice (GMP)  
guide lines. In order to achieve this, a sacrificial ECM - producing cell layer was transfected  
using a protein producing fibronectin vector on an electrospun scaffold, biofuctionalizing the  
scaffold with a biologically bespoke ECM. Scaffolds with wild type untran sfected cells and no  






with a detergent based method and the hybrid synthetically derived ECM - polymer scaffolds  
seeded with HepG2 liver cells for validation . Results were validated using multiple well  
characterized  methods,  including  mechanical  quantitation,  Q - PCR  and  
immunohistochemistry. The synthetically derived  PLA - ECM  scaffolds exert   biological  
influence upon liver cells, manipulating their microenvironm ent and resulting in alterations in  
gene expression profile, protein synthesis and cell attachment and survival. Such data  
demonstrates promise as a unique method of creating biologically bespoke ECMs and  
exerting influence upon cell populations both  in vi vo  and  in vitro .   
These novel scaffolds exhibit great promise both as an implantable patient treatment for liver  
tissue engineering, for adaptation to other tissues and as a useful tool for development of 3D  
liver cell culture platforms with potential for  both  in vivo  cell analysis and novel pharmaceutical  
research.  
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